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ABSTRACT
Cell surface receptors undergo degradation but the biochemical basis for such control
remains poorly defined. Endothelial cells express vascular endothelial growth factor
receptor 2 (VEGFR2) which binds to circulating VEGF-A, stimulating signal
transduction and new blood vessel sprouting i.e. angiogenesis. A central hypothesis is
that ubiquitin-modifying enzymes play a key role(s) in the endothelial response to
VEGF-A. Work presented in this thesis provides evidence for a novel pathway requiring
the E1 ubiquitin-activating enzyme, UBA1, in controlling basal plasma membrane
VEGFR2 levels. Evidence suggests that this ubiquitin-linked regulatory pathway
controls VEGFR2 levels by modulating constitutive receptor recycling and degradation.
Programming basal plasma membrane VEGFR2 levels influences the intensity and
duration of the endothelial response to circulating ligands such as VEGF-A. After
identification of an UBA1-dependent pathway for modulating VEGFR2 ubiquitination,
the UBA1-interacting E2 ubiquitin-conjugating enzymes were screened. The E2
enzymes, UBE2D1 and UBE2D2, regulate basal VEGFR2 turnover downstream of
UBA1. Another feature of regulating VEGFR2 ubiquitination involves a potential role
for de-ubiquitinating enzymes (DUBs). There is evidence that a specific DUB enzyme,
USP8, regulates VEGFR2 de-ubiquitination, trafficking, signal transduction and
proteolysis. Depletion of USP8 caused VEGFR2 accumulation in early endosomes,
perturbed VEGFR2 ubiquitination and impaired VEGF-A-stimulated signal
transduction. In addition, de-ubiquitination is linked to production of a previously
unidentified VEGFR2 cleavage product. Thus, controlling VEGFR2 de-ubiquitination
has important consequences for the endothelial cell response and vascular physiology.
VEGFR2 is the predominant receptor through which VEGF-A regulates pro-angiogenic
signal transduction. Conversely, the role of VEGFR1 in endothelial cells is considered
anti-angiogenic. Novel synthetic protein scaffolds called Adhirons were screened for
interaction with VEGFR1 or VEGFR2. Adhirons to VEGFR2 inhibited VEGF-A-
stimulated signal transduction and endothelial tube formation. In contrast, Adhirons to
VEGFR1 increased VEGF-A-stimulated signal transduction, thus promoting increased
tubulogenesis. These findings suggest that inhibition of VEGFR1 can stimulate pro-
angiogenic responses. Adhirons represent a new class of synthetic tools with potential
applications in medical diagnostics, disease therapy and biomarker profiling.
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1CHAPTER 1
INTRODUCTION
1.1. Angiogenesis and the vascular endothelium
1.1.1. A brief history of angiogenesis
Ancient Egyptian and Greek medicine acknowledged the existence of a vascular
network in humans. The Greek physician, Galen, identified differences between venous
and arterial blood in the 2nd century AD (Aird, 2011). Not until 1628 did the British
physician William Harvey propose that the heart pumps blood through a circulatory
system with direct connections between arteries and veins (Aird, 2011). The capillary
network was discovered in 1661 by Italian physician Marcello Malpighi and the
endothelial cell component of the vascular system identified in 1865 by Wilhelm His Sr.
(Aird, 2011, Loukas et al., 2008).
Angiogenesis as a contributing factor to malignant tumour growth was first proposed by
Judah Folkman in the 1970’s (Folkman, 1971). His work led to the development of
angiogenesis inhibitors for cancer treatment. Over a decade later, Napoleone Ferrara
cloned and characterised vascular endothelial growth factor (VEGF) for its ability to
induce in vivo angiogenesis (Leung et al., 1989). In 1996, the first clinical trial using
VEGF for the treatment of critical limb ischaemia was published by Jeffery Isner (Isner
et al., 1996). Today, researchers are actively developing therapeutic agents to stimulate
angiogenesis in the brain, heart and peripheral vasculature.
1.1.2. Building a vascular network
In the developing mammalian embryo, blood vessels provide oxygen and the trophic
signals required to instruct organ morphogenesis (Coultas et al., 2005). Endothelial
precursors (angioblasts) differentiate into endothelial cells and assemble into a primitive
vascular plexus of small capillaries in a process known as vasculogenesis. These cells
already have a genetically pre-programmed arterial or venous cell fate. The earliest
marker for endothelial and haematopoietic progenitors is VEGF receptor 2 (VEGFR2),
2the major receptor for VEGF-A (Coultas et al., 2005). VEGFR2 is essential for healthy
mammalian development as homozygous VEGFR2-/- knockout mice die at embryonic
day E8.5, exhibiting impaired haematopoietic and endothelial cell development and
formation of an insufficient vascular network (Shalaby et al., 1995). This mimics the
VEGFA−/− knockout mouse phenotype suggesting that VEGF-A signal transduction is
also essential for development of both systems (Carmeliet et al., 1996) (Table 1.1). In
addition, correct VEGFA gene dosage is essential for normal mammalian health and
development. Heterozygous VEGFA+/- knockout mice die between embryonic days E11
and E12 due to a deformed vascular network (Carmeliet et al., 1996, Ferrara et al.,
1996).
Vessel sprouting, migration and remodelling progressively expand the vascular plexus
into a highly organised vascular network of larger vessels, creating functional
circulation in a process known as angiogenesis. Recruited pericytes and vascular
smooth muscle cells cover nascent endothelial cell channels during arteriogenesis to
regulate vessel perfusion and provide vessel strength. Genetic studies have revealed
insights into the key regulators and mechanisms of embryonic angiogenesis. For
example, the receptor COUP-TFII regulates venous specification whilst NOTCH family
members drive the arterial gene programme. VEGF is a key regulator of vascular
endothelial cell sprouting, whilst angiopoietin (ANG)-1 and platelet-derived growth
factor (PDGF)-BB recruit mural cells to cover endothelial channels (Carmeliet, 2005).
The requirement for a precise balance of stimulatory and inhibitory signals, such as
angiopoietins, chemokines, integrins, oxygen sensors, junctional molecules and
endogenous inhibitors highlights the complexity of angiogenesis.
1.1.3. Vascular development
The characterisation of vascular-mutant phenotypes in mice has advanced our
understanding of normal vascular development. Embryonic phenotypes that fail to
develop different aspects of normal vasculature have been reported for defective
VEGF/VEGFR, ANG/Tie, PDGF, transforming growth factor-β (TGF-β), ephrin and 
NOTCH systems (Coultas et al., 2005). During neoangiogenesis in tumour tissue, many
of these signalling pathways are re-activated (Bikfalvi and Bicknell, 2002). A healthy
adult vasculature contains quiescent endothelial cells that are arrested in G0 of the cell
Genotype Phenotype
VEGF-A+/- Die at E11/12 – impaired angiogenesis & blood-island
formation/deformed vascular network
VEGF-A-/- Die at E8.5 – impaired haematopoietic and endothelial cell
development and formation of an insufficient vascular
network
VEGF-B-/- No overt vascular defects – smaller hearts, abnormal
cardiac contraction
VEGF-C-/- Embryonically lethal - absence of lymphatic vessel
formation, no vascular defects
VEGF-D-/- Same as VEGF-C-/-
VEGFR1-/- Die at E8.5-E9.5 – vessel obstruction due to endothelial cell
hyperproliferation
VEGFR1-TK-/- Normal blood vessel formation however defects in VEGF-
A-dependent macrophage migration
VEGFR2-/- Die at E8.5 – impaired haematopoietic and endothelial cell
development and formation of an insufficient vascular
network
VEGFR2-Y1173 → F Same as VEGFR2-/-
VEGFR2-Y1214 → F No obvious phenotype
VEGFR3-/- Die at E10.5 - impaired hierarchical formation of peripheral
blood vasculature
VEGFR3-TK-/- Normal blood vessel development but impaired lymphatic
development
Table 1.1. VEGFR-VEGF murine models and phenotypes. Information taken
from Fong et al., 1995, Carmeliet et al., 1996, Dumont et al., 1998, Zhang et al.,
2010, Shibuya, 2014.
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4cycle, have long half-lives and are protected against overexposure to the autocrine
action of maintenance signals such as NOTCH, VEGF, fibroblast growth factors (FGFs)
and ANG-1 (Carmeliet and Jain, 2011, Lampugnani and Dejana, 2007). Endothelial
cells are equipped with oxygen sensors and hypoxia-inducible factors (HIFs). These
enable vessels to fulfil their role as oxygen suppliers, allowing adjustments in vessel
shape to optimise blood flow. Quiescent endothelial cells form a monolayer of phalanx
cells interconnected by junctional molecules such as claudins and vascular endothelial-
cadherin (VE-cadherin). Pericytes coat the endothelial cell layer to supress cell
proliferation whilst secreting survival signals such as ANG-1 and VEGF to form a
common basement membrane and promote vessel tightness. In the confluent
endothelium, ANG-1 binds to its receptor, TIE-2, and induces TIE-2 clustering at cell-
cell junctions to maintain quiescence (Saharinen et al., 2008) (Fig. 1.1). Contrastingly,
ANG-2 binds TIE-2 to competitively antagonise ANG-1 signalling, enhancing mural
cell detachment, vascular permeability and tubulogenesis. Upon sensing an angiogenic
signal such as ANG-2, secreted by hypoxic, inflammatory or tumour cells, pericytes
detach from the quiescent vessel wall and become liberated from the basement
membrane by matrix metalloproteinase (MMP)-mediated proteolysis. Endothelial cell
junctions are loosened and the nascent vessel dilates (Carmeliet and Jain, 2011) (Fig.
1.1).
Permeability of the endothelial cell layer is increased by VEGF-induced loosening of
adherens junctions (endothelial cadherin complexes and cell adhesion molecules such as
platelet/endothelial cell adhesion molecule-1 (PECAM-1)), causing plasma proteins to
extravasate and lay down a provisional extracellular matrix (ECM) scaffold. Integrin
signalling promotes endothelial cell migration onto the ECM. Angiogenic molecules
such as VEGF and FGF are liberated from the ECM by proteases, creating a pro-
angiogenic environment. To prevent excess endothelial cell chemotaxis towards the
angiogenic signal and to build a perfuse tube, one endothelial cell i.e. the tip cell is
selected to lead the vascular sprout upon expression of VEGFRs, neuropilins (NRPs)
and the NOTCH ligands (delta-like 4 (DLL4) and Jagged1). Following VEGF-A
stimulation, VEGFR2 upregulates DLL4 expression to dictate tip cell specification.
DLL4 activates NOTCH in neighbouring stalk cells to down-regulate VEGFR2 and
upregulate VEGFR1 levels (Fig. 1.2). Thus, these stalk cells become less responsive to
VEGF-A but more sensitive to placental growth factor (PlGF) (Carmeliet and Jain,
52011). As cells meet new neighbours these signalling pathways are constantly re-
evaluated - endothelial cells continuously compete for tip cell selection by fine tuning
VEGFR1 versus VEGFR2 expression (Jakobsson et al., 2010). Another NOTCH ligand,
Jagged1, is pro-angiogenic and opposes DLL4 activity. Jagged1 is expressed by stalk
cells and promotes tip cell specification by down-regulating reciprocal NOTCH-DLL4
signalling in the adjacent tip cell (Benedito et al., 2009) (Fig. 1.2). Jagged1 also
antagonises NOTCH-DLL4 signalling between stalk cells, facilitating sufficient
VEGFR expression in the immature vascular plexus and sustaining responsiveness to
VEGF, promoting proliferation and the dynamic emergence of new tip cells (Benedito
et al., 2009) (Fig. 1.1). Furthermore, NOTCH signalling in stalk cells upregulates a
NOTCH inhibitor, NOTCH-regulated ankyrin repeat protein (NRARP), in a negative
feedback cycle (Phng et al., 2009). NOTCH, Wnts, FGF and PlGF stimulate
neighbouring stalk cells to divide and elongate the stalk. A lumen is established through
VEGF, VE-cadherin, CD34 and Hedgehog signalling. Filopodia on tip cells sense
environmental guidance cues such as ephrins and semaphorins. In addition, release of
EGF-like domain protein 7 (EGFL7) by stalk cells into the ECM conveys positional
information about neighbouring cells so that the stalk elongates correctly (Carmeliet and
Jain, 2011) (Fig. 1.1). Myeloid bridge cells assist fusion with an adjacent vessel branch,
initiating blood flow in a process termed anastomosis. The vessel matures when
endothelial cells resume there quiescent phalanx state i.e. when oxygen levels are
sufficient to reduce expression of pro-angiogenic factors. Signals such as PDGF-B,
ANG-1, ephrin-B2, NOTCH and TGF-β promote pericyte coverage. Protease inhibitors 
such as tissue inhibitors of metalloproteinases (TIMPs) and plasminogen activator
inhibitor-1 (PAI-1) promote basement membrane deposition and re-establishment of
junctions for optimal flow (Carmeliet and Jain, 2011).
HIF-1α drives a hypoxia-inducible program that renders endothelial cells responsive to 
angiogenic signals. Prolyl hydroxylase domain (PHD) proteins are oxygen sensors that
hydroxylate HIF proteins when sufficient oxygen is available. Hydroxylated HIFs are
targeted for proteasomal degradation (Majmundar et al., 2010). During hypoxia, PHDs
are inactive and HIFs initiate transcriptional responses including upregulation of
angiogenic factors such as VEGF (Fraisl et al., 2009). In pathophysiological conditions
such as cancer, HIFs can be activated under normoxia by oncogenes and growth factors,
6protecting tumour cells from oxygen deprivation. Whereas HIF-1α activity promotes 
vessel sprouting, HIF-2α regulates vascular maintenance (Fraisl et al., 2009). 
Interestingly, hypoxia-induced upregulation of VEGF can occur independently of HIF-
1α. Under these circumstances, the metabolic regulator, peroxisome proliferator-
activated receptor gamma co-activator (PGC)-1α, upregulates VEGF levels in 
preparation for oxidative metabolism after revascularisation of ischaemic tissues (Arany
et al., 2008).
1.1.4. The vascular endothelium
An endothelial cell monolayer forms the vascular endothelium and lines the lumen of all
blood vessels. This layer is both exposed to the bloodstream and in contact with the
basement membrane and underlying tissue. Thus, the endothelium is vital for regulating
blood pressure, thrombosis, permeability, immune function and haemostasis. The
endothelium performs such a diverse array of functions by expressing a range of growth
factors, hormones, regulatory molecules and their cognate receptors (Onat et al., 2011).
The quiescent endothelial cell monolayer remains contact-inhibited due to the unique
presence of VE-cadherin-enriched adherens junctions between cells (Dejana et al.,
2008). In addition, capillaries in regions of strict transcellular control such as those
forming the blood-brain barrier possess ‘tight’ junctions formed by claudin and cadherin
bridges. Together, these adhesive intercellular junctions promote endothelial cell
adhesion, contact inhibition, vessel permeability, maintenance of cell polarity, cell
growth and survival. Adherens junctions are also essential for correct organisation of
new vessels during embryo development and during adult tissue proliferation (Dejana et
al., 2008). During angiogenesis or subconfluency, endothelial cells are in a proliferative
state which is responsive to growth factor stimulation. Upon reaching confluence, these
elongated cells take on characteristic cobblestone morphology. In this state, highly
organised cell-cell junctions lose their ability to respond to growth factor and switch to
a survival over proliferative phenotype. Vascular damage disrupts cell junctions,
causing a switch to an active phenotype which promotes cell proliferation and migration
in the wound (Odell et al., 2012). By regulating cell permeability, adherens junctions
respond to endogenous growth factors such as VEGF. Upon exposure to VEGF,
tyrosine phosphorylation of VE-cadherin increases vascular permeability and leukocyte
diapedesis (Dejana et al., 2008).
Figure 1.1. Model of angiogenesis. During angiogenesis tip cell selection, vessel
branching and vessel quiescence occur consecutively. (1) In the presence of
angiogenic factors, endothelial tip cell specification requires breakdown of the
basement membrane, loosening of cell-cell junctions and pericyte detachment. (2)
Tip cells migrate towards guidance signals, stalk cells proliferate and a lumen is
formed. Myeloid cells secrete additional angiogenic factors and provide a bridge
to aid fusion with a neighbouring vessel. (3) Lumen formation enables perfusion
of the new vessel. Quiescence is resolved by basement membrane deposition,
pericyte maturation and re-establishment of adherens junctions. Adapted from
Carmeliet and Jain (2011).
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Figure 1.2. NOTCH signalling dictates endothelial tip cell specification. Cells
exposed to the highest concentration of VEGF-A elevate expression of the
NOTCH ligand, DLL4. In neighbouring stalk cells, DLL4 activates NOTCH to
downregulate VEGFR2 expression. These stalk cells also express the DLL4
antagonist, Jagged1, which inhibits DLL4-mediated NOTCH activation in the tip
cell, leading to upregulated VEGFR2 expression and increased chemotactic
responsiveness to exogenous VEGF-A. The overall effect is reduced branching
but generation of perfuse vessels. Adapted from Adams and Eichmann (2010).
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91.1.5. Adult blood vessels and disease
Blood vessels evolved for the transport of haematopoietic cells to supply oxygen and
nutrients, to dispose of waste and for immune surveillance. Although fundamental for
tissue growth and regeneration, angiogenesis is associated with a plethora of diseases.
During adulthood, most blood vessels remain quiescent however endothelial cells retain
their ability to rapidly proliferate in response to physiological stimuli such as hypoxia.
Neovascularisation in response to tissue damage is a key component of wound healing.
In diseases in which this stimulus becomes abnormal, the balance between stimulators
and inhibitors is skewed, resulting in an angiogenic switch. Excessive angiogenesis
occurs in disorders characterised by abnormal vascular growth and remodelling such as
ocular, malignant and inflammatory disorders, obesity, diabetes, multiple sclerosis,
asthma and endometriosis (Folkman, 2007). Contrastingly, insufficient angiogenesis is
associated with stroke, neurodegeneration, ischaemic heart disease and preeclampsia,
linked to vessel regression or malformation, endothelial cell dysfunction and inhibited
revascularisation (Carmeliet, 2005). Cardiovascular disease covers all diseases of the
heart and circulation, including stroke, heart disease, heart failure, atrial fibrillation and
cardiomyopathy and is responsible for more than a quarter of all deaths in the UK
(about 425 people per day). Within this category, coronary heart disease (CHD) is the
UK’s single biggest killer and the leading cause of death worldwide
(https://www.bhf.org.uk/.../heart-statistics/cardiovascular-disease-statistics). CHD is
characterised by blocked blood supply to the heart caused by atherosclerosis. Thus, it is
desirable to develop pro-angiogenic drugs as high impact therapies to promote tissue
regeneration in cardiovascular disease. Conversely, anti-angiogenic therapeutic agents
could be beneficial for treatment of malignant diseases associated with excessive
angiogenesis.
Adult tissues can become vascularised by alternative mechanisms to neovascularisation.
In cancer, vessel co-option involves tumour cells hijacking the existing vasculature in a
process called vessel mimicry (Carmeliet and Jain, 2011). Additionally, cancer stem-
like cells can generate a tumour endothelium (Wang et al., 2010b).
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1.2. Vascular endothelial growth factors (VEGFs)
1.2.1 The VEGF family
The VEGF superfamily and its cognate receptors are highly conserved in metazoan
species (Ponnambalam and Alberghina, 2011). Many of the VEGF genes play essential
roles in animal development and function. However, a recurring theme is the subversion
of VEGF ligand and receptor function in a range of pathologies including cancer,
atherosclerosis, age-related macular degeneration and pre-eclampsia.
The VEGF superfamily consists of five structurally-related members of angiogenic and
lymphangiogenic polypeptides: VEGF-A, VEGF-B, VEGF-C, VEGF-D and PlGF (Fig.
1.3). These growth factors are highly conserved with subtle differences in the
distribution of charged residues determining receptor binding specificity (Fig. 1.4).
VEGFs regulate blood and lymph vessel development in an isoform-specific manner
through activation of receptor tyrosine kinases VEGFR1 (Flt-1), VEGFR2 (KDR) and
VEGFR3 (Flt-4) (Roskoski, 2007). VEGF polypeptides form homodimers but
heterodimers of VEGF-A and PlGF also occur naturally (DiSalvo et al., 1995).
Complexity in the VEGF family is heightened by alternative splicing of VEGF-A,
VEGF-B and PlGF and proteolytic processing of VEGF-C and VEGF-D. This allows
multiple protein isoforms with distinct receptor and extracellular matrix binding
properties to be encoded by a single gene (Ferrara, 2010).
The human VEGFA gene encodes a pre-mRNA with at least 8 exons and 7 introns
(Robinson and Stringer, 2001). Alternative RNA splicing produces at least 7 pro-
angiogenic isoforms of human VEGF-A which encode polypeptides of 121, 145, 148,
165, 183, 189 or 206 residues (a isoforms) and 5 anti-angiogenic isoforms of 121, 145,
165, 183 and 189 residues denoted VEGF-Axxxb (Fig. 1.5). Recent work has shown that
VEGFA mRNA also undergoes programmed translational read-through to generate an
anti-angiogenic VEGF-Ax isoform containing a unique 22 amino acid C-terminal
extension (Eswarappa et al., 2014). Each VEGF-A isoform contains exons 1-5 which
encode the signal sequence (exon 1), N-terminus dimerisation domain (exon 2),
VEGFR1-binding and N-glycosylation site (exon 3), VEGFR2-binding site (exon 4) and
a plasmin cleavage site (exon 5) (Fig. 1.5). Exons 6a, 6b, 7a and 7b encode the heparin-
Figure 1.3. In silico modelling of VEGF proteins. Ribbon and stick diagrams
depicting the structure of receptor bound VEGF-A (PDB id: 4KZN), VEGF-B
(PDB id: 2XAC), VEGF-C (PDB id: 2X1W), VEGF-D (PDB id: 2XV7) and
PlGF (PBD id: 1RV6). Taken from Smith et al. (2015).
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Figure 1.4. Structural differences between VEGF-A, PlGF and VEGF-C
influence VEGFR binding. (A) Ribbon diagram depicting the structural
similarities between VEGF-A (blue) (PDB id: 3V2A), PlGF (green) (PDB id:
1RV6) and VEGF-C (cyan) (PDB id: 4BSK). (B) A model of VEGF-A binding to
VEGFR2 using the PlGF dimer as a template for VEGF-A binding to the Ig-like
domains. (C) Structures of VEGF-A (top), PlGF (middle) and VEGF-C (bottom)
reveal that although the fundamental fold is similar, the distribution of
hydrophobic (purple) and polar (cyan) residues highlights differences between
VEGFR1-binding ligands, VEGF-A and PlGF, and VEGFR3-binding ligand,
VEGF-C. (D) Structures of VEGF-A (top), PlGF (middle) and VEGF-C (bottom)
rotated 90° with positive (blue), negative (red), aliphatic (yellow) and aromatic
(purple) residues highlighted. (E) Structures of VEGF-A (top), PlGF (middle) and
VEGF-C (bottom) rotated 90° with positive (blue) and negative (red) residues
highlighted. Taken from Smith et al. (2015).
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3’ UTR5’ UTR 1 2 3 4 5 6a 6b 7 8
Signal
sequence
N-terminus
VEGFR1
binding site
VEGFR2
binding site
Plasmin cleavage site
Heparin binding site
1 2 3 4 5 6a 6b 7 8a
1 2 3 4 5 6a 7 8a
1 2 3 4 5 6a’ 7 8a
1 2 3 4 5 7 8a
1 2 3 4 5 7
1 2 3 4 5 6a 8a
1 2 3 4 5 8a
1 2 3 4 5 6a 7 8b
1 2 3 4 5 6a’ 7 8b
1 2 3 4 5 7 8b
1 2 3 4 5 6a 8b
1 2 3 4 5 8b
VEGF-A206a
VEGF-A189a
VEGF-A183a
VEGF-A165a
VEGF-A148a
VEGF-A145a
VEGF-A121a
VEGF-A189b
VEGF-A183b
VEGF-A165b
VEGF-A145b
VEGF-A121b
Pro-angiogenic (a isoforms)
Anti-angiogenic (b isoforms)
Figure 1.5. Exon arrangement of VEGF-A splice isoforms. The VEGFA gene
encodes a pre-mRNA with at least 8 exons. Alternative RNA splicing produces at
least 7 pro-angiogenic isoforms of human VEGF-A which encode polypeptides of
121, 145, 148, 165, 183, 189 or 206 residues (a isoforms) and 5 anti-angiogenic
isoforms of 121, 145, 165, 183 and 189 residues denoted VEGF-Axxxb. A
premature stop codon causes truncation of VEGF-A148 (orange). Exon 6a can also
be truncated (6a’). Adapted from Fearnley et al. (2013).
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binding domain and their variable inclusion significantly influences the biological
properties of each VEGF-A isoform (Fig. 1.5). Those isoforms containing exon 6a such
as VEGF-A145 and VEGF-A189 are weaker chemotactic cytokines and mitogens (Lee et
al., 2010, Kawamura et al., 2008, Plouet et al., 1997). Exon 6a has a preponderance of
basic amino acids which directly reduce VEGFR2-VEGF-A binding (Jia et al., 2001).
Interestingly, exon 6-containing isoforms do not inhibit VEGF-A-stimulated VEGFR1
activity and can promote VEGFR1-mediated vascular permeability (Plouet et al., 1997,
Ancelin et al., 2002).
Signal transduction is linked to regulating proximal and distal splice site selection on
the primary RNA e.g. specifying the C-terminal 6 amino acids with either the pro-
angiogenic CDKPRR (exon 8a) or anti-angiogenic SLTRKD (exon 8b) sequence
(Harper and Bates, 2008). Reduced co-receptor binding could explain the anti-
angiogenic properties of VEGF-A165b in combination with competition between VEGF-
A165b and pro-angiogenic VEGF-A165a for binding to VEGFR2 (Harper and Bates, 2008,
Kawamura et al., 2008). The C-terminal SLTRKD sequence in the anti-angiogenic
VEGF-A165b isoform cannot bind the co-receptor, NRP1, leading to a VEGFR2 protein
complex which exhibits reduced tyrosine kinase activity (Harper and Bates, 2008).
Down-regulated VEGF-A165b expression correlates with a switch to a pro-angiogenic
phenotype associated with multiple pathologies including diabetic retinopathy and
several adult epithelial cancers (Perrin et al., 2005, Varey et al., 2008). Conversely,
upregulated VEGF-A165b expression in skin and circulatory tissues of patients with
systemic sclerosis or peripheral arterial disease hinders angiogenesis and vascular repair
(Manetti et al., 2010).
Human VEGFB contains 7 exons and encodes at least 2 isoforms with alternative splice
acceptor sites present in exon 6 (Olofsson et al., 1996, Grimmond et al., 1996). The
VEGF-B167 C-terminus contains the highly basic NRP1/heparin-binding domain
whereas the more freely diffusible VEGF-B186 isoform has a hydrophobic C-terminus
which undergoes O-linked glycosylation and proteolytic processing (Olofsson et al.,
1996). Within the VEGF family, VEGF-C and VEGF-D are unique in being initially
synthesised as precursor proteins containing long N- and C-terminal propeptides
(Joukov et al., 1997, Achen et al., 1998). Proteolytic removal of both the N- and C-
propeptides releases mature, bioactive VEGF-D containing the central VEGF-homology
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domain. Such processing increases VEGF-D affinity for VEGFR3. Furthermore, only
mature VEGF-D binds VEGFR2 (Stacker et al., 1999). Although two mouse VEGF-D
isoforms have been described, little is known about alternate RNA splicing of human
VEGF-C or VEGF-D (Baldwin et al., 2001).
Four PlGF isoforms with distinct properties are encoded by the PGF gene. The most
commonly expressed isoforms are PlGF-1 (131 amino acids) and PlGF-2 (152 amino
acids) (Maglione et al., 1993). The PlGF-2 exon 6 heparin-binding domain facilitates
binding to heparin and NRP1. Contrastingly, PlGF-1 and PlGF-3 (203 amino acids) do
not contain exon 6 (Maglione et al., 1991). PlGF-3 contains an additional 216
nucleotide insertion between exons 4 and 5. PlGF-4 (224 amino acids) consists of the
same sequence as PlGF-3 plus the exon 6-encoded heparin-binding domain (Holmes
and Zachary, 2005). These larger PlGF isoforms may function similarly to VEGF-A189
and VEGF-A206 (Holmes and Zachary, 2005).
1.2.2. VEGF-receptor interactions
VEGFs bind to the extracellular domain of VEGFRs and additional cell surface-
expressed co-receptors e.g. heparan sulphate glycoproteins (HSPGs), NRPs, integrins
and ephrin B2 (Grunewald et al., 2010, Sawamiphak et al., 2010). PlGF and VEGF-B
specifically bind VEGFR1 and NRP1 while VEGF-A binds both VEGFR1 and
VEGFR2 (Errico et al., 2004, Olofsson et al., 1998, Makinen et al., 1999). VEGF-C and
VEGF-D bind VEGFR2 and VEGFR3 (Takahashi and Shibuya, 2005) (Fig. 1.6).
Distinct splice variants of VEGF-A assemble specific receptor/co-receptor complexes.
Spatial and temporal aspects of VEGFR signal transduction can be influenced by the
restricted diffusion of heparan sulphate (HS)-binding VEGFs and is further modulated
by VEGF interactions with the ECM (Koch et al., 2011). Binding of VEGF-A165a and
VEGF-A189 to HSPGs and NRP1 promotes ternary complex formation and VEGFR2
signal transduction. NRP1 binding to VEGF-A165a enhances VEGFR2-VEGF-A165a
complex formation and tyrosine kinase activity. For example, optimal p38 mitogen-
activated protein kinase (MAPK) activation is achieved through NRP1-enhanced
VEGF-A165a signal transduction (Kawamura et al., 2008). In contrast, VEGF-A121 is
freely diffusible and NRP1 binding does not promote ternary complex formation with
VEGFR2, reducing signal transduction (Pan et al., 2007). Despite PlGF only binding
Figure 1.6. The VEGFR receptor tyrosine kinase subfamily. Schematic
illustrating VEGFR structure and VEGF ligand specificity. Ig-like domains
mediate interaction between VEGFR monomers to promote complex assembly.
Adapted from Smith et al. (2015).
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VEGFR1, activation of VEGFR2 could occur indirectly through VEGF-A displacement
from VEGFR1, thus increasing VEGF-A bioavailability for VEGFR2 (Carmeliet et al.,
2001). Interestingly, PlGF/VEGF-A heterodimers can induce VEGFR1/VEGFR2
dimerisation and downstream VEGFR2 activation (Tarallo et al., 2010).
The widely differing function of VEGFR1-specific ligands, VEGF-B and PlGF, raises
the possibility that VEGFR1-induced cellular outcomes are regulated by co-receptor
recruitment and/or cell-specific intracellular signalling events (Koch and Claesson-
Welsh, 2012). VEGF-B-stimulated fatty acid synthesis in endothelial cells is crucial in
organs which experience high metabolic stress, such as the heart, and involves both
VEGFR1 and NRP1 activation (Hagberg et al., 2010). Therapeutic potential is
highlighted in cardiac endothelial cells where VEGF-B promotes physiological
angiogenesis and revascularisation of the ischaemic myocardium (Li et al., 2008b). In
contrast, PlGF expression is associated with cancer progression and required for
inflammation-associated angiogenesis (Carmeliet et al., 2001). PlGF promotes
pathological angiogenesis in several inflammatory disease states in which VEGFR1-
regulated recruitment of bone marrow-derived monocytes precedes deposition of
angiogenic growth factors (Carmeliet et al., 2001). Tumours exhibiting increased PlGF
secretion suggest a functional link between VEGFR1 activity and cancer progression.
1.3. Vascular endothelial growth factor receptors (VEGFRs)
The receptor tyrosine kinase (RTK) subfamily containing membrane-bound VEGFRs
comprises of VEGFR1, VEGFR2 and VEGFR3. VEGFRs exhibit structural and
sequence homologies and comprise an extracellular ligand-binding domain consisting of
7 immunoglobulin (Ig)-like repeats, a transmembrane domain, a juxtamembrane
domain, a split tyrosine kinase domain and a C-terminal tail.
1.3.1. VEGFR1
The VEGFR1 gene contains 30 exons and encodes an estimated 151 kDa
transmembrane receptor which undergoes post-translational modification to produce a
~180 kDa mature glycoprotein (Kendall and Thomas, 1993, Devries et al., 1992).
VEGF-A has highest affinity for VEGFR1 (Devries et al., 1992) but the activated
receptor exhibits relatively weak tyrosine kinase activity and forms a non-productive
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signalling complex (Robinson and Stringer, 2001, Waltenberger et al., 1994). The poor
tyrosine kinase activity of VEGFR1 arises from structural properties of the activation
loop, a repressor sequence in its juxtamembrane domain and a lack of positive
regulatory tyrosine residues (Gille et al., 2000, Meyer et al., 2006, Ito et al., 1998).
VEGFR1 is expressed in various cell types including both quiescent and actively
proliferating endothelial cells, haematopoietic stem cells, monocytes, macrophages and
tumour cells (Roskoski, 2007, Koch and Claesson-Welsh, 2012, Robinson and Stringer,
2001). VEGFR1 is essential for mammalian development as homozygous VEGFR1-/-
knockout mice die between embryonic days E8.5 and E9.5 after endothelial
hyperproliferation leads to blood vessel obstruction (Fong et al., 1995) (Table 1.1). The
VEGFR1 primary RNA transcript undergoes alternative splicing to generate a soluble
VEGFR1 isoform (sFlt-1; sVEGFR1) of ~110 kDa. This soluble isoform comprises Ig-
like domains 1-6 of the VEGFR1 ectodomain and a unique 31 residue sequence at the
C-terminus (Shibuya, 2001). sVEGFR1 can be a potent inhibitor of VEGF-A, VEGF-B
and PlGF signal transduction (Olsson et al., 2006).
In leukaemia cells, PlGF and VEGF-A induce tyrosine phosphorylation of VEGFR1
and increase ectodomain shedding. This occurs via activation of protein kinase C (PKC)
and metalloproteases such as tumour necrosis factor α (TNFα) converting enzyme 
(TACE) (Rahimi et al., 2009). TACE activity generates sVEGFR1 and an intracellular
cytoplasmic fragment; detachment of this fragment from the plasma membrane requires
γ-secretase/presenilin activity (Cai et al., 2011).  
One view is that VEGFR1 has positive or negative regulatory roles in angiogenesis
depending on biological conditions. A negative regulatory role arises from sVEGFR1
acting as a decoy receptor to sequester VEGF-A away from VEGFR2 or by formation
of non-signalling VEGFR1/VEGFR2 heterodimers (Kendall et al., 1994). A positive
regulatory role could occur under pathological conditions of tumour growth where
abnormally high expression of VEGFR1-specific ligands leads to elevated VEGFR1
tyrosine kinase activity which promotes angiogenesis (Hiratsuka et al., 2001).
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1.3.2. VEGFR2
Immature VEGFR2 has an estimated molecular mass of ~152 kDa and undergoes
translocation to the endoplasmic reticulum and N-linked glycosylation along the
secretory pathway to produce a mature glycoprotein with a mass of ~200-230 kDa
(Waltenberger et al., 1994, Koch et al., 2011). Only mature, fully glycosylated VEGFR2
undergoes efficient trans-autophosphorylation upon VEGF stimulation (Takahashi and
Shibuya, 1997). Alternative splicing generates soluble VEGFR2 (sVEGFR2) which is
present in plasma and multiple tissues including the heart, spleen, skin, ovary and
kidney. This sVEGFR2 can sequester free VEGF-C, thus preventing VEGFR3
activation and inhibiting lymphatic endothelial cell proliferation (Albuquerque et al.,
2009). VEGFR2 expression is predominantly restricted to endothelial cells and
haematopoietic stem cell precursors, with peaks in expression during embryonic
development (Millauer et al., 1993).
VEGF-A binds VEGFR2 with a relatively high affinity (Kd ~150 pM); however, this
parameter is ~10-fold lower than that of VEGFR1 (Kd ~15 pM) (Vaisman et al., 1990).
Nonetheless, the majority of VEGF-A-regulated angiogenic outcomes are attributed to
its interaction with VEGFR2. VEGFR2 is considered a more potent tyrosine kinase
which targets numerous substrates including membrane proteins, cytoplasmic enzymes
and adaptor proteins (Roskoski, 2007, Quinn et al., 1993). VEGFR2 is thus considered
the major pro-angiogenic receptor which regulates blood vessel development and
homeostasis in response to circulating VEGFs (Quinn et al., 1993, Roskoski, 2007).
VEGFR2 expression is down-regulated in quiescent adult vasculature (Eichmann et al.,
1997), likely to reduce the magnitude of VEGFR2-regulated pro-angiogenic responses
(Kanno et al., 2000).
1.3.3. VEGFR3
VEGFR3 is an essential regulator of lymphoendothelial function and
lymphangiogenesis. Upon co-translational insertion of newly synthesised VEGFR3 into
the endoplasmic reticulum this ~195 kDa precursor protein undergoes N-linked
glycosylation and proteolytic cleavage within the fifth Ig-like domain. This generates an
N-terminal polypeptide which forms a stable disulphide linkage with the carboxyl half
of the VEGFR3 precursor (Pajusola et al., 1993). VEGFR3 complexity is further
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increased by alternative splicing to produce both long and short isoforms (Galland et al.,
1993, Pajusola et al., 1992). The VEGFR3 short isoform lacks 65 residues proximal to
the C-terminus; this is only present in humans and likely arose through a retroviral
integration event during human speciation (Hughes, 2001). Furthermore, the VEGFR3
short isoform lacks two cytoplasmic phosphorylation epitopes which are detected in
VEGFR3 homodimers but not in VEGFR2/VEGFR3 heterodimers (Dixelius et al.,
2003). VEGFR3-/- knockout mice die during embryogenesis between E10 to E11 due to
impaired hierarchical formation of the peripheral blood vasculature and defects in
cardiac remodelling (Dumont et al., 1998) (Table 1.1). The role(s) of VEGFR3 in
lymphatic endothelial cell responses is well-studied; however, VEGFR3 expression is
also upregulated in vascular endothelial cells during angiogenesis (Carmeliet et al.,
2009, Koch and Claesson-Welsh, 2012). VEGFR3 expression is detected in non-
endothelial cells such as macrophages, neuronal progenitors and osteoblasts, whilst its
functional presence in tumours is much debated (Koch and Claesson-Welsh, 2012).
Mice expressing kinase-deficient VEGFR3 maintain normal physiological blood vessel
development but exhibit impaired lymphatic development (Zhang et al., 2010) (Table
1.1). VEGFR3 mutations which perturb tyrosine kinase activity are associated with
variants of hereditary lymphoedema, reinforcing the pivotal role of VEGFR3 in
lymphatic endothelial cell function (Irrthum et al., 2000).
1.4. VEGFR signal transduction
Most parenchymal cells express and secrete growth factors such as VEGF-A. These
ligands act in a paracrine manner on neighbouring endothelial cells to regulate VEGFR-
mediated signal transduction and influence endothelial, lymphatic, epithelial and neural
cell responses (Ruiz de Almodovar et al., 2009, Ponnambalam and Alberghina, 2011,
Eichmann and Simons, 2012). Notably, autocrine VEGF-A-induced signal transduction
is considered essential for maintaining endothelial cell survival (Lee et al., 2007).
VEGF-stimulated signal transduction regulates a host of endothelial cell responses
including proliferation, migration, permeability and cell-cell interactions.
Activation of the cytoplasmic tyrosine kinase domain by ligand-induced VEGFR homo-
or heterodimerisation causes conformational changes that expose an ATP-binding site
(Nilsson et al., 2010). The exchange of ADP for ATP initiates trans-
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autophosphorylation of key tyrosine residues on the receptor dimer which create
docking sites for SH2-domain-containing adaptor molecules and trigger waves of
intracellular signal transduction (Stuttfeld and Ballmer-Hofer, 2009). VEGFR tyrosine
kinase activity is tightly regulated by ubiquitination, internalisation and de-
phosphorylation by protein tyrosine phosphatases (PTPs) such as PTP1B and vascular
endothelial PTP (VE-PTP) (Kappert et al., 2005).
1.4.1. VEGFR1-regulated signal transduction
A highly postulated model is that VEGFR1 acts as a ‘VEGF trap’ (Kendall et al., 1994).
Nonetheless, VEGF-A binding to VEGFR1 Ig-like domains 2 and 3 can trigger low
levels of trans-autophosphorylation at specific VEGFR1 cytoplasmic tyrosine residues
Y794, Y1169, Y1213, Y1242, Y1309, Y1327, and Y1333 (Cunningham et al., 1997, Yu
et al., 2001, Wiesmann et al., 1997) (Fig. 1.7). Patterns of VEGFR1 tyrosine
phosphorylation are ligand-dependent e.g. Y1309 phosphorylation is induced by PlGF
binding and linked to downstream Akt activation and changes in cell physiology
(Autiero et al., 2003).
Computational modelling suggests VEGFR1/VEGFR2 heterodimers comprise 10-50%
of activated VEGFR complexes in response to VEGF-A; such modelling predicts low
incidence of VEGFR1 homodimers when VEGFR2 levels are relatively high (Mac
Gabhann and Popel, 2007). Functional coupling of VEGFR1 and VEGFR2 through
heterodimerisation and trans-autophosphorylation could modulate endothelial cell
responses (Koch et al., 2011). Surprisingly, VEGFR1-TK-/- knock out mice expressing
truncated VEGFR1 lacking tyrosine kinase activity are viable and exhibit normal blood
vessel formation during development; however such mice exhibit defects in VEGF-A-
dependent macrophage migration (Shibuya, 2014) (Table 1.1). Other studies on
heterozygous VEGFR1-TK+/- transgenic mice suggest that VEGFR1 tyrosine kinase
activity is required for angiogenesis during tumour metastasis, in some inflammatory
diseases, stroke, liver repair, gastric ulcer healing and various carcinomas and
glioblastomas (Shibuya, 2014). Although VEGFR1 is considered to be a ‘poor’ tyrosine
kinase with limited signalling output, therapeutics aimed at this RTK could be an
attractive option for certain diseases (Shibuya, 2006).
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VEGFR1 is functionally linked to endothelial cell migration and actin reorganisation
through receptor for activated C kinase 1 (RACK1) activation (Wang et al., 2011) (Fig.
1.7). Additionally, activated VEGFR1 upregulates urinary-type plasminogen activator
(uPA) and PAI-1 levels which influence p38 MAPK regulation of actin dynamics,
extracellular matrix degradation and cell migration (Carmeliet, 2005, Ewan et al., 2006)
(Fig. 1.7). VEGFR1-dependent activation of phosphoinositide-3-kinase (PI3K) is linked
to endothelial cell proliferation and tubulogenesis (Cai et al., 2003) (Fig. 1.7). Other
targets of VEGFR1-mediated signal transduction include phospholipase Cγ1 (PLCγ1), 
growth factor receptor-bound protein 2 (Grb2) and protein tyrosine phosphatase non-
receptor type 11/SH2 domain-containing tyrosine phosphatase 2 (PTPN11/SHP2) (Ito et
al., 1998). VEGFR1 activation generates cytoplasmic pY794 and pY1169 epitopes that
promote PLCγ1 recruitment, leading to phosphatidylinositol-4,5-bisphosphate (PIP2)
cleavage and production of diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3)
(Roskoski, 2007, Cunningham et al., 1997) (Fig. 1.7). IP3 binding to the membrane-
bound IP3 receptor (IP3R) in the endoplasmic reticulum facilitates Ca2+ ion translocation
into the cytosol. One consequence of such activity is engagement of the calmodulin-
calcineurin pathway which causes de-phosphorylation of nuclear factor of activated T-
cell (NFAT) family members leading to their activation, nuclear translocation and
stimulation of gene transcription at specific loci (Koch et al., 2011) (Fig. 1.7). This pro-
angiogenic pathway promotes an inflammatory response (Jiang and Liu, 2009).
VEGFR1-specific ligands, PIGF and VEGF-B, bind to monocytes and stimulate
intracellular signalling events including activation of the extracellular signal-regulated
kinase 1/2 (ERK1/2), Akt and p38 MAPK pathways (Tchaikovski et al., 2008).
1.4.2. VEGFR2-regulated signal transduction
VEGFR2-specific signal transduction influences endothelial cell proliferation,
migration, survival and tubulogenesis. Ligand binding to the VEGFR2 extracellular
domain triggers cytoplasmic tyrosine kinase activation and trans-autophosphorylation at
residues Y801, Y951, Y1054, Y1059, Y1175, Y1214, Y1223, Y1305, Y1309 and
Y1319 (Fig. 1.8). The VEGFR2-pY951 epitope provides a binding site for SH2 domain-
containing T-cell-specific adaptor molecule (TSAd) which is functionally linked to
endothelial cell migration and vascular permeability (Matsumoto et al., 2005) (Fig. 1.8).
Generation of VEGFR2-pY1059 enables recruitment of the proto-oncogene and soluble
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Figure 1.7. VEGFR1-mediated signal transduction. Schematic of the signal
transduction cascades activated upon ligand binding to VEGFR1 with tyrosine
(Y) phosphorylation sites indicated. Y1309 (boxed) is only phosphorylated by
PlGF stimulation. Binding of signalling adaptors to VEGFR1 phospho-tyrosine
epitopes initiates activation of downstream signalling proteins and leads to
specific biological outcomes. Restricted tyrosine phosphorylation and the
presence of a repressor sequence in the juxtamembrane domain are possible
mechanisms for the weak kinase activity of VEGFR1. Adapted from Koch et al.
(2011).
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tyrosine kinase Src which further promotes phosphorylation of residue Y1175 (Fig.
1.8). VEGFR2-pY1175-mediated recruitment of PLCγ1 causes PIP2 hydrolysis, DAG
release and subsequent activation of PKC and MAPK enzymes (e.g. ERK1/2) which
influence gene expression and cell proliferation (Takahashi et al., 2001) (Fig. 1.8).
Furthermore, VEGF-A stimulates both membrane and soluble VEGFR1 expression
through VEGFR2 and PKC-dependent pathways (Raikwar et al., 2013). VEGF-A-
stimulated ERK1/2 activation leads to the hyperphosphorylation of activating
transcription factor 2 (ATF-2), causing elevated expression of vascular endothelial cell
adhesion molecule 1 (VCAM-1) and promoting endothelial-leukocyte interactions
(Fearnley et al., 2014); this provides a MAPK-regulated gene expression mechanism
that links angiogenesis and inflammation.
The VEGFR2-pY1175 epitope can also bind adaptor protein SH2-domain-containing
adaptor protein B (Shb) which facilitates interaction with focal adhesion kinase (FAK)
and contributes to endothelial cell migration and attachment (Holmqvist et al., 2003)
(Fig. 1.8). Shb activation of PI3K results in sequential activation of Akt and endothelial
nitric oxide synthase (eNOS) which promote cell survival and nitric oxide (NO)-
induced vascular permeability, respectively (Roskoski, 2007, Olsson et al., 2006) (Fig.
1.8). Generation of the VEGFR2-pY1214 epitope enables recruitment of adaptor protein
Nck and a cytoplasmic tyrosine kinase, Fyn. Nck-Fyn complex formation regulates
phosphorylation of p21-activated protein kinase 2 (PAK2), which in turn activates cell
division cycle 42 (Cdc42) and p38 MAPK (Lamalice et al., 2006); impacting on cell
migration through increased actin remodelling (Fig. 1.8). VEGF-regulated PI3K
activation mediates cell survival through sequential phosphoinositide-dependent protein
kinase 1 (PDK1) and Akt activation. Akt is a multifunctional regulator that can inhibit
Bcl-2-associated agonist of cell death (BAD) and caspase 9, thus blocking apoptosis
(Datta et al., 1999) (Fig. 1.8).
Other post-translational modifications such as methylation are involved in VEGFR2
activation. VEGFR2 methylation takes place at multiple lysine and arginine residues,
such as residue L1041 which is proximal to the kinase domain activation loop.
Although methylation is ligand-independent, it enhances tyrosine phosphorylation and
kinase activity in response to VEGF (Hartsough et al., 2013). In addition, VEGFR2 is
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Figure 1.8. VEGFR2-mediated signal transduction. Schematic of the signal
transduction cascades activated upon VEGF binding to VEGFR2 with tyrosine
(Y) phosphorylation sites indicated. Binding of signalling adaptors to VEGFR2
phospho-tyrosine epitopes initiates activation of downstream signalling proteins
and leads to specific biological outcomes. Phosphorylation of Y1054 and Y1059
is essential for VEGFR2 kinase activity. Adapted from Koch et al. (2011).
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acetylated at a dense cluster of four lysine residues in the kinase insert domain and at a
single lysine within the kinase activation loop (Zecchin et al., 2014). The
acetyltransferase p300 and two histone deacetylases, HDAC5 and HDAC6, regulate
VEGFR2 acetylation in a process essential for controlling sustained ligand-dependent
trans-autophosphorylation and downstream signal transduction (Zecchin et al., 2014).
1.5. VEGF and metabolism
In contrast to other cells and tissues, the endothelium relies heavily on glycolysis to
produce ATP as an energy source; the contribution of glucose oxidation or
mitochondrial respiration to ATP production is relatively low. This endothelial
phenotype is superficially similar to the glycolytic phenotype exhibited by transformed
tumour cells i.e. the Warburg effect. The glycolytic flux in endothelial cells is >200-fold
higher in comparison to glucose, fatty acid or glutamine oxidation (De Bock et al.,
2013a). However, under conditions of stress, mitochondrial respiration can serve as a
reserve mechanism for ATP synthesis (Eelen et al., 2013).
1.5.1. VEGF and glycolysis
Different lines of evidence suggest that VEGFs have strong regulatory roles in
endothelial cell metabolism. The endothelial glucose transporter 1 (GLUT1) mediates
glucose influx in a passive manner (De Bock et al., 2013a). Interestingly, GLUT1 levels
are elevated during hypoxia (Ulyatt et al., 2011). VEGF-A stimulation increases the
glycolytic rate of endothelial cells through increased PI3K and Akt-stimulated
expression of GLUT1, lactate dehydrogenase-A (LDH-A) and phosphofructokinase-
2/fructose-2,6-bisphosphate (PFKFB3) (Yeh et al., 2008, De Bock et al., 2013b, Eelen
et al., 2013). VEGF-A stimulates PFKFB3-driven glycolysis in endothelial tip cells
preferentially to other endothelial cells within the developing vascular sprout (De Bock
et al., 2013b). If this upregulation fails due to gene knockdown of PFKFB3, glycolysis,
endothelial cell migration, proliferation and vascular sprouting are inhibited (De Bock et
al., 2013b). Overexpression of PFKFB3 in endothelial stalk cells confers tip cell-like
behaviour, overriding other regulatory signals (Eelen et al., 2013, De Bock et al.,
2013b). Thus glucose metabolism regulates angiogenic fate, rather than simply being
the engine that drives it (Jang and Arany, 2013).
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Compared to glycolysis, oxidative phosphorylation produces ~20-fold more ATP
(Locasale and Cantley, 2011). As endothelial cells are exposed to relatively high
circulatory blood oxygen levels, the importance of glycolysis in endothelial cell
metabolism seems paradoxical (Eelen et al., 2013). One explanation is that the
endothelium must maintain high metabolic activity to promote angiogenesis in hypoxic
environments thus enabling oxygen-independent ATP synthesis (Eelen et al., 2013).
Endothelial glycolysis is increased in pathological conditions such as pulmonary
hypertension where oxygen consumption is reduced (Fijalkowska et al., 2010).
1.5.2. VEGF and the pentose phosphate pathway (PPP)
Endothelial cell dependence on glycolysis promotes diversion of glycolytic
intermediates into side branches of this pathway, such as the pentose phosphate pathway
(PPP) (Fig. 1.9). Oxidation of glucose-6-phosphate to pentose sugars by glucose-6-
phosphate dehydrogenase (G6PD) facilitates nucleotide synthesis, NO production,
reductive biosynthesis of lipids and production of reduced glutathione (GSH); an
important cellular redox buffer (Cairns et al., 2011) (Fig. 1.9). G6PD inhibition
decreases VEGF-A-stimulated VEGFR2 tyrosine phosphorylation, eNOS activation and
NO production, in addition to inhibiting endothelial cell migration, proliferation and
tubulogenesis (Leopold et al., 2003, Pan et al., 2009). The oxidative branch of the PPP
(oxPPP) generates NADPH and ribose-5-phosphate. VEGF-A stimulates oxPPP flux
(Vizan et al., 2009); increasing both plasma membrane localisation and activity of
G6PD (Pan et al., 2009) and creating a positive feedback loop (Fig. 1.9).
Glucose flux through the hexosamine biosynthesis pathway (HBP) facilitates protein
glycosylation. Interaction between VEGFR2 N-linked glycans with the N-glycan-
binding protein, galectin-3 facilitates plasma membrane retention and receptor
activation, thereby promoting VEGF-A-stimulated angiogenesis (Markowska et al.,
2011).
1.5.3. VEGF and the polyol pathway
Elevated glucose levels (hyperglycaemia) are characteristic of diabetes-related
pathologies and promote vascular dysfunction. The polyol pathway removes excess
glucose from the glycolytic pathway by aldose reductase-catalysed reduction of glucose
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Figure 1.9. VEGF-A endothelial metabolism and glycolysis. Endothelial cell
reliance on glycolysis promotes diversion of glycolytic intermediates into side
branches of this pathway, such as the pentose phosphate pathway (PPP). VEGF-A
stimulation of oxPPP flux increases glucose-6-phosphate dehydrogenase (G6PD)
plasma membrane localisation and enzymatic activity, thus creating a positive
feedback loop. G6PD also promotes VEGFR2 tyrosine phosphorylation and
downstream eNOS activation. VEGF-A-stimulated activation of the PI3K/Akt
pathway leads to increased GLUT1, LDH-A and PFKFB3 expression. Taken from
Smith et al. (2015).
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to sorbitol which is then converted to fructose (Tang et al., 2012). Polyol pathway
activity is required for physiological angiogenesis by influencing VEGFR2-regulated
signal transduction (Tammali et al., 2011). Inactivation of aldose reductase inhibits
PI3K/Akt and nuclear factor κ of activated B cells (NF-κB) signal transduction 
pathways and down-regulates VEGFR2 levels. Furthermore, downstream VEGF-A-
stimulated synthesis and secretion of intercellular adhesion molecule (ICAM), VCAM,
interleukin-6, MMP2 and MMP9 is blocked upon aldose reductase depletion (Tammali
et al., 2011).
1.5.4. VEGF and fatty acid oxidation (FAO)
Endothelial cells can utilise fatty acid oxidation (FAO) in the absence of glucose to
compensate for reduced ATP synthesis (Dagher et al., 2001). VEGF-A-activated
VEGFR2 targets fatty acid-binding protein 4 (FABP4) to promote endothelial cell
proliferation (Elmasri et al., 2009). VEGF-B stimulates expression of fatty acid
transporter proteins 3 and 4 (FATP3, FATP4) in the endothelium. This increases lipid
uptake and transport to tissues such as the heart and skeletal muscle (Hagberg et al.,
2010). VEGF-B also activates AMP-activated protein kinase (AMPK) which is required
for aortic endothelial cell proliferation independently of FAO (Reihill et al., 2011).
Neutralising antibodies to VEGF-B restore insulin sensitivity and glucose tolerance by
decreasing endothelial-to-tissue lipid transport, indicating that ectopic lipid deposition
contributes to type 2 diabetes mellitus (T2DM) disease progression (Carmeliet et al.,
2012, Hagberg et al., 2010). Expression of fatty acid synthase (FAS), which catalyses
de novo lipid synthesis, is highly upregulated in cancer cells. FAS activity provides
additional lipid supply to proliferating cells for membrane biogenesis, conferring a
survival and growth advantage (Santos and Schulze, 2012). In contrast, FAS expression
is low or undetectable in healthy adult tissues given that diet is the primary lipid source.
In the absence of FAS, reduced post-translational palmitoylation of VEGFR2 and
eNOS decreases VEGFR2 cell surface levels and downstream eNOS activation,
resulting in reduced angiogenesis (Wei et al., 2011).
1.5.5. VEGF and cholesterol efflux
Endothelial cholesterol efflux is essential for angiogenesis (Fang et al., 2013). ATP-
binding cassette transporters regulate cellular cholesterol efflux onto apolipoprotein A-1
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(ApoA-1) and apoA-1-containing high-density lipoprotein particles which unload
excess cholesterol in the liver for metabolism or excretion via the bile pathway.
Cholesterol efflux depletes plasma membrane lipid rafts resulting in negative regulatory
effects on VEGFR2 activity and thus on VEGF-A-stimulated angiogenesis (Fang et al.,
2013). In contrast, apolipoprotein B (ApoB) upregulates VEGFR1 levels which impairs
angiogenesis by reducing VEGFR2-VEGF-A binding (Avraham-Davidi et al., 2012).
1.6. VEGF and disease
1.6.1. VEGF and cancer
VEGF expression and activity is associated with many pathological conditions. Lactate
inhibition of the oxygen-sensing PHD2 promotes activation of HIF-1α which in turn 
upregulates VEGF expression in cancer cells (De Saedeleer et al., 2012). Additionally,
lactate activates VEGFR2 in a ligand-independent manner (Ruan and Kazlauskas,
2013). Germline mutations in the VHL tumour suppressor gene result in Von-Hippel
Lindau (VHL) disease, an autosomal dominant inherited disorder which predisposes to
a variety of tumours including ocular hemangioblastomas. HIF-1 and -2 play a
significant role in angiogenesis, cellular growth, proliferation and metabolism in
response to tissue hypoxia. When VHL is inactivated HIF-1 and -2 induce a hypoxic
gene response that includes upregulation of VEGF-A (Maher et al., 2011). The
development and advancement of vascular tumours characteristically found in VHL
patients is driven by the constitutive upregulation of HIF activity (Maher et al., 2011).
High cellular VEGF levels have been associated with advanced disease stages, drug
resistance and poor prognosis in several leukaemias, myelomas and lymphomas (Paesler
et al., 2012). Many lymphomas and leukaemias secrete a mixture of VEGFs and express
at least one VEGFR (Paesler et al., 2012). Leukaemia-derived VEGF-A promotes
normal endothelial cells to secrete pro-leukaemic factors such as granulocyte-
macrophage colony-stimulating factor (GM-CSF), thus highlighting the existence of a
positive feedback loop. This phenomenon strongly increases the likelihood of disease
relapse (Trujillo et al., 2012). Interestingly, VEGFR2 is constitutively phosphorylated in
acute myeloid leukaemia (AML) cells (Santos and Dias, 2004). Elevated VEGF-A
levels are also associated with acute lymphocytic leukaemia (ALL) (Koomagi et al.,
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2001). VEGF-A expression promotes ALL cell survival and growth in an autocrine
manner (Aguayo et al., 2003). VEGF-A-stimulated phosphorylation of B-cell
lymphoma-2 (Bcl-2) and diminished cytochrome c release blocks ALL cell apoptosis
(Wang et al., 2005).
1.6.2. VEGF and diabetes mellitus
Abnormal VEGF-A levels are strongly associated with endothelial dysfunction in
multiple cardiovascular risk factors including T2DM, hyperglycaemia (Feener and
King, 1997), hypertension, hypercholesterolaemia (Zeiher et al., 1993) and smoking
(Heitzer et al., 2001). Likewise, VEGF-A levels are perturbed in coronary arterial
disease (Heitzer et al., 2001) and heart failure (Hornig et al., 1998). VEGF-A resistance
is associated with increased circulating VEGF-A levels in metabolic syndrome.
Moreover, insulin-resistant states such as T2DM correlate with VEGF-A resistance
(Waltenberger, 2009). Monocytes from DM patients exhibit defects in VEGF-A-
stimulated and VEGFR1-dependent signalling pathways, causing reduced chemotaxis
(Tchaikovski et al., 2009, Tchaikovski et al., 2008). Other secondary effects of the
chronic DM disease state and examples of pre-activated intracellular pathways include
reactive oxygen species (ROS) production, PTP inhibition, activation and upregulation
of receptor for advanced glycation end-products (RAGE) and hyperglycaemia-induced
production of advanced glycation end-products (AGE) (Waltenberger, 2009) (Fig.
1.10). This wide spectrum of biochemical dysfunction leads to constitutive activation of
downstream protein kinases such as ERK1/2, p38 MAPK and Akt, thus desensitising
VEGF-activated signal transduction pathways (Waltenberger, 2009) (Fig. 1.10). During
hyperglycaemia, ROS stimulates ligand-independent VEGFR2 phosphorylation and
activation within the biosynthetic secretory pathway leading to depleted plasma
membrane levels and a deficient endothelial cell response to VEGF-A (Warren et al.,
2014) (Fig. 1.10). Chronic DM exemplifies an angiogenic paradox: it correlates with
both enhanced (diabetic retinopathy and chronic wounds) and reduced (arteriogenesis
and impaired collateral vessel growth) angiogenesis (Simons, 2005a, Werner et al.,
2003). VEGF levels are elevated (Sasso et al., 2005) whilst angiogenic responses are
reduced (VEGF resistance) (Tchaikovski et al., 2009). It is possible that VEGF
resistance diminishes VEGF responses during short-term stimulation of angiogenesis,
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whilst long-term stimulation causes a net increase in neovascularisation due to
prolonged exposure to VEGF, despite a weaker response (Waltenberger, 2009).
Increased GLUT1 expression precedes elevated VEGF levels in mesangial cells (Wang
et al., 2010a). Conversely, treatment of these cells with VEGF promotes increased
GLUT1 levels and glucose uptake, indicating that VEGF is a potent stimulus of GLUT1
synthesis and creating a positive feedback cycle. This bidirectional stimulation between
GLUT1 and VEGF indicates a pro-sclerotic role for VEGF in diabetic nephropathy
(Heilig et al., 2013). Diabetic glomerulosclerosis is characterised by mesangial
expansion, accumulation of ECM proteins and tubulointerstitial fibrosis. Disease
development is accelerated by hyperglycaemia. Increased cellular glucose availability
drives the expression of proteins associated with diabetic nephropathy including ANG-2
and VEGF (Chiarelli et al., 2009). Similarly, diabetes is induced in NO knockout mice
which show elevated VEGF expression and develop diabetic glomerulosclerosis. Under
normal circumstances, VEGF triggers NO release. Endothelial cell-derived NO acts
with VEGF as a trophic factor for the endothelium and prevents smooth muscle and
endothelial cell proliferation and macrophage infiltration (Nakagawa, 2007). A model
for diabetic glomerulosclerosis is proposed in which VEGF and NO ‘uncoupling’
promotes diabetic nephropathy (Nakagawa, 2007). Importantly, a VEGF neutralising
antibody prevents diabetes-induced increase in glomerular volume (Flyvbjerg et al.,
2002).
1.6.3. VEGF and hypercholesterolaemia
Stimulation of angiogenesis is desirable under conditions of hypoxia and ischaemia.
Hypercholesterolaemia provides a link between angiogenesis and ischaemic vascular
disease (Jin et al., 2013). Increased VEGFR2 degradation in endothelial cells exposed to
low-density lipoprotein (LDL) attenuates VEGF-induced signal transduction through
Akt and ERK1/2. Decreased VEGFR1 and VEGFR2 levels following LDL exposure
inhibits endothelial cell migration, proliferation and tubulogenesis (Jin et al., 2013).
Thus, hypercholesterolaemia compromises pro-angiogenic responses to VEGF in
ischaemic vascular disease (Jin et al., 2013).
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Figure 1.10. Diabetes-associated ROS attenuates VEGF-A-stimulated
endothelial cell responses. During hyperglycaemia, ROS stimulates ligand-
independent VEGFR2 phosphorylation and activation within the biosynthetic
secretory pathway leading to depleted plasma membrane levels and a deficient
response to VEGF-A. Secondary effects of the chronic DM disease state and
examples of pre-activated intracellular pathways include ROS production, PTP
inhibition, activation and upregulation of RAGE and hyperglycaemia-induced
production of AGE. This wide spectrum of biochemical dysfunction leads to
constitutive activation of downstream ERK1/2, p38 MAPK and Akt, thus
desensitising VEGF-stimulated signal transduction pathways.
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Adverse effects of cholesterol metabolism and its oxidised products are associated with
expression of angiogenic proteins, such as VEGF, in retinal pigment epithelial cells. In
age-related macular degeneration (AMD), deposition of 7-ketocholesterol and oxidised
cholesterol increases expression of VEGF and induces a pro-angiogenic environment
for neovascularisation (Sharma et al., 2014). Impaired cholesterol transport and
accumulation in macrophages further increases the number of cells that secrete pro-
angiogenic VEGF, thus accelerating the disease phenotype (Sharma et al., 2014).
1.7. VEGF as a drug target
Pathological angiogenesis is associated with multiple diseases. Strategies to promote
revascularisation of ischaemic tissues or to inhibit angiogenesis in cancer, ocular, skin
or joint disorders are potential therapeutic targets. Clinical trials testing the pro-
angiogenic capability of VEGF have produced suboptimal results (Simons, 2005b).
Angiogenic complexity underlies the failure of these trials to stimulate growth of
functional vessels. Angiogenesis does not cause malignancy but promotes tumour
growth and metastasis. Unlike tumour cells, endothelial cells are genomically stable and
therefore considered ideal therapeutic targets that would not develop resistance to anti-
angiogenic therapy (Carmeliet, 2005).
1.7.1. Anti-VEGF drugs
Anti-angiogenic therapy has been targeted towards members of the VEGF family and
associated VEGFRs due to their essential role in angiogenesis (Tugues et al., 2011).
Bevacizumab (Avastin) is a humanised monoclonal antibody to VEGF-A approved to
treat renal cell carcinoma (RCC), metastatic colorectal cancer, metastatic breast cancer,
advanced non-squamous, non-small cell lung cancer and recurrent multiforme
glioblastoma (Tarallo and De Falco, 2015). Aflibercept (Zaltrap, VEGF Trap-Eye) is a
recombinant fusion protein consisting of the extracellular VEGF-A-binding domains of
VEGFR1 and VEGFR2 fused to an Fc domain (Fig. 1.11). This new anti-angiogenic
molecule acts as a decoy receptor to block VEGF-A, VEGF-B and PlGF activity and
has been approved for the treatment of metastatic RCC (Ciombor et al., 2013).
High levels of VEGF-A in ocular fluid are associated with AMD, diabetes and
ischaemic central retinal vein occlusion (Sennino and McDonald, 2012). Current
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treatments that directly target circulating VEGF-A in diseases such as wet AMD include
Pegaptanib (Macugen), a pegylated 28-base ribonucleic aptamer that selectively binds
the herparin-binding domain of VEGF-A165 (Fig. 1.11). Ranibizumab (Lucentis) is a
recombinant pan-VEGF-A antibody fragment derived from Bevacizumab also approved
to treat AMD (Fig. 1.11). Ranibizumab is smaller than Bevacizumab to deliver more
effective retinal penetration (Sennino and McDonald, 2012). The use of anti-VEGF
drugs as monotherapy for treatment of AMD has proved successful with increased
visual acuity experienced by 30% of patients (Sennino and McDonald, 2012).
1.7.2. Tyrosine kinase inhibitors (TKIs)
Tyrosine kinase inhibitors (TKIs) constitute another class of anti-angiogenic drugs
approved for cancer therapy. These inhibitors disrupt VEGFR1 and/or VEGFR2 signal
transduction and often interfere with the activity of other receptor tyrosine kinases such
as fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor
(PDGFR) (Mendel et al., 2003, Hasinoff and Patel, 2010). The most successful VEGF-
related therapies which provide the greatest improvement in progression-free survival in
cancer patients are Sorafenib and Sunitinib (Jain et al., 2006) (Fig. 1.11). Sorafenib
(Nexavar) is a TKI approved for the treatment of metastatic RCC and hepatocellular
carcinoma (Fontanella et al., 2014). The anti-cancer drug Sunitinib (Sutent) is a member
of the indolinone family of compounds and is approved to treat RCC and
gastrointestinal stromal tumours (Fontanella et al., 2014). Although providing short-
term benefits, the activity of these drugs is limited by introduction of compensatory
pathways or resistance mechanisms (Hasinoff and Patel, 2010, Zhang et al., 2011). For
example, VEGF-A inhibition increases hypoxia which in turn upregulates pro-
angiogenic factors such as FGF and PlGF, promoting recruitment of pro-angiogenic
bone marrow-derived cells to induce tumour revascularisation (Sennino and McDonald,
2012). Maintaining the correct balance of inhibition between a select group of RTKs
including VEGFRs and FGFRs thus appears clinically relevant (Hasinoff and Patel,
2010, Zhang et al., 2011). One strategy to combat drug resistance to VEGF inhibitors is
development of multi-targeted TKIs. For example, Nintedanib (Vargatef) is a small
molecule multi-target TKI of FGFR, PDGFR and VEGFR used in the treatment of non-
small-cell lung cancer (Caglevic et al., 2015). JK-31 is a multi-kinase inhibitor that
targets VEGFR2 and cyclin-dependent kinase 1 (CDK1) to simultaneously inhibit pro-
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angiogenic signal transduction and cell cycle progression in endothelial cells (Latham et
al., 2014) (Fig. 1.11). Another multi-targeted tyrosine kinase inhibitor JK-P3 inhibits
the intrinsic catalytic activity of VEGFR2, FGFR1 and FGFR3 (Latham et al., 2012).
The ability of multi-targeted TKIs to simultaneously inhibit multiple signalling
pathways enables them to overcome redundant angiogenic factors considered to be a
key mechanism underlying resistance to anti-VEGF therapy (Huang and Carbone,
2015). Emerging anti-angiogenic agents that selectively inhibit VEGFR2 activity
include Ramucirumab, a fully humanised monoclonal antibody targeting the
extracellular domain of VEGFR2, and Apatinib, a small molecule inhibitor of the
intracellular domain (Fontanella et al., 2014) (Fig. 1.11). Advancement in anti-
angiogenic therapies is needed to prolong progression-free survival of responsive
patients by years rather than months with most only effective in combination with
chemotherapy (Sennino and McDonald, 2012).
Current VEGF therapies target cancer or AMD however future research directions are
emerging for VEGF-targeted therapeutics. VEGF plays a crucial protective role in the
nervous system. Reduced levels of VEGF and other growth factors are associated with
neurodegenerative diseases. Additionally, VEGF has been identified as a causative
factor in several motor neuron degenerative diseases and epilepsy (Morin-Brureau et al.,
2012). VEGF is of particular interest due to its role in cross-talk between the nervous
and vascular systems.
1.8. VEGFR trafficking
1.8.1 Ubiquitin-linked protein modification
A key feature of cellular regulation is the reversible modification of protein substrates to
influence protein function e.g. enzymatic activity, multiprotein assemblies, etc. One
such modification is protein ubiquitination (Herrmann et al., 2007). In humans,
ubiquitin is a 76 amino acid highly conserved polypeptide encoded by 4 genes. The
UbB and UbC genes consist of head to tail repeats of 3 or 9 ubiquitin units, respectively.
UBA52 and RPS27A/UBA80 encode ribosomal subunits which fuse to the C-terminus of
a single copy of ubiquitin (Clague et al., 2015). Polypeptides comprising ubiquitin
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Figure 1.11. Therapeutic inhibitors of VEGFR2 signal transduction.
Schematic depicting target sites of anti-angiogenic agents that inhibit VEGFR2-
mediated signal transduction. VEGF-Axxx; non-specific VEGF-A isoform.
Adapted from Smith et al. (2015)
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repeats are rapidly processed by peptidases belonging to the de-ubiquitinase (DUB)
family of enzymes to generate free ubiquitin (Monia et al., 1989). Early work carried
out by Varshavsky and colleagues using murine ts85 cells with temperature-sensitive
mutations in the UBA1 gene showed reduced ubiquitin conjugation, decreased protein
turnover and cell cycle arrest at non-permissive temperature, demonstrating that
ubiquitin mediates proteolysis and lysosomal degradation of the vast majority of short-
lived proteins (Ciechanover et al., 1984, Zacksenhaus and Sheinin, 1990, Ciechanover,
2006). It has since been discovered that ubiquitination also regulates intracellular
signalling and trafficking pathways. Specific ubiquitination of target substrates leads to
proteolysis and/or intracellular redistribution, thus affecting cellular outputs. Many
RTKs undergo ligand-dependent ubiquitination including epidermal growth factor
receptor (EGFR), PDGFR, c-Met, VEGFR1 and VEGFR2 (Carter et al., 2004, Petrelli
et al., 2002, Soubeyran et al., 2002). Ubiquitin conjugation to target proteins involves
three sequential steps of an E1-E2-E3 cascade. The ratio of E1:E2:E3 in terms of gene
number is 2:35:>300 although this is not reflected in terms of total copy number which
is estimated to be 1:3:2 in HeLa cells (Clague 2015).
E1 enzymes consist of 3 domains and initiate the activation and conjugation of a
number of ubiquitin-like proteins (UBLs), including ubiquitin, small ubiquitin modifier
(SUMO) and NEDD8 to target proteins. An adenylation domain of two ThiF-homology
motifs binds ATP and the appropriate UBL (Duda et al., 2005). A catalytic cysteine
domain (CCD) is the acyl carrier for ubiquitin, and the C-terminal ubiquitin-fold
domain (Ufd) recruits specific E2s (Walden et al., 2003).
It was originally thought that UBA1 was the sole E1 enzyme in humans, as is the case
in the yeast Saccharomyces cerevisiae where a single E1 mediates ubiquitin
presentation to all E2 enzymes (Dohmen et al., 1995). Subsequent studies have
identified another E1 enzyme which activates ubiquitin (UBA6) and 6 E1 enzymes that
activate ubiquitin-like proteins (UBA2, UBA3, UBA5, UBA7, ATG7 and NAE1). E1
ubiquitin activation is initiated by Mg2+-ATP binding to the carboxyl-terminal glycine
of ubiquitin. Formation of an ubiquitin adenylate intermediate facilitates ubiquitin
donation to a cysteine residue in the E1 active site and formation of a thiol ester bond
(Fig. 1.12). UBA1 catalyses ATP-AMP exchange, from ATP binding to thiol ester
formation, at a maximum turnover number of 1-2 s-1 making it an efficient enzyme
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(Haas and Rose, 1982). However, the catalytic rate (kcat) of substrate ubiquitination is
reported as 10-100 fold slower (Mastrandrea et al., 1999). High E1 efficiency accounts
for the ability of 8 human E1s to activate ubiquitin or ubiquitin-like proteins for the
600-700 downstream E3 ligases (Li et al., 2008a).
Each E1 enzyme carries two molecules of activated ubiquitin, one as an adenylate and
the other as a thiol ester. The thiol-linked ubiquitin is transferred down the conjugation
cascade to an active site cysteine in one of 35 E2 (ubiquitin-conjugating) enzymes
(Pickart, 2001). An additional 4 E2s receive ubiquitin-like proteins (Clague et al., 2015,
Gao et al., 2013). Some E2s are capable of transferring ubiquitin directly to substrate.
Alternatively, an E3 ubiquitin ligase forms a complex with the target substrate and
catalyses the transfer of ubiquitin from the E2 to the є-amino group of a lysine residue 
on the target protein (Pickart, 2001) (Fig. 1.12). The HECT (homologous to E6-AP (E6-
associated protein) C-terminus) family and the RING between RING (RBR) families of
E3 ligases contain a conserved active site cysteine which accepts ubiquitin from the
cognate E2 prior to final substrate transfer (Hochstrasser, 2006). There are 28 HECT
E3s and 14 RBR E3s in mammalian cells. The major pool of E3s belongs to the
RING/U-box families which do not receive ubiquitin but function as adaptor proteins to
ensure proximity of the E2 enzyme and substrate protein (Clague et al., 2015).
The ubiquitin polypeptide contains seven lysines (K6, K11, K27, K29, K33, K48, K63)
which can be further conjugated to other ubiquitin monomers to form branched
polyubiquitin chains. In mammalian cells, the majority of ubiquitin is conjugated to
target proteins as a single unit (monoubiquitin). Monoubiquitination of specific lysine
residues in RTKs regulates endocytosis and endosome-lysosome trafficking (Haglund et
al., 2003b). Linear ubiquitin chains occur when the C-terminal glycine of one ubiquitin
is conjugated to the N-terminal methionine of another (M1-linked) (Walczak et al.,
2012). Monoubiquitinated Lys 48 (K48) residues can undergo chain elongation by
addition of a pre-formed polyubiquitin oligomer (K48-polyUb); this is associated with
targeting the modified protein for degradation (Pickart, 2001). In contrast, Lys63 (K63)-
polyUb chains mediate substrate targeting for trafficking through the endosome-
lysosome system (Adhikari and Chen, 2009). VEGFR2 undergoes both mono- and
polyubiquitination (Meyer et al., 2011).
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Figure 1.12. The E1-E2-E3 ubiquitin conjugation system. Addition of
ubiquitin to a substrate protein is a multi-step process involving a cascade of 3
enzymes; the E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating and
the E3 ligase. Adapted from Woelk et al. (2007).
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The specificity of protein ubiquitination likely depends upon chaperones and scaffold
proteins that promote substrate recognition linked to the sequestration of components
within the ubiquitin network. Sequential complex assembly based on multiple ubiquitin-
ubiquitin-binding domain (UBD) interactions enables the propagation of intracellular
signalling events which control the dynamics of receptor trafficking (Grabbe et al.,
2011). Ubiquitin signals are recognised by the UBDs of ubiquitin receptors which form
non-covalent transient electrostatic interactions with either the ubiquitin moiety or with
the linkage region between ubiquitin chains (Ikeda et al., 2010). Monoubiquitination of
RTKs stimulates interaction with enzymes or membrane-bound factors which recognise
such modifications. Ubiquitin-binding proteins specify the type of ubiquitin
modification via their individual UBD; the ubiquitin-interacting motif (UIM) (Polo et
al., 2002), ubiquitin-conjugating enzyme-like (UBC)/ubiquitin E2 variant (UEV)
(Ponting et al., 1997), ubiquitin-associated (UBA) (Hofmann and Bucher, 1996) and
Cue-1-homologous (CUE) (Shih et al., 2003) domain. Many UIMs promote
ubiquitination of the proteins that contain them and are frequently found within
regulatory proteins which recognise ubiquitinated cargo and regulate membrane
trafficking pathways (Bilodeau et al., 2002, Polo et al., 2002, Shih et al., 2003).
DUBs consist of a superfamily of enzymes that can be subdivided into five distinct
DUB subsets with differing specificities for the isopeptide bond that links ubiquitin
chains. These enzymes play a distinct but crucial role in RTK trafficking and recycling
(Clague et al., 2012). Ubiquitin-specific proteases (USPs), ubiquitin C-terminal
hydrolases (UCHs), Josephins and ovarian tumour proteases (OTUs) are cysteine-
dependent proteases. The fifth family, Jab1/MPN domain-associated
metalloisopeptidases (JAMM/MPN+), are zinc-dependent metalloenzymes (Clague et
al., 2015). Although it is known that VEGFR2 is recycled from endosomes back to the
plasma membrane, it is unknown which DUB prevents its lysosomal degradation. Two
DUBs, associated molecule with the Src homology 3 (SH3) domain of STAM (AMSH)
and ubiquitin-specific protease Y (USP8), are known to play a role in EGFR recycling
and trafficking (McCullough et al., 2004, Mizuno et al., 2005).
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1.8.2. Role of ESCRTs in endosomal sorting and trafficking
Endosomal sorting ensures that only ubiquitinated RTK reaches the lysosome for
terminal degradation with the remaining receptor recycled from early endosomes back
to the plasma membrane. Four individual endosomal sorting complex required for
transport (ESCRT) complexes (ESCRT0, I, II and III) are central components of the
multivesicular body (MVB) biogenesis machinery. Endocytic proteins and ubiquitin
receptors such as hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs),
signal transducing adaptor molecule (STAM) and epidermal growth factor receptor
substrate 15 (Eps15) provide the initial engagement point between ubiquitinated
transmembrane receptor and ESCRT machinery (Fig. 1.13). This enables sorting of
membrane-linked cargo into MVBs by forming a multivalent ubiquitin binding complex
for trafficking to lysosomes (Bilodeau et al., 2002, de Melker et al., 2001). The adaptor
protein, Eps15, is recruited to ubiquitinated RTKs and, via its UIM, facilitates transport
along the endocytic pathway (Polo et al., 2002). Hrs endosomal recruitment requires
heterodimerisation with its binding partner STAM to form the ESCRT-0 complex; this
involves direct interaction with clathrin at regions concentrated in a ‘bilayered’ clathrin
coat (Raiborg et al., 2002). Hrs binds to early endosomal membranes by interaction of
its FYVE (Fab1, YOTB, Vac1, EEA1) domain with phosphatidylinositol-3-phosphate.
ESCRT-0 can bind several ubiquitin moieties at once through the UIM of STAM and
the di-ubiquitin motif (DIUM) of Hrs (Grabbe et al., 2011). Hrs recruits ESCRT-I to
endosomes via direct interaction with tumour susceptibility gene 101 (TSG101),
facilitating forward movement through the endosome-lysosome system (Urbe et al.,
2003).
STAM is constitutively recruited to early endosomes as part of the ESCRT-0 complex
and interacts with endosomal DUBs, AMSH and USP8, via the SH3 domain of STAM
and their shared STAM binding motif; PX(V/I)(D/N)RXXXKP (Tanaka, 1999, Kato et
al., 2000). De-ubiquitination facilitates receptor recycling and is essential for
maintaining the free ubiquitin pool upon which receptor trafficking is dependent.
Similar to the co-ordinated but opposing effects of kinase and phosphatase activity,
ubiquitination is kept in balance by DUB activity (Wing, 2003). USP8 is a cysteine
protease and member of the USP family of DUB enzymes. The zinc-dependent
ubiquitin isopeptidase, AMSH (McCullough et al., 2004), contains a JAMM motif and
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is a member of the isopeptidase family of DUBs (Hochstrasser, 2002). USP8 and
AMSH catalyse complete breakdown of polyubiquitin into its component monomers,
preferentially generating monoubiquitin (McCullough et al., 2004). In contrast to
AMSH, USP8 is able to process both K48- and K63-linked polyubiquitin chains
(McCullough et al., 2004, Mizuno et al., 2005, Row et al., 2006).
Once internalised cargo has been committed for degradation, conjugated ubiquitin is
recycled and removed by AMSH and USP8 which are recruited to late endosomal
compartments by direct interaction with ESCRT-III (Clague and Urbe, 2006). AMSH
prevents lysosomal degradation and promotes recycling of substrates such as EGFR by
processing K63-linked polyubiquitin chains and is itself ubiquitinated by the E3
ubiquitin ligase, Smurf2. Smurf2-mediated down-regulation of AMSH restricts
recycling following receptor activation to promote a return to quiescence. (McCullough
et al., 2004, Clague and Urbe, 2006, Li and Seth, 2004).
Ubiquitination of Hrs and STAM inhibits their function by masking ubiquitin-binding
sites and interfering with binding to ubiquitinated cargo (Hoeller et al., 2006).
Following acute EGF stimulation, USP8 translocates to endosomes where it protects
STAM from proteasomal degradation (Mizuno et al., 2005). Hrs and STAM direct
ubiquitinated EGFR towards the lysosome for degradation (Clague and Urbe, 2001) and
show increased co-distribution with VEGFR2 at early endosomes upon VEGF-A
stimulation (Ewan et al., 2006). ESCRT-0 is an integral complex for endosomal sorting
and blocking its activity by Hrs depletion stimulates proteasome-mediated VEGFR2
proteolysis (Bruns et al., 2010).
1.8.3. VEGFR trafficking and localisation
VEGFR1 is a plasma membrane resident RTK however ~80% is located within a stable
pool in the Golgi apparatus along the secretory pathway (Mittar et al., 2009). VEGF-A-
stimulated activation of plasma membrane VEGFR2 is linked to cytosolic Ca2+ ion flux,
causing transient redistribution of VEGFR1 to the plasma membrane via a trans-Golgi
network-to-plasma membrane route. This negative feedback model regulates VEGF-A-
mediated cellular responses (Mittar et al., 2009). VEGFR1 levels are relatively
insensitive to VEGF-A stimulation, unlike VEGFR2 (Ewan et al., 2006, Mittar et al.,
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2009). Activated VEGFR1 is internalised through clathrin-mediated endocytosis by
ternary complex formation with Cas-Br-M murine ecotropic retroviral transforming
sequence homologue E3 ubiquitin protein ligase (Cbl) (Duval et al., 2003) and adaptor
protein CD2-associated protein (CD2AP), followed by association with clathrin
(Kobayashi et al., 2004).
VEGFR2 is localised to the Golgi, plasma membrane, early endosomes and perinuclear
caveolae in non-stimulated endothelial cells (Bruns et al., 2009, Jopling et al., 2011,
Manickam et al., 2011, Bhattacharya et al., 2005). Resting VEGFR2 is distributed
between the plasma membrane (~40%) and an internal early endosomal pool (~60%),
with constitutive recycling between the two compartments (Gampel et al., 2006, Jopling
et al., 2011, Jopling et al., 2014). Recent work has revealed requirement for syntaxin 6
and the kinesin motor protein, kinesin family member 13B (KIF13B) in biosynthetic
VEGFR2 trafficking through the Golgi apparatus en route to the plasma membrane
(Manickam et al., 2011, Yamada et al., 2014). Resting VEGFR2 undergoes a relatively
fast rate of ligand-independent, constitutive internalisation which does not require
tyrosine kinase activity (Gampel et al., 2006, Lampugnani et al., 2006, Jopling et al.,
2011). However, phosphorylation of residues Y1054 and Y1059 is required for clathrin-
dependent internalisation of activated VEGFR2 (Dougher and Terman, 1999).
Activated VEGFR2 undergoes endocytosis and targeting for recycling or degradation
(Miaczynska et al., 2004) (Fig. 1.13). VEGF-A stimulation promotes ~40-60%
degradation of plasma membrane and endosomal VEGFR2 pools (Gampel et al., 2006).
VEGFR2 redistributes from early to late endosomes depending on VEGF-A
concentration and duration of stimulation; nonetheless, a significant early endosomal
pool of VEGFR2 is maintained (Gampel et al., 2006).
1.8.4. Receptor tyrosine kinase internalisation
Internalisation of resting VEGFR2 is clathrin-dependent (Lampugnani et al., 2006,
Bruns et al., 2010). Upon VEGF-A stimulation, exit of VEGFR2 from lipid
rafts/caveolae facilitates clathrin-dependent endocytosis (Jopling et al., 2011). Limited
EGF stimulation results in almost exclusive clathrin-dependent internalisation of non-
ubiquitinated EGFR and promotes onwards recycling (Fig. 1.14). Higher concentrations
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of EGF saturate clathrin-dependent endocytosis, causing ubiquitinated EGFR to
preferentially internalise by a clathrin-independent, lipid raft-dependent pathway that
promotes lysosomal degradation (Sigismund et al., 2005, Sigismund et al., 2013) (Fig.
1.14). Similarly, the chosen method of VEGFR2 internalisation could depend upon
receptor fate. Nonetheless, release of receptors from adherens junctions (Lampugnani et
al., 2006) or caveolae (Labrecque et al., 2003) seems to be an indispensable step in
receptor internalisation.
Caveolae consist of lipid raft domains enriched in the scaffold protein, caveolin-1,
sphingolipids and cholesterol. VEGFR2 is enriched in plasma membrane caveolae and
could preferentially internalise via a caveolar pathway when being directed for
degradation (Feng et al., 2000). Activated VEGFR2 exits lipid raft/caveolae fractions
and associates with ADP ribosylation factor 6 (ARF6) and Ras-related C3 botulinum
toxin substrate 1 (RAC1) in focal adhesions, where it interacts with a subpopulation of
Tyr14 phosphorylated caveolin before transport to perinuclear caveosomes via a
clathrin-independent pathway (Labrecque et al., 2003). Clathrin-dependent versus
clathrin-independent internalisation of VEGFR1 and VEGFR2 could imply that receptor
homodimers are segregated into discrete regions of the plasma membrane and are
internalised by two independent pathways (Mukherjee et al., 2006). Other reports have
found no evidence for caveolin-dependent VEGFR2 internalisation (Lampugnani et al.,
2006).
Ubiquitination and/or phosphorylation of RTKs provides a sorting signal which adaptor
proteins identify to initiate clathrin-dependent endocytosis (Heilker et al., 1999).
Adaptor protein complexes select cargo for inclusion into vesicles, recruit soluble
clathrin and initiate clathrin polymerisation. Clathrin-coated pits (CCPs) are formed
when clathrin polymerisation promotes membrane scission. Detachment from the
plasma membrane is controlled by the GTPase, dynamin-2 (Huang et al., 2003, van
Delft et al., 1997). The adaptor protein-2 (AP-2) complex is heterotetrameric and
mediates clathrin-dependent EGFR endocytosis by binding to dileucine/tyrosine-based
cytoplasmic sorting motifs (Huang et al., 2003). AP-2 independent mechanisms of
EGFR internalisation have been identified including a pathway involving the SH2
domain-containing protein, Grb2 (Jiang et al., 2003).
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EGFR ubiquitination is associated with receptor internalisation, particularly in the
presence of high ligand concentrations where UIM-containing adaptor proteins recruit
ubiquitinated receptors to CCPs (Sigismund et al., 2005). Internalisation of
Tropomyosin receptor kinase A (TrkA) receptor upon nerve growth factor (NGF)
binding is also dependent on ubiquitination. Conflicting studies suggest that
ubiquitination is dispensable for EGFR internalisation (Huang et al., 2007) whilst G-
protein-coupled receptors (GPCRs) internalise through an ubiquitin-independent,
clathrin-dependent pathway. (Tanowitz and Von Zastrow, 2002). Additionally, FGFR1
and TGF-β receptor undergo constitutive internalisation independently of tyrosine 
kinase activity (Reilly et al., 2004).
1.8.5. The role of Rab GTPases
Ubiquitinated VEGFR2 travels through the endosome-lysosome system via a series of
targeted fusion steps regulated by decreasing vesicular pH. Following clathrin-
dependent endocytosis, the small Rab GTPase family members, Rab5a and Rab7a, have
regulatory roles in VEGFR2 trafficking and signal transduction in early and late
endosomes respectively (Jopling et al., 2009, Rodman and Wandinger-Ness, 2000) (Fig.
1.13). Rab proteins are members of the Ras superfamily of small GTPases localised to
distinct intracellular organelles and perform vital roles in membrane trafficking
(Stenmark and Olkkonen, 2001). As molecular switches, Rab GTPases cycle between
an inactive GDP-bound state and an active GTP-bound state (Grosshans 2006). Guanine
nucleotide exchange factors (GEFs) promote GTP binding whilst GTPase-activating
proteins (GAPs) increase GTP to GDP hydrolysis to regulate nucleotide exchange
(Mohrmann and van der Sluijs, 1999). Active Rab proteins interact with multiple
effector proteins to co-ordinate membrane trafficking through the endocytic pathway
(Jordens et al., 2005). Rab localisation within the endosomal membrane is restricted by
recruitment of specific effector proteins (de Renzis et al., 2002). Rab proteins fulfil their
essential role in membrane transport through interaction with the soluble N-
ethylmaleimide-sensitive attachment protein receptors (SNAREs), recruitment of motor
proteins and vesicle tethering and fusion (Grosshans et al., 2006, Woodman, 2000).
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Figure 1.13. VEGFR2 trafficking through the endosome-lysosome system.
Activated VEGFR2 undergoes clathrin-dependent endocytosis and delivery to
ESCRT-0-positive early endosomes. This endosomal VEGFR2 is recycled back to
the plasma membrane or trafficked to late endosomes and multivesicular bodies
(MVBs) for terminal lysosomal degradation.
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1.8.6. Endosome-linked signal transduction
Following VEGF-A stimulation, phosphorylated and ubiquitinated VEGFR2 is
transported to early endosomes after recognition by the ubiquitin-linked receptor
complex, ESCRT-0 (Grabbe et al., 2011). Increasing evidence has suggested a link
between RTK trafficking and signalling from early endosomes. Early endosomal
localisation of VEGFR2 is essential for optimal activation of Akt and ERK1/2 signal
transduction pathways (Lanahan et al., 2010, Wang et al., 2010b). In contrast, PLCγ1 
and p38 MAPK signalling is linked to cell surface VEGFR2 localisation (Lampugnani
et al., 2006, Chen et al., 2010, Sawamiphak et al., 2010). The rate of ligand-induced
RTK internalisation is often higher than the rate of lysosomal degradation, resulting in
prolonged localisation of signalling receptors in early endosomes (Sorkin and Von
Zastrow, 2002). Co-localisation of signalling adaptor proteins Grb2, Shc and Son of
Sevenless (SOS) with endosomal EGFR is linked to continued Ras signal transduction
(Sorkin et al., 2000, Di Guglielmo et al., 1994, Oksvold et al., 2001). The level of
internalisation of a range of plasma membrane receptors dictates MAPK activation,
suggesting the existence of a ‘signalling endosome’ from which activated receptors
continue to co-ordinate downstream signal transduction pathways (von Zastrow and
Sorkin, 2007). Inhibition of EGFR, GPCR and β2-adrenergic receptor (β2AR)
endocytosis supresses activation of MAPK and PI3K signalling (Vieira et al., 1996,
Daaka et al., 1998). Furthermore, internalisation rate influences temporal regulation of
plasma membrane signal transduction, thus the endosome may provide a mechanism to
prolong intracellular signalling (von Zastrow and Sorkin, 2007). Interestingly,
differential growth factor binding also alters signalling output. For example, EGF and
TGF-α dissociate from EGFR at different points along the endocytic pathway as a result 
of individual sensitivities to endosomal pH (Sorkin and Von Zastrow, 2002).
Endosomes also direct spatial regulation of signalling events. The distinct biochemical
composition of endosomal membranes (i.e. enrichment of PtdIns-3-P) enables the
selective recruitment of signalling mediators. This could promote a greater level of
specificity by preventing unwanted interactions between signalling adaptors, many of
which are shared by different pathways (Miaczynska et al., 2004).
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1.8.7. VEGFR2 recycling
A primary role of early endosomes is to sort proteins for lysosomal degradation or
recycling. RTKs can recycle multiple times to the plasma membrane before
commitment to lysosomal degradation. Upon removal of ligand, receptors are free to re-
integrate into the plasma membrane and respond to additional growth factor (Sorkin et
al., 1991). Constitutive RTK recycling is rare; the majority of RTKs are localised to the
plasma membrane and undergo a slow rate of constitutive internalisation (Herbst et al.,
1994). However, TGF-β receptor constitutively recycles via a perinuclear compartment 
with internalisation and recycling rates unaffected by ligand (Mitchell et al., 2004).
Constitutive recycling pathways between the plasma membrane and early endosome
have also been described for several GPCRs, neurokinin-1 receptor (NK1R) and the
cannabinoid receptor, CB1 (Roosterman et al., 2004, Leterrier et al., 2004).
Upregulation of VEGFR2 recycling upon VEGF-A stimulation is evidenced by the
clustering of small VEGFR2-positive vesicles beneath the plasma membrane which do
not stain with clathrin antibodies but associate with microtubules just below the cell
surface (Gampel et al., 2006). Recycling of activated VEGFR2 occurs through Rab4a-
or Rab11a-positive endosomes and follows a short loop (Rab4a) or long loop (Rab11a)
pathway (Ballmer-Hofer et al., 2011, Jopling et al., 2014) (Fig. 1.13). Long loop
recycling occurs in coordination with NRP1 trafficking following transition from
Rab4a-postive vesicles. Rab4a-Rab11a transition is co-ordinated by interaction between
the C-terminal PDZ-binding motif of synectin, myosin VI and the NRP-1 C-terminal
motif, SEA (Ser-Glu-Ala) (Ballmer-Hofer et al., 2011, Cai and Reed, 1999, Wang et al.,
2003, Chittenden et al., 2006). Receptor recycling via Rab11a-positive endosomes is
VEGF-A isoform-dependent. For example, VEGF-A165b is unable to bind NRP1 and
fails to promote Rab11a-dependent recycling (Ballmer-Hofer et al., 2011). In contrast to
VEGFR2, EGFR and PDGFR have very low rates of recycling and are instead targeted
for immediate lysosomal degradation upon ligand stimulation, providing more
permanent signalling down-regulation (Rubin et al., 2005, Marmor and Yarden, 2004).
There is evidence to suggest that VEGFR2 is recycled through a non-conventional
pathway in VEGF-stimulated cells (Gampel et al., 2006). Phosphorylated VEGFR2 can
undergo VE-cadherin-mediated, clathrin-dependent internalisation into endosomal
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compartments where it avoids degradation, retains activation of signalling pathways and
promotes sustained cell migration and proliferation (Lampugnani et al., 2006). VEGFR2
is internalised more rapidly when VE-cadherin is absent or not clustered at intercellular
contacts (Lampugnani et al., 2006). Interaction between VEGFR2 and VE-cadherin
blocks receptor-mediated endocytosis and increases CD148-dependent tyrosine de-
phosphorylation (Lampugnani et al., 2006). Activated VEGFR2 recruits adaptor protein
TSAd which activates downstream tyrosine kinase, c-Src (Sun et al., 2012). Src
activation of PAK2 mediates phosphorylation of serine residues on VE-cadherin at
multiple sites located within the binding region for p120-catenin (Weis et al., 2004,
Adam et al., 2010). Subsequent dissociation of p120-catenin and VE-cadherin exposes a
short endocytic motif (DEE), leading to disruption of adherens junctions and promoting
vascular permeability (Nanes et al., 2012). VEGFR2 and VE-cadherin are sorted at the
plasma membrane, follow independent endocytic pathways and do not co-localise
within endocytic vesicles (Sandilands et al., 2004). c-Src undergoes a novel endocytic
recycling pathway and co-localises with peripheral VEGFR2-positive vesicles in
VEGF-A-stimulated cells (Gampel et al., 2006, Sandilands et al., 2004). Thus, both
VEGFR2 and c-Src are recycled together through the same endocytic recycling
pathway. In quiescent endothelial cells, VEGFR2 is stored in intracellular Rab4/Rab11-
negative vesicles and delivered to the plasma membrane in a c-Src activation-dependant
manner in response to VEGF-A (Gampel et al., 2006); uniquely to other RTKs.
Recycling vesicles are targeted towards the leading edge of the cell in migrating
fibroblasts to enhance response to chemotactic signals and promote forward movement
in response to EGF (Bailly et al., 2000). Similar events may occur to VEGFR2 in
endothelial cells to reinforce guidance of the tip cell towards the pro-angiogenic signal
(Gerhardt et al., 2003).
1.9. VEGFR2 proteolysis
Intrinsic tyrosine kinase activity of VEGFR2 precedes receptor ubiquitination and is
required for VEGF-dependent down-regulation (Ewan et al., 2006, Singh et al., 2005).
K48-linked polyubiquitin chains mediate VEGFR2 degradation whilst K63-linked
polyubiquitin is associated with receptor trafficking (Meyer et al., 2011). Internalised
VEGFR2 continues to signal from multiple cellular compartments until it is committed
for recycling or degradation (Murdaca et al., 2004). VEGFR2 is directed for lysosomal
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degradation after ubiquitination by E3 ligases c-Cbl or β-transducin repeat containing 
E3 ubiquitin protein ligase (β-TrCP1) (Bruns et al., 2010, Meyer et al., 2011, Duval et 
al., 2003).
1.9.1. The role of c-Cbl
VEGF-A stimulates RING domain-containing E3 ubiquitin ligase, c-Cbl, to promote
VEGFR2 ubiquitination, signalling down-regulation and lysosomal degradation (Duval
et al., 2003). However, contradictory studies suggest that c-Cbl activity is dispensable
for VEGFR2 ubiquitination and proteolysis (Singh et al., 2005, Singh et al., 2007).
Alternatively, active c-Cbl could process ubiquitin signals for MVB sorting to indirectly
down-regulate VEGFR2 activity (Le Roy and Wrana, 2005).
One possibility is that c-Cbl targets PLCγ1 for VEGF-A-stimulated ubiquitination 
whilst a different E3 enzyme ubiquitinates VEGFR2 (Singh et al., 2007). PLCγ1 is an 
essential adaptor for c-Cbl binding to pY1054 and pY1057 residues located within the
VEGFR2 tyrosine kinase domain. VEGFR2-mediated activation of c-Cbl suppresses
phosphorylation and promotes ubiquitination of PLCγ1 without effecting its degradation 
(Singh et al., 2007, Meyer et al., 2011). c-Cbl-mediated down-regulation of PLCγ1 
activity may encourage direct recruitment of other binding partners and intracellular
signalling adaptors to shift the balance of signals transmitted from VEGFR2 to favour
its degradation.
EGFR undergoes tyrosine phosphorylation-dependent, c-Cbl-mediated ubiquitination
and degradation (Lu and Hunter, 2009). c-Cbl mono-ubiquitinates tyrosine
phosphorylated EGFR at the plasma membrane and remains associated with the
receptor during its transport through the endocytic pathway prior to lysosomal
degradation (de Melker et al., 2001, Haglund et al., 2003a) (Fig. 1.14). Grb2 binding to
activated EGFR mediates interaction with c-Cbl (Huang and Sorkin, 2005). Limited
EGFR ubiquitination could be sufficient to attach activated EGFR-c-Cbl complexes to
the UIM of Hrs and facilitate downstream regulatory events, including degradation
(Stern et al., 2008, Urbe et al., 2003). At the plasma membrane c-Cbl can ubiquitinate
its own negative regulator, Sprouty2, in a ligand-dependent manner, restoring its ability
to bind EGFR and promote receptor ubiquitination (Rubin et al., 2003). Cbl-interacting
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protein 85 (CIN85) is recruited to endophilin and disabled 2 (DAB2) to promote both
clathrin-dependent and clathrin-independent EGFR endocytosis (Soubeyran et al., 2002,
Kowanetz et al., 2003a, Kowanetz et al., 2003b, Sigismund et al., 2005) (Fig. 1.14).
CIN85 and c-Cbl are mono-ubiquitinated after receptor activation; CIN85 binds
multiple molecules of c-Cbl and the resulting oligomer leads to clustering of activated
EGFR (Kowanetz et al., 2003a). Ubiquitination of c-Cbl provides binding sites for other
UIM-containing endocytic adaptor proteins, such as epsin and Eps15, thus aiding
endosomal recruitment of EGFR (Le Roy and Wrana, 2005). Adaptor protein, Alix,
interacts with c-Cbl via direct binding to CIN85 and endophilins and decreases EGFR
internalisation and ubiquitination in an activation-independent manner (Schmidt et al.,
2004). However, phosphorylation by Src kinases antagonises the inhibitory function of
Alix on receptor endocytosis (Schmidt et al., 2005). Furthermore, modulation of Hrs
ubiquitination, phosphorylation and protein levels by c-Cbl may influence composition
of the endocytic sorting machinery to provoke EGFR lysosomal degradation; regulating
the fate of both Hrs and EGFR at the level of endosomal sorting (Stern et al., 2007).
1.9.2. The role of Nedd4
The HECT domain-containing E3 enzyme, Nedd4, mediates mono-ubiquitination of
ubiquitin receptors such as Hrs, Eps15 and epsins. Hrs is proposed to be involved in
endosomal sorting of activated VEGFR2 and displays increased tyrosine
phosphorylation following VEGF stimulation (Ewan et al., 2006). As an indirect
consequence of the ubiquitination of proteins involved in VEGFR2 endocytosis, Nedd4
has been proposed to play a role in activated VEGFR2 degradation but no role in its
ubiquitination. Decreased levels of VEGFR2 following Nedd4 expression imply a role
for Nedd4 in VEGFR2 down-regulation (Murdaca et al., 2004). Conversely, Nedd4 can
protect EGFR from c-Cbl mediated degradation by ubiquitinating c-Cbl and targeting it
for proteasomal degradation, thereby prolonging EGFR signalling (Katz et al., 2002,
Magnifico et al., 2003). Interestingly, direct association between Grb10 and Nedd4
blocks VEGFR2 degradation (Murdaca et al., 2004). Excess Grb10 could sequester
Nedd4 in the cytoplasm or disrupt the Nedd4-Grb10-Eps15 ternary complex and
thereby restrict receptor endocytosis (Murdaca et al., 2004). Similarly, Sprouty-2
sequesters c-Cbl away from activated EGFR to prevent its degradation (Dikic and
Giordano, 2003, Haglund et al., 2005, Takayama et al., 2005).
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1.9.3. The role of β-TrcP1 
The PEST (rich in Pro, Glu, Ser and Thr residues) motif is commonly found in short-
lived proteins degraded by the ubiquitin system (Rechsteiner and Rogers, 1996).
VEGFR2 has a unique C-terminal PEST domain-like sequence with eight possible
serine/threonine phosphorylation sites which promote VEGFR2 ubiquitination and
down-regulation. Activation of the protein kinase A (PKA) and p38 MAPK pathways
upon Y1175 phosphorylation attenuates VEGFR2 degradation (Meyer et al., 2011). In
contrast, pS1188 and pS1191 epitopes promote VEGFR2 ubiquitination and
degradation. The phosphodegron motif, pS1188, recruits certain F-box-containing E3
ubiquitin ligases to VEGFR2. Some studies on F-box containing E3 ligase, β-TrcP1, 
suggest that it targets VEGFR2 for 26S proteasome-mediated degradation (Meyer et al.,
2011). Other studies have shown that a related E3 enzyme, β-TrcP2, is not required for 
VEGFR2 ubiquitination (Bruns et al., 2010).
1.9.4. The role of PKC
VEGF-A-stimulated ubiquitination or activation of non-classical PKC isozymes
promotes increased trafficking and proteolysis of VEGFR2 in the endosome-lysosome
system (Bruns et al., 2010, Ewan et al., 2006, Jopling et al., 2009, Singh et al., 2005).
VEGF-A may promote degradation of VEGFR2 independently of c-Cbl and PLCγ1 by 
downstream activation of non-classical PKC isozymes (signalling components that
negatively regulate VEGFR2 signal transduction at the receptor level). Direct or indirect
(by another serine/threonine kinase) PKC-mediated S1188 and S1191 phosphorylation
of the VEGFR2 C-terminal domain marks the receptor for PKC-mediated
internalisation and proteasomal degradation (Singh et al., 2005). PKC activation is
associated with metalloproteinase mediated ectodomain ‘shedding’ from
transmembrane receptors to release biologically active extracellular or cytoplasmic
domain fragments. However, inhibition of metalloproteinases and γ-secretases has no 
effect on VEGFR2 proteolysis (Bruns et al., 2010). It is unknown whether PKC-
stimulated internalisation of VEGFR2 follows a caveolae- or clathrin-mediated
pathway. In contrast to VEGFR2, PKC-mediated EGFR phosphorylation inhibits
tyrosine kinase activation to down-regulate receptor signalling rather than stimulate
degradation (Lund et al., 1990).
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1.9.5. VEGFR2 proteolytic fragments
VEGFR2 proteolysis is tightly regulated with evidence for at least two distinct
proteolytic events associated with the endosome-lysosome system. A 26S proteasome-
regulated step, associated with early endosomes and C-terminal domain cleavage,
occurs prior to lysosomal processing of the extracellular/luminal domain (Ewan et al.,
2006, Bruns et al., 2010) (Fig. 1.13). Post-translational modification and recruitment of
signalling proteins bestows the VEGFR2 C-terminal domain with important regulatory
roles in VEGFR2 stability and signalling (Meyer et al., 2011). Proteasome-mediated
VEGFR2 proteolysis regulates signal transduction through the Akt, eNOS and MAPK
pathways (Bruns et al., 2010). VEGF-A stimulation causes degradation of mature
VEGFR2 and an associated increase in levels of a 160 kDa VEGFR2-related
polypeptide (Ewan et al., 2006, Bruns et al., 2010). Production of the 160 kDa fragment
requires VEGF-A-stimulated tyrosine kinase activity and results from cytoplasmic
domain removal within an endosomal compartment (Bruns et al., 2010). VEGFR2
monoubiquitination precedes production of the 160 kDa fragment and could provide a
sorting signal to mediate proteasome recognition on early endosomes before final
degradation in the lysosome (Bruns et al., 2010) (Fig. 1.13). Limited proteolysis of
activated, endosomal VEGFR2 alters intracellular signalling outputs and endothelial
cell migration (Bruns et al., 2010). The VEGFR2 C-terminal domain appears to control
receptor activity by playing a central role in both receptor signalling and degradation
(Singh et al., 2005).
1.9.6. The role of chaperone proteins in VEGFR2 degradation
Chaperone proteins such as heat shock protein (HSP) of 70 kDa (HSP70) and related
family member, HSP90, are implicated in VEGFR2 ubiquitination, trafficking and
turnover (Bruns et al., 2012). HSP70 is associated with VEGFR2 degradation following
clathrin-dependent endocytosis whilst HSP90 stabilises VEGFR2 levels (Bruns et al.,
2012). Thus, the HSP70-HSP90 axis is essential for regulating VEGFR2 homeostasis.
Another chaperone protein involved in VEGFR2 stabilisation is phosducin-like 3
(PDCL3). Receptor ubiquitination and degradation is inhibited by binding of PDCL3 to
the juxtamembrane domain of VEGFR2 thus increasing VEGF-A-stimulated tyrosine
phosphorylation (Srinivasan et al., 2013).
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1.10. Hypothesis and Aims
In heart attack patients there is a clinical need to promote vascular regeneration after
angioplasty, stenting or coronary artery bypass surgery. Angiogenesis can stimulate
arterial repair after heart attacks. Endothelial cells line all blood vessels and express
VEGFR2 to bind soluble VEGF-A, stimulating angiogenesis. VEGF-A-stimulates
VEGFR2 ubiquitination and downstream proteolysis but the regulatory factors involved
are unclear. This project aims to use RNAi screening as a tool to identify ubiquitinating
and DUB enzymes that regulate VEGFR2 turnover in primary human endothelial cells.
Such understanding could be used to manipulate VEGFR2 levels, thus altering
endothelial function and stimulating vascular regeneration in cardiovascular disease. A
central hypothesis is that VEGFR2 ubiquitination is linked to downstream signalling
outputs and endothelial function. Such work is also relevant to diseases defined by
excessive angiogenesis such as cancer, ocular and inflammatory disorders where
ubiquitination enzyme activity or inhibition of DUBs could restrict angiogenesis and be
of therapeutic benefit.
VEGF gene therapy or administration of recombinant VEGF-A to stimulate blood
vessel repair has proved problematic with side effects such as oedema and tissue
swelling (Isner et al., 1996). An alternative, less explored approach is to target VEGFR-
associated proteins (effectors) that modulate proteolytic sensitivity, thus promoting a
better pro-angiogenic outcome in cardiovascular disease therapy. This work tests the
hypothesis that manipulation of VEGFR2 ubiquitination and proteolysis affects vascular
outputs such as endothelial cell migration and tubulogenesis, key requirements for
vascular repair and regeneration. In the longer term, using gene therapy and/or small
molecule inhibitors that target ubiquitin-modifying enzymes could provide improved
treatments for damaged arteries. The combined experimental approaches described in
this thesis will further our understanding of the role of post-translational VEGFR2
modification on the endothelial response to VEGF-A at a biochemical, cellular and
functional level.
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CHAPTER 2
MATERIALS AND METHODS
2.1. Materials
2.1.1. General reagents
Recombinant VEGF-A165 was gifted from Genentech Inc. (San Francisco, USA). All
chemicals were of analytical grade and purchased from Sigma-Aldrich (Poole, UK)
unless stated otherwise. Primary and secondary antibodies were used as described in
Table 2.1.
2.1.2. Primary cells
Human dermal microvascular endothelial cells (HDMECs) were purchased from
PromoCell (Heidelberg, Germany). Human umbilical vein endothelial cells (HUVECs)
were isolated from umbilical cords obtained with informed patient consent from patients
undergoing elective Caesarean section at Leeds General Infirmary. Ethical approval
(reference CA03/020) was granted by the Leeds NHS Hospitals Local Ethics
Committee (UK).
2.2. Methods
2.2.1. Isolation of primary HUVECs
The umbilical vein was cannulated with an 18-gauge blunt needle and flushed twice
with 50 ml PBS. The umbilical cord was clamped at one end using a haemostat and the
umbilical vein filled with 0.1% (w/v) type IIS collagenase in MCDB131 (Life
Technologies, Paisley, UK) for 20 min to detach the endothelial cells. The vein was
flushed with 50 ml PBS and the detached cells collected. Cells were pelleted via
centrifugation at 140 g for 5 min. The supernatant was aspirated and cells re-suspended
in endothelial cell growth medium (ECGM) containing 50 ng/ml amphotericin B. Cells
were seeded into a 75 cm2 vented tissue culture flask (Nunc, Copenhagen, Denmark)
pre-coated with 0.1% (w/v) pig skin gelatin (PSG). After 24 h, the cells were washed
with PBS 5 times and the medium replaced. Isolated cells were characterised via
Antigen Species Concentration
(mg/ml)
Dilution
factor
Source
Akt Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
phospho-Akt (S473) Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
CD63 Mouse 0.25 IF: 1:200 AbCam (Cambridge, UK)
EEA1 Mouse 0.25 IF: 1:200 BD Transduction Labs (Oxford, UK)
eNOS Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
phospho-eNOS (S117) Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
ERK1/2 Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
phospho-ERK1/2 (T202/Y204) Mouse 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
Goat IgG Donkey, HRP 0.4 IB: 1:5000 Stratech Scientific (Newmarket, UK)
Goat IgG Donkey, AlexaFluor 488 2.0 IF: 1:200 Life Technologies (Paisley, UK)
LAMP2 Mouse 0.5 IF: 1:100 Santa Cruz Antibodies (California, USA)
Mouse IgG Donkey HRP 0.4 IB: 1:5000 Stratech Scientific (Newmarket, UK)
Mouse IgG Donkey, AlexaFluor 594 2.0 IF: 1:200 Life Technologies (Paisley, UK)
p38 MAPK Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
phospho- p38 MAPK (T180/Y182) Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
PECAM1 (CD31) Mouse 0.2 IF: 1:1000 Santa Cruz Antibodies (California, USA)
PLCγ1 Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
phospho-PLCγ1 (Y783) Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
Rabbit IgG Donkey, HRP 0.4 IB: 1:5000 Stratech Scientific (Newmarket, UK)
Rabbit IgG Donkey, AlexaFluor 594 2.0 IF: 1:200 Life Technologies (Paisley, UK)
TGN46 Rabbit 1.0 IF: 1:1000 University of Leeds
Transferrin receptor (TfR; CD71) Mouse 0.2 IB: 1:1000 Santa Cruz Antibodies (California, USA)
α-tubulin Mouse 2.0 IB: 1:8000 Sigma Aldrich (Poole, UK)
UBA1 Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
UBE2D1 Rabbit 0.5 IB: 1:1000 AbCam (Cambridge, UK)
UBE2D2 Rabbit 0.5 IB: 1:1000 AbCam (Cambridge, UK)
USP8 Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
Ubiquitin (FK2) Mouse 0.5 IB: 1:1000 Caymen Chemicals (Michigan, USA)
K48-linked ubiquitin (Apu2) Rabbit 0.5 IB: 1:1000 Millipore (Watford, UK)
K63-linked ubiquitin (Apu3) Rabbit 0.5 IB: 1:1000 Millipore (Watford, UK)
VEGFR1 Goat 0.1 IB: 1:1000
IF: 1:100
R&D Systems (Minnesota, USA)
VEGFR2 extracellular domain Goat 0.1 IB: 1:1000
IF: 1:100
R&D Systems (Minnesota, USA)
VEGFR2 cytoplasmic domain Goat 0.1 IB: 1:1000 University of Leeds
phospho-VEGFR2 (Y1175) Rabbit 0.5 IB: 1:1000 Cell Signal Technology (Massachusetts, USA)
Table 2.1. Primary and secondary antibodies. Details of antibody species,
concentration, dilution factor and source. IB; immunoblot, IF; immunofluorescence.
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immunofluorescence microscopy of common endothelial cell markers (Fig. 2.1).
2.2.2. Cell passage
HUVECs were cultured in ECGM in a T75 vented tissue culture flask pre-coated with
0.1% (w/v) PSG and incubated at 37°C in a hydrated 5% CO2 atmosphere until ~70-
80% confluent. ECGM was aspirated and the cells washed in PBS prior to incubation in
1 ml TrypLETM Express (Invitrogen, Amsterdam, Netherlands) at 37°C for 4 min.
Trypsinisation was quenched with 5 ml DMEM (+10% foetal calf serum (Life
Technologies)). Cells were centrifuged at 140 g for 5 min and the pellet re-suspended in
6 ml ECGM. The ECGM was replaced every 2 days. Cells were split 1:3 and cultured
up to passage 5.
2.2.3. VEGF-A stimulation for analysis of intracellular signalling
pathways and pharmacological inhibition of protein synthesis or
ubiquitination
Endothelial cells were serum-starved in MCDB131 (+0.2% (w/v) BSA) for 2 h prior to
treatment with 25 ng/ml VEGF-A165 (0-60 min), 20 μg/ml CHX (0-80 min) or 10 μM 
PYR41 (1 h) and lysed for immunoblotting or immunofluorescence microscopy.
2.2.4. Adhiron treatment of cells
HUVECs were serum-starved in MCDB131 (+0.2% (w/v) BSA) for 2 h, pre-treated
with 100 μg/ml Adhiron for 30 min and stimulated with 25 ng/ml VEGF-A.  
2.2.5. Preparation of whole cell lysates
Medium was aspirated and cells washed twice with ice-cold PBS. Cells were lysed in
2% (w/v) SDS (+ 1mM PMSF, in PBS) and detached using a sterile cell scraper.
Lysates were stored at -20°C. For immunoblot analysis, lysates were incubated at 95°C
for 5 min and sonicated for 3 s. Protein concentration was determined using a
bicinchoninic acid (BCA) assay.
2.2.6. Lipid-based transfection of siRNA duplexes
Endothelial cells were reverse transfected using lipofectamine RNAiMax (Invitrogen) in
Figure 2.1. Characterisation of HUVECs. (A) A confluent HUVEC monolayer
grown on gelatin-coated surfaces and visualised by phase-contrast microscopy at
4x magnification. Scale bar represents 1000 μm. Immunofluorescence
microscopy of confluent HUVECs labelled with primary antibodies to (B)
PECAM1, (C) VEGFR1 or (D) VEGFR2 followed by species-specific secondary
antibodies (green). Nuclei were stained with DNA-binding dye, DAPI (blue).
Scale bar represents 70 μm.
VEGFR2VEGFR1
Transmission PECAM1
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6- or 96-well plates with siRNA duplexes as follows.
20 nM non-targeting control siRNA:
5’-UGGUUUACAUGUCGACUAA-3’
5’-UGGUUUACAUGUUGUGUGA-3’
5’-UGGUUUACAUGUUUUCUGA-3’
5’-UGGUUUACAUGUUUUCCUA-3’
20 nM UBA1 siRNA:
5’-GCGUGGAGAUCGCUAAGAA-3’
5’-CCUUAUACCUUUAGCAUCU-3’
5’-CCACAUAUCCGGGUGACAA-3’
5’-GAAGUCAAAUCUGAAUCGA-3’
20 nM USP8 siRNA:
5’-UGAAAUACGUGACUGUUUA-3’
5’-GGACAGGACAGUAUAGAUA-3’
5’-AAAUAAAGCUCAACGAGAA-3’
5’-GGCAAGCCAUUUAAGAUUA-3’
20 nM UBE2D1 siRNA:
5’-CAACAGACAUGCAAGAGAA-3’
5’-GAAAGAAUUGAGUGAUCUA-3’
5’-UACCAGAUAUUGCACAAAU-3’
5’-GCACAAAUCUAUAAAUCAG-3’
20 nM UBE2D2 siRNA:
5’-UCAGAAGUAUGCGAUGUAA-3’
5’-CUAUCAGGGUGGAGUAUUU-3’
5’-GUCCAUCUGUUCUCUGUUG-3’
5’-CCGAAGGAGCUACGUCUUA-3’
All siGENOME SMARTpool siRNA duplexes were used according to the
manufacturer’s instructions (Dharmacon, GE Healthcare, Little Chalfont, UK). 15 μl of 
2 μM siRNA was added to each well of a 6-well plate. 4 μl RNAiMax was incubated 
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with 301 μl serum/antibiotic-free OptiMEM (Invitrogen) for 5 min at room temperature. 
The transfection reagent mix was added to the siRNA and incubated for ~20 min at
room temperature. Endothelial cells were seeded at ~250,000 cells per well in 1.2 ml
serum/antibiotic-free OptiMEM. Cells were incubated for 6 h with siRNA duplexes
before replacing the media with ECGM. After 72 h, cells were processed for lysis and
immunoblotting or immunofluorescence microscopy.
2.2.7. SDS-PAGE
25 μg of whole cell lysate was re-suspended in an equal volume of 2X SDS sample 
buffer (1 M Tris-HCl pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 0.1% (w/v)
bromophenol blue and 4% (v/v) mercaptoethanol) and incubated at 95°C for 5 min.
Lysates were loaded onto a 10% (w/v) SDS-polyacrylamide resolving gel with a 5%
(w/v) SDS-polyacrylamide stacking gel and run at 130 V for 90 min in SDS-running
buffer (192 mM glycine, 25 mM Tris, 0.1% (w/v) SDS).
2.2.8. Immunoblotting
Proteins subjected to SDS-PAGE were transferred onto nitrocellulose membrane (0.2
μm pore size) (Schleicher & Schuell, Bath, UK) in transfer buffer (106 mM glycine, 25 
mM Tris, 0.1% (w/v) SDS, 20% (v/v) methanol) at 300 mA for 3 h at 4°C. Membranes
were incubated in 5% (w/v) skimmed milk (in TBS-T (20 mM Tris-HCl pH 7.6, 137
mM NaCl, 0.1% (v/v) Tween-20)) for 30-60 min on a rocker. Membranes were rinsed
in TBS-T, incubated in primary antibodies (Table 2.1) overnight at 4°C and washed 3
times for 10 min in TBS-T prior to incubation in HRP-conjugated secondary antibodies
(Table 2.1) for 1 h at room temperature, followed by a second round of TBS-T washes
and detection using the chemiluminescent solution, EZ-ECL (Geneflow, Nottingham,
UK).
2.2.9. Immunoprecipitation
HUVECs were serum-starved for 2 h prior to CHX treatment or VEGF-A stimulation,
washed twice in ice-cold PBS and lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-
HCl, pH 7.4, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 2 mM EDTA, 1%
(v/v) NP-40, 50 mM NaF, 1 mM PMSF, 10 mM iodoacetamide) at 4°C. Lysates were
cleared by centrifugation at 16000 g for 15 min at 4°C. Equal concentrations of
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supernatant were incubated with 1 μg/ml goat anti-VEGFR2 for 2 h at 4°C and 
immunoisolated with 25 μl 50:50 protein G-Sepharose slurry (Millipore, Watford, UK) 
overnight at 4°C. Beads were washed 3 times in RIPA buffer and proteins eluted by
heating at 95°C for 5 min in 40 μl 2X SDS sample buffer before SDS-PAGE and
immunoblot analysis.
2.2.10. Cell surface biotinylation
HUVECs were serum-starved for 2 h prior to CHX treatment or VEGF-A stimulation,
washed twice in ice-cold PBS, cell surface biotinylated by incubation with 0.25 mg/ml
biotin (in 2 mM CaCl2, 2 mM MgCl2 in PBS) for 45 min at 4°C, washed in TBS to
quench biotinylation and lysed in NP-40 buffer (1% (v/v) NP-40, 50 mM Tris-HCl pH
7.5, 150 mM NaCl, 1 mM PMSF) for 5 min at 4°C. Cell surface proteins were isolated
using 35 μl NeutraAvidin agarose beads (ThermoFisher, Massachusetts, USA) 
overnight at 4°C. Beads were washed 3 times in NP-40 buffer and proteins eluted by
heating at 95°C for 5 min in 40 μl 2X SDS sample buffer before SDS-PAGE and 
immunoblot analysis.
2.2.11. Immunofluorescence microscopy
For immunofluorescence microscopy, serum-starved HUVECs were treated with CHX
or VEGF-A in 96-well plates or on coverslips before being fixed in 10% (v/v) formalin
(Sigma-Aldrich) for 5 min at 37°C. Cells were washed 3 times in PBS before
permeabilisation in 0.1% Triton X-100 (v/v) for 4 min at room temperature. Cells were
washed 3 times in PBS and incubated in 5% (w/v) BSA (in PBS) for 60 min at room
temperature to block non-specific antibody binding. Cells were washed 3 times in PBS
and incubated in primary antibody diluted in 1% (w/v) BSA (in PBS) overnight at room
temperature. Cells were washed 3 times in PBS and incubated in species-specific
AlexaFluor-conjugated secondary antibodies and 2 μg/ml DNA-binding dye, 4',6-
diamidino-2-phenylindole (DAPI) in 1% (w/v) BSA (in PBS) for 2-3 h at room
temperature. Cells were washed 3 times in PBS and coverslips mounted onto slides
using Fluoromount G (Southern Biotech, Alabama, USA). Images were acquired using
an Evos-fI inverted digital microscope (Life Technologies) at 20X magnification or a
Delta Vision wide-field deconvolution microscope (Applied Precision Inc., Issaquah,
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USA) at 60X magnification. Fluorescence intensity was quantified using NIH ImageJ
(http://rsb.info.nih.gov/ij/).
2.2.12. Plasma membrane protein recycling assay
Serum-starved HUVECs were incubated in VEGFR2, transferrin receptor or FGFR1
primary antibody for 30 min at 37°C before VEGF-A stimulation for 15 or 30 min at
37°C. In some experiments cells were pre-treated with 20 μM monensin. Cell surface 
primary antibody was stripped by washing once in acidic, serum-free MCDB131 (pH 2)
at 4°C followed by washing twice in normal medium. Cells were incubated in
secondary antibody (anti-sheep AlexaFlour488, Life Technologies) for 15 or 30 min (30
or 60 min total recycling time, respectively) at 37°C before fixation for 5 min at 37°C
and staining with 1 μg/ml DNA-binding dye, DAPI. Only cell surface VEGFR2 that had 
bound primary antibody and undergone internalisation and subsequent recycling would
be available to bind secondary antibody after acid-washing. Thus, only VEGFR2 that
recycled one or more times was visualised. Images were acquired using an Evos-fI
inverted digital microscope at 20X magnification or a Delta Vision wide-field
deconvolution microscope at 60X magnification. Fluorescence intensity was quantified
using NIH ImageJ (http://rsb.info.nih.gov/ij/).
2.2.13. Cell proliferation assay (BrdU incorporation)
HUVECs were seeded in 96-well plates at 2 x 103 cells per well in ECGM. After 24 h,
cells were serum starved in MCDB131 (+0.2% (w/v) BSA) for 2 h prior to stimulation
with 25 ng/ml VEGF-A for 24 h. At the 20 h time point 10 μM bromodeoxyuridine 
(BrdU) was added for 4 h and a cell proliferation ELISA performed according to
manufacturer’s instructions (Roche Diagnostics, Mannheim, Germany). Colour change
was developed using 3,3’5,5’-tetramethylbenzidine solution and the reaction quenched
with 1 M H2SO4. Absorbance was measured at 450 nm using a variable wavelength 96-
well plate reader (Tecan, Mannedorf, Switzerland).
2.2.14. Cell migration assay
HUVECs were seeded in starvation medium (MCDB131 (+0.2% (w/v) BSA)) at 3 x 104
cells per well in an 8 μm pore size transwell filter inserted into a 24-well companion 
plate (BD Biosciences, Oxford, UK). To set up a chemotactic gradient for cells to
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migrate towards, ECGM (control) or MCDB131 (+0.2% (w/v) BSA) containing 25
ng/ml VEGF-A was added to the lower chamber. Cells were incubated for 24 h before
being fixed and stained with 0.2% (w/v) crystal violet in 20% (v/v) methanol. Non-
migrated cells were removed from the upper chamber using a cotton bud. 3-5 random
fields were imaged per transwell filter.
2.2.15. Endothelial cell tubulogenesis assay
Primary human foreskin fibroblasts (Promocell) were cultured to confluency in DMEM
containing 10% (v/v) FCS, 1% (v/v) non-essential amino acids and 1% sodium pyruvate
in 48-well plates. 6.5 x 103 HUVECs were seeded onto the fibroblast monolayer in a 1:1
mixture of DMEM:ECGM. After 24 h, medium was replaced with ECGM (+ 25 ng/ml
VEGF-A) and subsequently replaced every 48 h for 7 days. Tubules were fixed in 10%
(v/v) formalin for 20 min at room temperature, blocked in 1% (w/v) BSA for 60 min at
room temperature, stained with 1 μg/ml endothelial specific marker PECAM-1 primary 
antibody overnight at room temperature and incubated in anti-mouse secondary
antibody (AlexaFluor 594) and DNA-binding dye, DAPI, for 2 h at room temperature.
Tubules were washed three times in PBS between each of the above stages. Images
were acquired using an Evos-fI inverted digital microscope. Five random fields were
imaged per well at 10X magnification. Both total tubule length and the number of
branch points were quantified from each photographic field using the open source
software AngioQuant (www.cs.tut.fi/sgn/csb/angioquant).
2.2.16. Statistical analysis
Statistical analysis was performed using a one-way analysis of variance (ANOVA) and
Tukey’s post-test analysis for multiple comparisons or two-way ANOVA followed by
the Bonferroni multiple comparison test using GraphPad Prism software (La Jolla,
USA). Significant differences between control and test groups were evaluated with p
values less than 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) indicated on the
graphs. Error bars in graphs denote ± standard error of the mean (SEM) from results of
at least three independent experiments.
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CHAPTER 3
Basal VEGFR2 ubiquitination modulates signal
transduction and endothelial function
3.1. Introduction
Cell surface receptors undergo degradation but the biochemical basis for such control
remains poorly defined. Endothelial cells express VEGFR2 which binds to circulating
VEGF-A, stimulating signal transduction and new blood vessel sprouting i.e.
angiogenesis (Olsson et al., 2006, Shibuya, 2010). VEGF-A plays essential roles in both
health and disease states (Ferrara, 1999). VEGF-A-stimulated pathological angiogenesis
is important in chronic inflammatory diseases, cancer and retinopathy (Coultas et al.,
2005, Carmeliet, 2005, Ferrara and Kerbel, 2005) whilst insufficient angiogenesis leads
to damaged blood vessels causing tissue ischaemia and heart disease (Ungvari et al.,
2010). Multiple controls must exist to enable endothelial cells to integrate RTK
activation, trafficking and turnover in regulating functional responses. It is unclear how
endothelial cells regulate basal VEGFR2 levels to control the intensity of downstream
signal transduction pathways which in turn regulate cellular outcomes.
VEGF-A binding to plasma membrane VEGFR2 causes tyrosine kinase activation and
post-translational modifications such as tyrosine trans-autophosphorylation and
ubiquitination (Koch and Claesson-Welsh, 2012, Ewan et al., 2006). Ligand-activated
VEGFR2 undergoes ubiquitin-linked proteolysis (Bruns et al., 2010, Ewan et al., 2006)
but regulation of basal VEGFR2 levels is ill-defined. Ubiquitination is one mechanism
to control protein degradation and/or intracellular localisation (Ciechanover et al.,
2000), suggesting such post-translational modification(s) could be used to control
resting VEGFR2 levels. Protein ubiquitination requires E1 ubiquitin-activating enzyme
activity, followed by an E2 ubiquitin-conjugating enzyme working in concert with an
E3 ubiquitin ligase (Hershko and Ciechanover, 1992). Eight human E1 enzymes initiate
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the activation and conjugation of a number of ubiquitin-like proteins to target proteins,
including ubiquitin, SUMO and NEDD8 (Pickart, 2001).
Herein, we provide evidence for a novel pathway requiring the E1 ubiquitin-activating
enzyme, UBA1, which programs basal ubiquitin-dependent recycling and proteolysis of
resting VEGFR2 to control plasma membrane VEGFR2 levels. This regulatory
mechanism controls the initial endothelial response to VEGF-A. VEGFR2 undergoes
VEGF-A-independent constitutive degradation via a UBA1-dependent pathway.
Depletion of endothelial UBA1 levels caused increased endosome-to-plasma membrane
VEGFR2 recycling and reduced proteolysis. UBA1 depletion thus elevated VEGF-A-
stimulated signal transduction, exemplified by increased activation of downstream
signalling enzymes such as PLC1 and ERK1/2. Importantly, UBA1-depleted
endothelial cells also displayed increased VEGF-A-stimulated tubulogenesis. Our study
reveals the existence of an ubiquitin-linked regulatory pathway that controls VEGFR2
levels by modulating ligand-independent receptor recycling and degradation.
Programming basal plasma membrane VEGFR2 levels sets a threshold to influence the
intensity and duration of the endothelial response to circulating ligands such as VEGF-
A.
3.2. Results
3.2.1. UBA1 regulates basal VEGFR2 levels
Ligand-stimulated ubiquitination of VEGFR2 facilitates trafficking and degradation in
the endosome-lysosome system (Bruns et al., 2010). Previous studies have shown that
in resting primary endothelial cells, VEGFR2 undergoes proteolysis (Mittar et al., 2009,
Ulyatt et al., 2011) but the mechanism underlying this phenomenon was unknown. To
characterise such a constitutive, ligand-independent pathway(s) that controls basal
VEGFR2 levels, we reasoned that an ubiquitin-linked mechanism targets inactive
VEGFR2 for proteolysis. To test this idea, screening of the 8 human E1-like enzymes
revealed that UBA1 or UBA2 depletion caused a significant increase in basal VEGFR2
levels in primary human endothelial cells (Fig. 3.1A). Quantification revealed ~2-fold
increase in mature VEGFR2 levels in UBA1-depleted cells compared to control cells
(Fig. 3.1B). The RNAi screen was repeated in the presence of VEGF-A for 120 min to
identify candidate E1s for regulating proteolysis of active VEGFR2. Unexpectedly,
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Figure 3.1. An RNAi screen for the E1 enzymes that regulate VEGFR2
turnover. (A) Endothelial cells treated with non-targeting, UBA1, UBA2, UBA3,
UBA5, UBA6, UBA7, ATG7 or NAE1 siRNA were lysed and immunoblotted
with antibodies to VEGFR2. (B) Quantification of VEGFR2 levels in primary
human endothelial cells treated with non-targeting, UBA1, UBA2, UBA3, UBA5,
UBA6, UBA7, ATG7 or NAE1 siRNA. (C) Endothelial cells treated with non-
targeting, UBA1, UBA2, UBA3, UBA5, UBA6, UBA7, ATG7 or NAE1 siRNA
were stimulated with 25 ng/ml VEGF-A for 120 min, lysed and immunoblotted
with antibodies to VEGFR2. Error bars denote ±SEM (n≥3). p<0.01 (**),
p<0.001 (***).
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immunoblot analysis revealed E1 depletion did not affect VEGFR2 degradation over
120 min VEGF-A stimulation (Fig. 3.1C).
The effect of UBA1 depletion on basal VEGFR2 levels was confirmed by
immunofluorescence microscopy of control and UBA1-depleted endothelial cells
stained with antibodies to VEGFR1 or VEGFR2 (Fig. 3.2A, B). Whilst UBA2 regulates
SUMOylation, UBA1 and UBA6 are the only E1 ubiquitin-activating enzymes known
to regulate attachment of ubiquitin to target proteins (Haas et al., 1982, Pelzer et al.,
2007). Although VEGFR2 levels increased ~2-fold in UBA1-depleted cells, VEGFR1
levels were unaffected by UBA1 depletion (Fig. 3.2C). Importantly, UBA6 depletion
did not affect VEGFR2 levels (Fig 3.2A, B). Thus, UBA1 is an E1 ubiquitin-activating
enzyme that regulates constitutive VEGFR2 degradation. To confirm that UBA1
activity is required for basal VEGFR2 degradation, we used the pharmacological
inhibitor PYR41 on endothelial cells (Fig. 3.3A). Quantification of control or PYR41-
treated cells revealed a statistically significant increase in resting VEGFR2 levels upon
treatment with PYR41 (Fig. 3.3B). These findings provide evidence for ubiquitin-
dependent control of basal VEGFR2 levels.
3.2.2. UBA1 regulates constitutive ubiquitination and degradation of
VEGFR2
Blocking protein synthesis using cycloheximide (CHX) in endothelial cells enables
monitoring of mature VEGFR2 degradation in the absence of ligand (Shaik et al.,
2012). We combined CHX treatment and UBA1 depletion to assess effects on distal
pools of mature VEGFR2 associated with the plasma membrane, endosomes and
lysosomes. To test how UBA1 depletion affects basal VEGFR2 turnover, we used
RNAi to deplete UBA1 in primary HUVECs, followed by CHX treatment (Fig. 3.4).
Immunoblotting confirmed that basal VEGFR2 levels were elevated upon UBA1
depletion although tyrosine phosphorylation was not evident (Fig. 3.4A) suggesting
VEGFR2 activation was not required for degradation via this pathway. Importantly,
UBA1 depletion did not affect basal levels of other plasma membrane receptors such as
FGFR1 or transferrin receptor (TfR) (Fig. 3.4A). Quantification revealed that under
control conditions, ~60% of mature VEGFR2 underwent degradation over an 80 min
period of CHX treatment (Fig. 3.4B). In contrast, UBA1-depleted endothelial cells
exhibited ~40% increase in basal VEGFR2 levels before CHX addition (t=0 min; Fig.
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3.4B). Furthermore, ligand-independent VEGFR2 degradation was less pronounced in
UBA1-depleted cells after 80 min CHX treatment with only ~30% decrease in VEGFR2
levels (Fig. 3.4B). Depletion of UBA1 thus causes a rise in VEGFR2 levels which
undergo reduced degradation upon inhibition of new protein synthesis. Morphological
analysis of VEGFR2 distribution using quantitative microscopy further supported a role
for UBA1 in basal VEGFR2 degradation (Fig. 3.5A). Comparison of control and
UBA1-depleted endothelial cells revealed that basal VEGFR2 (t=0 min) levels were
~40% higher in UBA1-depleted cells (Fig. 3.5B). Upon the addition of CHX, control
endothelial cells exhibited ~55% ligand-independent VEGFR2 degradation after 60 min
CHX treatment (Fig. 3.5B). However, upon UBA1 depletion basal VEGFR2 levels were
reduced by only ~20% in the presence of CHX for 60 min (Fig. 3.5B).
To test the functional requirement for UBA1 in VEGFR2 turnover in other types of
blood vessels, we examined this phenomenon in primary human dermal capillary
endothelial cells (HDMECs) (Fig. 3.6A). VEGFR2 is abundant in HDMECs and its
levels are clearly elevated upon UBA1 depletion (Fig. 3.6A). Quantification showed
~20-30% increase in basal VEGFR2 levels (Fig. 3.6B). In addition, CHX treatment for
up to 80 min did not significantly reduce VEGFR2 levels in UBA1-depleted cells (Fig.
3.6B). UBA1 is thus required for ligand-independent VEGFR2 turnover in endothelial
cells derived from different types of blood vessels.
The effects of UBA1 depletion on basal VEGFR2 levels suggested that ubiquitination
could be one means of programming resting VEGFR2 for degradation. To test this idea,
we immunoprecipitated mature VEGFR2 from CHX-treated control or UBA1-depleted
endothelial cells and evaluated ubiquitination status using immunoblot analysis (Fig.
3.7A). In control endothelial cells subjected to CHX treatment, ubiquitinated VEGFR2
levels gradually increased by ~50%, peaking after 60 min (Fig. 3.7A, B). In contrast,
UBA1-depleted cells displayed no such peak; ligand-independent VEGFR2
ubiquitination remained low and relatively unchanged. Notably, UBA1 depletion
reduced peak ubiquitination of VEGFR2 by ~60% in comparison to control cells (Fig.
3.7B). These findings support a requirement for UBA1 in basal VEGFR2 ubiquitination
to target this membrane receptor for degradation.
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Figure 3.2. UBA1 regulates basal VEGFR2 levels. (A) Immunofluorescence
microscopy of endothelial cells transfected with non-targeting, UBA1 or UBA6
siRNA and stained with antibodies to either VEGFR1 or VEGFR2 followed by
fluorescent species-specific secondary antibodies (green). Nuclei were stained
with DNA-binding dye, DAPI (blue). Scale bar represents 70 μm. VEGFR2 (B)
or VEGFR1 (C) levels in endothelial cells treated with non-targeting, UBA1 or
UBA6 siRNA determined by quantitative microscopy. Error bars denote ±SEM
(n≥3). p<0.05 (*), p<0.01 (**).
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Figure 3.3. Pharmacological inhibition of UBA1 increases basal VEGFR2
levels (A) Endothelial cells treated with the UBA1-specific small molecule
inhibitor PYR41 (10 μM) for 1 h were lysed and immunoblotted with antibodies
to VEGFR2, VEGFR1 or transferrin receptor (TfR). (B) Quantification of
VEGFR2 levels in endothelial cells treated with PYR41. Error bars denote ±SEM
(n≥3). p<0.05 (*).
A
B
Control PYR41
0.0
0.5
1.0
1.5
*
Re
la
tiv
e
VE
G
FR
2
le
ve
ls
72
VEGFR2
Tubulin
CHX (min) 0 20 40 60 80 0 20 40 60 80
Control UBA1 siRNA
UBA1
TfR
0 20 40 60 80
0.0
0.5
1.0
1.5
2.0
Control siRNA
UBA1 siRNA** ** *
CHX treatment (min)
Re
la
tiv
e
VE
G
FR
2
le
ve
ls
p-VEGFR2
FGFR1
VEGFR1
A
B
Figure 3.4. UBA1 regulates ligand-independent VEGFR2 degradation. (A)
HUVECs transfected with non-targeting or UBA1 siRNA were treated with 20
μg/ml cycloheximide (CHX) over a time course of 80 min and immunoblotted for
phospho-VEGFR2, VEGFR2, VEGFR1, FGFR or TfR. (B) Quantification of
VEGFR2 levels in HUVECs transfected with non-targeting or UBA1 siRNA and
treated with 20 μg/ml CHX for 80 min. Error bars denote ±SEM (n≥3). p<0.05
(*), p<0.01 (**).
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Figure 3.5. Immunofluorescence microscopy reveals UBA1 regulates ligand-
independent VEGFR2 degradation. (A) HUVECs transfected with non-
targeting or UBA1 siRNAwere treated with 20 μg/ml CHX over a time course of
60 min and processed for immunofluorescence microscopy using antibodies to
VEGFR2 followed by fluorescent species-specific secondary antibodies (green).
Nuclei were stained with DNA-binding dye, DAPI (blue). Scale bar represents
200 μm. (B) VEGFR2 levels in HUVECs treated with 20 μg/ml CHX determined
by quantitative microscopy. Error bars denote ±SEM (n≥3). p<0.01 (**), p<0.001
(***), p<0.0001 (****).
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Figure 3.6. UBA1 regulates ligand-independent VEGFR2 degradation in
capillary endothelial cells. (A) HDMECs transfected with non-targeting or
UBA1 siRNAwere treated with 20 μg/ml CHX over a time course of 80 min and
immunoblotted for phospho-VEGFR2, VEGFR2 or TfR. (B) Quantification of
VEGFR2 levels in HDMECs transfected with non-targeting or UBA1 siRNA and
treated with 20 μg/ml CHX for 80 min. Error bars denote ±SEM (n≥3). p<0.05
(*).
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Figure 3.7. UBA1 regulates basal ubiquitination of VEGFR2. (A) Primary
human endothelial cells transfected with non-targeting or UBA1 siRNA were
treated with 20 μg/ml CHX and lysed. VEGFR2 was immunoprecipitated using
antibodies to VEGFR2 and immunoblotted to monitor ubiquitin status using a
pan-ubiquitin antibody. (B) Quantification of ubiquitinated VEGFR2 (Ub-
VEGFR2) levels in endothelial cells transfected with non-targeting or UBA1
siRNA and treated with 20 μg/ml CHX. Relative Ub-VEGFR2 levels were
normalised against both IgG and VEGFR2. Error bars denote ±SEM (n≥3).
p<0.05 (*), p<0.01 (**). IP; immunoprecipitate, WCL; whole cell lysate.
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3.2.3. UBA1 regulates basal VEGFR2 recycling
RTK ubiquitination at the plasma membrane precedes internalisation and delivery to
early endosomes (Haglund and Dikic, 2012, Ewan et al., 2006, Clague and Urbe, 2001).
Ligand-stimulated VEGFR2 ubiquitination promotes trafficking to late endosomes and
terminal degradation in lysosomes (Ewan et al., 2006, Bruns et al., 2010). RTK de-
ubiquitination in early endosomes is associated with endosome-to-plasma membrane
recycling (Clague and Urbe, 2006). Furthermore, it has been previously shown that
VEGFR2 undergoes substantial constitutive ligand-independent recycling via
endosomes (Jopling et al., 2011). One possibility is that upon UBA1 depletion,
VEGFR2 undergoes decreased basal ubiquitination which is a prerequisite for increased
endosome-to-plasma membrane recycling. To test this idea, we utilised a microscopy-
based VEGFR2 recycling assay (Jopling et al., 2011). Here, control or UBA1-depleted
endothelial cells were incubated with extracellular domain-specific antibodies to two
different RTKs expressed by endothelial cells i.e. VEGFR2 and FGFR1. Constitutive
RTK endocytosis and recycling was monitored using accessibility of either VEGFR2-
antibody or FGFR1-antibody complexes to a pulse of labelled secondary antibody. Only
VEGFR2-antibody or FGFR1-antibody complexes that had undergone endocytosis
followed by endosome-to-plasma membrane recycling were detected (Fig. 3.8A).
Quantification revealed that UBA1-depleted endothelial cells displayed ~2-fold increase
in basal endosome-to-plasma membrane recycling of VEGFR2 (Fig. 3.8B). In contrast,
FGFR1 recycling was unaffected by UBA1 depletion (Fig. 3.8C).
One prediction is that increased basal recycling of VEGFR2 increases overall plasma
membrane levels in UBA1-depleted cells. To test this hypothesis, endothelial cells were
treated with CHX to block new protein synthesis and then subjected to cell surface
biotinylation followed by affinity purification of biotinylated plasma membrane proteins
and immunoblot analysis (Fig. 3.9A). VEGFR2 plasma membrane levels were clearly
elevated upon UBA1 depletion, whereas another membrane protein and cell surface
receptor, transferrin receptor, was not significantly affected (Fig. 3.9A). Quantification
revealed that under control conditions, plasma membrane VEGFR2 levels were reduced
by ~55% after 80 min CHX treatment (Fig. 3.9B). In contrast, UBA1-depleted cells
exhibited ~25% increase in plasma membrane VEGFR2 under steady-state conditions
(t=0; Fig. 3.9B). Over an 80 min period of CHX treatment, there was less reduction in
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Figure 3.8. UBA1 regulates basal plasma membrane-to-endosome recycling
of VEGFR2. (A) Endothelial cells transfected with non-targeting or UBA1
siRNA were incubated with antibodies to VEGFR2 or FGFR1 for 30 min at 37°C
before being acid-washed to strip cell surface antibodies and incubated with
fluorescent species-specific secondary antibodies for 30 min at 37°C (green).
Cells were fixed prior to staining with DNA-binding dye, DAPI (blue). Only
VEGFR2 or FGFR1 that underwent plasma membrane-to-endosome-to-plasma
membrane recycling is visible. Scale bar represents 200 μm. VEGFR2 (B) or
FGFR1 (C) recycling was quantified in cells transfected with non-targeting or
UBA1 siRNA . Error bars denote ±SEM (n≥3). p<0.01 (**).
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Figure 3.9. UBA1 regulates plasma membrane levels of VEGFR2. (A)
Primary human endothelial cells transfected with non-targeting or UBA1 siRNA
were treated with 20 μg/ml CHX. Cell surface proteins were biotinylated, isolated
and immunoblotted for plasma membrane VEGFR2 (PM VEGFR2) or TfR. (B)
Quantification of cell surface VEGFR2 levels in endothelial cells transfected with
non-targeting or UBA1 siRNA and treated with 20 μg/ml CHX. Error bars denote
±SEM (n≥3). p<0.01 (**). IP; immunoprecipitate, WCL; whole cell lysate.
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plasma membrane VEGFR2 levels (Fig. 3.9B). Taken together, these data suggest that
UBA1 regulates basal endosome-to-plasma membrane VEGFR2 recycling and
VEGFR2 plasma membrane levels in an ubiquitin-dependent manner.
3.2.4. UBA1-mediated control of basal VEGFR2 levels modulates
VEGF-A-stimulated signal transduction
VEGF-A binding to plasma membrane VEGFR2 stimulates multiple signal transduction
pathways (Koch et al., 2011, Zhang et al., 2008). UBA1 depletion inhibits basal
VEGFR2 degradation leading to a net increase in VEGFR2 at the plasma membrane;
this could modulate VEGF-A-stimulated signal transduction. To test this idea, control or
UBA1-depleted endothelial cells were subjected to VEGF-A stimulation before probing
downstream signal transduction events using quantitative immunoblotting (Fig. 3.10A).
VEGFR2 trans-autophosphorylation of the cytoplasmic Y1175 epitope is a signature for
VEGFR2 activation (Koch et al., 2011). VEGF-A-stimulated appearance of VEGFR2-
pY1175 was clearly evident in both control and UBA1-depleted cells (Fig. 3.10A).
However, quantification showed ~30% increase in VEGFR2-pY1175 levels upon
UBA1 depletion (Fig. 3.10B).
Plasma membrane VEGFR2 activation is linked to recruitment of PLCγ1 followed by 
tyrosine phosphorylation on residue Y783 and increased phospholipase activity (Koch
et al., 2011). UBA1-depleted cells exhibited increased PLCγ1 phosphorylation (Fig. 
3.10A) corresponding to ~43% increase in PLCγ1-pY783 levels (Fig. 3.10C). A key 
feature of VEGF-A-stimulated signal transduction is activation of the MAPK pathway
which leads to phosphorylation and activation of ERK1/2, a key event in VEGF-A-
stimulated signal transduction (Koch and Claesson-Welsh, 2012). UBA1-depleted
endothelial cells displayed ~3-fold increase in VEGF-A-stimulated ERK1/2
phosphorylation in comparison to control cells (Fig. 3.10D). UBA1-mediated regulation
of basal VEGFR2 levels thus modulates the VEGF-A-stimulated response through
different signal transduction pathways. Interestingly, UBA1 depletion did not affect
VEGF-A-stimulated VEGFR2 degradation over a 60 min time course (Fig. 3.10A),
suggesting that a UBA1-dependent pathway is not required for ligand-stimulated
VEGFR2 degradation.
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Figure 3.10. UBA1 depletion upregulates VEGF-A-stimulated signal
transduction. Endothelial cells transfected with non-targeting or UBA1 siRNA
were treated with 25 ng/ml VEGF-A, lysed and immunoblotted for phospho-
VEGFR2 (Y1175), phospho-PLCγ1 (Y783) and phospho-ERK1/2 (T202/Y204).
Quantification of phospho-VEGFR2 (B), phospho-PLCγ1 (C) and phospho-
ERK1/2 (D) levels in endothelial cells transfected with non-targeting or UBA1
siRNA. Errors bars indicated ±SEM (n≥3). p<0.05 (*), p<0.001 (***).
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3.2.5. UBA1 regulates ubiquitination of VEGF-A-stimulated VEGFR2
The identification of UBA1 as a regulator of constitutive VEGFR2 ubiquitination raised
the question of whether UBA1 is also involved in ligand-stimulated VEGFR2
ubiquitination. To test this, control or UBA1-depleted endothelial cells were stimulated
with VEGF-A followed by immunoblot analysis of VEGFR2 ubiquitination status (Fig.
3.11). Following VEGF-A stimulation, VEGFR2 complexes isolated by
immunoprecipitation were subjected to immunoblotting using antibodies specific for
K48- and K63-linked forms of ubiquitin or with a pan-ubiquitin (FK2) antibody (Fig.
3.11A). In control cells, VEGFR2 ubiquitination peaked 15 min after VEGF-A
stimulation, correlating closely with receptor autophosphorylation (Fig 3.11A). In
UBA1-depleted cells, peak VEGF-A-stimulated VEGFR2 ubiquitination was ~60%
reduced (Fig. 3.11B). Furthermore, UBA1 depletion decreased the abundance of both
K48- and K63-linked polyubiquitin chains associated with the activated VEGFR2
complex (Fig. 3.11A). These findings show that UBA1 is also involved in
ubiquitination of ligand-activated VEGFR2. Examination of VEGFR2 degradation
revealed an interesting anomaly: although UBA1 depletion reduced ubiquitination of
activated VEGFR2, subsequent degradation was relatively unaffected (Fig. 3.11A).
Thus, UBA1-mediated ubiquitination of activated VEGFR2 does not regulate
downstream degradation. Whilst UBA1 controls basal turnover of resting VEGFR2,
additional complexity is introduced by VEGF-A stimulation, with potential
participation of other degradative pathways.
3.2.6. Basal VEGFR2 turnover regulates VEGF-A-dependent
endothelial cell tubulogenesis
VEGF-A-stimulated activation of VEGFR2 promotes downstream signal transduction
leading to new blood vessel sprouting, an essential feature of angiogenesis (Ferrara,
1999). In an organotypic endothelial-fibroblast co-culture assay, VEGF-A stimulated
tubulogenesis was revealed by monitoring the endothelial-specific protein PECAM-1
using immunofluorescence microscopy (Fig. 3.12A). Upon comparison of each non-
stimulated condition with the corresponding VEGF-A-stimulated condition for non-
transfected, control siRNA or UBA1 siRNA-treated cells, VEGF-A-dependent
tubulogenesis of UBA1-depleted cells was significantly higher than that of controls
(Fig. 3.12B, C). VEGF-A-stimulated endothelial tubule length increased by ~40% in
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UBA1-depleted cells (Fig. 3.12B). Furthermore, UBA1-depleted endothelial cells
displayed ~5-fold increase in VEGF-A-stimulated branch point number within the
endothelial network (Fig. 3.12C). Depletion of endothelial UBA1 thus increases VEGF-
A-stimulated tubulogenesis.
3.2.7. VEGF-A-dependent endothelial cell migration and proliferation
are increased upon UBA1 depletion
Other functional cellular outputs that are regulated by VEGF-A-stimulated signal
transduction include endothelial cell migration and proliferation (Koch and Claesson-
Welsh, 2012). In addition to tubulogenesis, it is possible that UBA1 depletion affects
these cellular responses. To test this idea, we carried out cell migration assays in which
control and UBA1-depleted endothelial cells migrated towards a chemotactic gradient
of increasing VEGF-A concentration (Fig. 3.13). Comparison of non-stimulated cells to
those treated with VEGF-A revealed that UBA1-depleted endothelial cells displayed a
pronounced ~70% increase in VEGF-A-stimulated cell migration (Fig. 3.13A, B).
Furthermore, we examined the requirement of UBA1 for VEGF-A-stimulated cell
proliferation. UBA1 depletion increased VEGF-A-dependent cell proliferation by ~40%
(Fig. 3.13C). Thus UBA1-mediated control of basal VEGFR2 recycling and degradation
impacts on endothelial cell responses stimulated by exogenous VEGF-A.
3.3. Discussion
Ubiquitination plays key roles in VEGFR2 trafficking and degradation (Ewan et al.,
2006, Bruns et al., 2010). We now provide evidence of a novel pathway requiring the
E1 enzyme, UBA1, to program basal VEGFR2 levels for degradation. Our study
provides a mechanism to precisely influence net plasma membrane and basal VEGFR2
levels, thus controlling RTK-mediated signal transduction and the cellular response to
extracellular ligand (Fig. 3.14). This ligand-independent pathway for surveillance of
VEGFR2 levels provides a mechanism for modulating the duration and intensity of
VEGF-A-stimulated signal transduction. Perturbation of UBA1 function using RNAi
increases plasma membrane VEGFR2 availability and elevates VEGF-A-stimulated
signal transduction events. Notably, elevated phosphorylation and activation of
VEGFR2, PLCγ1 and ERK1/2 was evident in UBA1-depleted cells. The link between 
plasma membrane protein ubiquitination and trafficking is highlighted by increased
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Figure 3.11. UBA1 regulates ubiquitination of VEGF-A-activated VEGFR2.
(A) Endothelial cells transfected with control or UBA1 siRNA, treated with 25
ng/ml VEGF-A and lysed. VEGFR2 was immunoprecipitated and immunoblotted
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(n≥3). p<0.001 (***). IP; immunoprecipitate, WCL; whole cell lysate.
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Figure 3.12. Basal VEGFR2 turnover regulates the VEGF-A-dependent
endothelial response. (A) Primary human endothelial cells transfected with non-
targeting or UBA1 siRNA were co-cultured on a bed of primary human
fibroblasts for 7 days, treated with 25 ng/ml VEGF-A, fixed and stained with an
antibody to PECAM-1 (red). Scale bar represents 1000 μm. Quantification of
VEGF-A-stimulated total tubule length (B) and total number of branch points (C)
relative to non-stimulated controls for non-transfected, control siRNA or UBA1
siRNA-treated endothelial cells. Error bars denote ±SEM (n≥3). p<0.05 (*),
p<0.01 (**). Gareth Fearnley (Ponnambalam Laboratory, University of Leeds)
contributed to the data shown in this figure.
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Figure 3.13. Basal VEGFR2 turnover regulates VEGF-A-dependent
endothelial cell migration and proliferation. (A) Primary human endothelial
cells transfected with non-targeting or UBA1 siRNA were seeded into transwell
migration chambers. Cells that migrated towards a chemotactic gradient of
VEGF-A over 24 h were fixed and stained with crystal violet. Scale bar
represents 1000 μm. (B) Quantification of VEGF-A-dependent migration of
endothelial cells transfected with non-targeting or UBA1 siRNA. (C)
Proliferation of endothelial cells transfected with control or UBA1 siRNA was
monitored by ELISA. Error bars denote ±SEM (n≥3). p<0.05 (*), p<0.01 (**),
p<0.001 (***).
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Figure 3.14. Ubiquitin-linked regulation of basal VEGFR2 recycling and
plasma membrane levels. UBA1-dependent ubiquitination regulates basal
VEGFR2 recycling and degradation. Ubiquitinated VEGFR2 is trafficked to
lysosomes (Lys) for degradation, whilst de-ubiquitination in early endosomes
(EE) promotes recycling to the plasma membrane. Controlling the balance
between basal VEGFR2 recycling and proteolysis regulates plasma membrane
VEGFR2 levels to set a threshold for VEGF-A-stimulated signal transduction,
thus impacting on downstream cellular responses.
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VEGFR2 endosome-to-plasma membrane recycling upon UBA1 depletion. Notably,
trafficking of another plasma membrane receptor, FGFR1, was relatively unaffected by
UBA1 depletion, suggesting specificity in this pathway for regulating basal VEGFR2
status. Finally, such regulation has significant consequences for VEGF-A-stimulated
cellular responses such as endothelial cell tubulogenesis, migration and proliferation:
reduction in UBA1 levels elevates the pro-angiogenic response to VEGF-A.
Ligand-stimulated ubiquitination of VEGFR2 programs terminal degradation in
lysosomes (Ewan et al., 2006). Conflicting studies implicate E3 ligases c-Cbl and -
TrCP1 in VEGF-A-stimulated proteolysis of VEGFR2 (Duval et al., 2003, Murdaca et
al., 2004, Shaik et al., 2012, Bruns et al., 2010, Singh et al., 2007). Furthermore, the
differences in proteolytic susceptibility of VEGFR1 and VEGFR2 under both resting
(Mittar et al., 2009) and hypoxic (Ulyatt et al., 2011) conditions suggest that endothelial
cells exploit VEGFR availability to fine-tune the cellular response to VEGF-A.
Interestingly, kinase-independent regulation of RTK function is highlighted by the
discovery that constitutive binding of cytosolic adaptors such as Grb2 to basal FGFR2
regulates downstream ligand-independent activation (Lin et al., 2012). Other work has
shown that constitutive ubiquitination and endocytosis of EGFR involves endocytic
adaptor protein, Hrs (Katz et al., 2002). Furthermore, recent work has highlighted a
kinase-independent role for EGFR in autophagy (Tan et al., 2015).
UBA1 regulates VEGF-A-stimulated VEGFR2 ubiquitination. K48-linked
polyubiquitin chains are associated with proteasomal degradation whilst K63-linked
chains are associated with membrane receptor trafficking in the endosome-lysosome
network (Pickart, 2001, Adhikari and Chen, 2009). VEGFR2 exhibited reduced
attachment of both K48- and K63-linked polyubiquitin chains upon UBA1 depletion.
Reduced VEGFR2 ubiquitination would be predicted to inhibit VEGF-A-stimulated
degradation however proteolysis of activated VEGFR2 was unaffected upon UBA1-
depletion. This suggested further complexity in the mechanisms underlying
programming of activated VEGFR2 for lysosomal degradation. One conclusion is that a
UBA1-regulated pathway controls constitutive VEGFR2 recycling and proteolysis as a
mechanism to adjust intensity of VEGF-A-stimulated signal transduction. It is likely
that multiple degradative pathways exist for regulating ligand-stimulated VEGFR2
turnover.
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UBA1 is an essential cellular enzyme expressed by many cells and tissues and is
implicated in regulating multiple pathways including DNA replication. Notably,
suppression of UBA1 activity in Schwann cells is linked to spinal muscular atrophy
(Sugaya et al., 2015, Aghamaleky Sarvestany et al., 2014). Other studies have identified
UBA1 as a novel target for the treatment of haematological malignancies (Yang et al.,
2007, Xu et al., 2010). It has not escaped our notice that UBA1-mediated surveillance
could be utilised for controlling RTK levels and cellular responses in different tissues.
The potential for UBA1 to be targeted for disease therapy is highlighted in certain
cancers (e.g. prostate cancer) which show reduced UBA1 levels
(http://www.proteinatlas.org/). Thus, decreased UBA1 expression could be linked to
increased angiogenesis in cancer. UBA1-mediated control of basal VEGFR2
availability for VEGF-A binding provides a dramatic alternative to the canonical view
of regulating RTK signal transduction. The existence of a kinase-independent pathway
that controls basal VEGFR2 levels to regulate VEGF-A signal transduction provides
new routes for therapeutic intervention. Blocking UBA1 activity could upregulate RTK
levels and alleviate disease states, such as ischaemic heart disease, to promote
angiogenesis, revascularisation and tissue regeneration. Conversely, promoting UBA1
activity could hinder tumour growth in response to circulating growth factors.
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CHAPTER 4
E2 ubiquitin-conjugating enzymes UBE2D1 and
UBE2D2 regulate basal VEGFR2 turnover and the
endothelial response
4.1. Introduction
Ligand-activated VEGFR2 undergoes ubiquitin-linked proteolysis (Bruns et al., 2010,
Ewan et al., 2006) but the factors that regulate basal VEGFR2 turnover are unknown.
Ubiquitination regulates membrane protein targeting for degradation and/or intracellular
localisation (Ciechanover et al., 2000), suggesting a functional role in modulating both
resting and activated RTK status. Protein ubiquitination requires initial action of an E1
ubiquitin-activating enzyme, followed by an E2 ubiquitin-conjugating enzyme working
in concert with an E3 ubiquitin ligase (Hershko and Ciechanover, 1992). E2 enzymes
conjugate ubiquitin by trans-thiolation and act as intermediaries between the E1 and E3
enzymes (Pickart, 2001).
Here, we build on previous work which identified a novel pathway requiring the E1
ubiquitin-activating enzyme, UBA1, to modulate basal plasma membrane VEGFR2
levels. We now show that the E2 ubiquitin-conjugating enzymes, UBE2D1 and
UBE2D2, regulate basal VEGFR2 turnover. This regulatory mechanism regulates the
initial endothelial response to VEGF-A. VEGFR2 undergoes VEGF-A-independent,
constitutive degradation via a UBE2D1/UBE2D2-dependent ubiquitin-linked pathway.
Endothelial UBE2D1 or UBE2D2 depletion increased endosome-to-plasma membrane
VEGFR2 recycling and reduced proteolysis. UBE2D1 or UBE2D2 depletion thus
elevated VEGF-A-stimulated signal transduction, exemplified by increased PLCγ1, p38 
MAPK, Akt and ERK1/2 activation. Importantly, UBE2D1 and UBE2D2-depleted
endothelial cells displayed increased VEGF-A-stimulated tubulogenesis. Our work
reveals the involvement of two E2 enzymes, UBE2D1 and UBE2D2, in programming
basal ubiquitin-dependent recycling and proteolysis of resting VEGFR2. Such
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regulation is important in controlling the endothelial response to exogenous ligand such
as VEGF-A.
4.2. Results
4.2.1. UBE2D1 and UBE2D2 regulate basal VEGFR2 levels
Our previous work identified a novel ligand-independent pathway for regulating
VEGFR2 levels in endothelial cells. This work highlighted the role of the E1 enzyme,
UBA1, in basal VEGFR2 ubiquitination, recycling and degradation. To identify which
of the 39 E2 ubiquitin-conjugating enzymes are involved in this pathway we used RNAi
to screen those which interact with UBA1 (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=UBA1) (Fig. 4.1A). Of the 20 E2s screened, quantification
revealed that siRNAs directed against UBE2D1, UBE2D2, UBE2E3, UBE2I, UBE2C,
UBE2H, UBE2K and UBE2N increased basal VEGFR2 levels (Fig. 4.1B).
4.2.2. UBE2D1 and UBE2D2 regulate the VEGF-A-stimulated
response
VEGF-A binding to plasma membrane VEGFR2 stimulates multiple signal transduction
pathways (Koch et al., 2011, Zhang et al., 2008). UBA1 mediates basal VEGFR2
turnover to regulate plasma membrane VEGFR2 levels, thus controlling the intensity of
VEGF-A-stimulated signal transduction. The E2(s) involved in this ligand-independent
pathway are unknown. To determine which E2(s) regulates this pathway we screened
those identified in Figure 4.1 for effects on VEGF-A-stimulated signal transduction.
Endothelial cells treated with control or individual E2 siRNAs were subjected to VEGF-
A stimulation before probing downstream signal transduction events using quantitative
immunoblotting. Of the 8 E2s screened, UBE2D1 and UBE2D2 depletion showed the
most pronounced effect on VEGF-A-stimulated signal transduction, VEGF-A-
stimulated VEGFR2 degradation and VEGF-A-induced production of a 160 kDa
VEGFR2 proteolytic fragment (Fig. 4.2, 4.3, 4.4, 4.5, 4.6). The cytoplasmic VEGFR2-
Y1175 epitope is autophosphorylated upon VEGF-A stimulation (Koch et al., 2011).
Quantitative analysis revealed that UBE2D1 and UBE2D2 depletion increased
VEGFR2-pY1175 levels by 58% and 50%, respectively (Fig. 4.7A). Plasma membrane
VEGFR2 activation is linked to recruitment, tyrosine phosphorylation and activation of
PLCγ1 (Koch et al., 2011). PLCγ1 phosphorylation increased by 55% in UBE2D1-
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Figure 4.1. An RNAi screen of the E2 ubiquitin-conjugating enzymes for
effects on basal VEGFR2 levels. (A) Endothelial cells treated with non-targeting
or individual E2-targeting siRNA were lysed and immunoblotted with antibodies
for VEGFR2. (B) Quantification of VEGFR2 levels in primary human endothelial
cells treated with non-targeting or E2-targeting siRNA. Error bars denote ±SEM
(n≥3). p<0.05 (*), p<0.01 (**), p<0.001 (***).
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Figure 4.2. A screen of UBE2D1, UBE2D2, UBE2E3 and UBE2I for effects on
VEGF-A-stimulated signal transduction. Phospho-VEGFR2 (A), phospho-
PLCγ1 (B), phospho-Akt (C), phospho-p38 MAPK (D) and phospho-ERK1/2 (E)
levels in endothelial cells transfected with non-targeting, UBE2D1 or UBE2D2,
UBE2E3 or UBE2I siRNA and subjected to a VEGF-A (25 ng/ml) time course (0,
5, 15 min) followed by lysis and quantitative immunoblotting. Error bars indicate
±SEM (n≥3). p<0.05 (*), p<0.01 (**), p<0.001 (***), p<0.0001 (****).
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Figure 4.3. A screen of UBE2D1, UBE2D2, UBE2E3 and UBE2I for effects on
VEGF-A-stimulated VEGFR2 levels. Quantification of VEGFR2 (A) and
VEGFR2-dervied 160 kD fragment (B) levels in endothelial cells transfected with
non-targeting, UBE2D1 or UBE2D2, UBE2E3 or UBE2I siRNA subjected to a
VEGF-A (25 ng/ml) time course (0, 5, 15, 30, 60 min) followed by lysis and
quantitative immunoblotting. Error bars indicate ±SEM (n≥3). p<0.05 (*), p<0.01
(**), p<0.001 (***), p<0.0001 (****).
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Figure 4.4. A screen of UBE2C, UBE2H, UBE2K and UBE2N for effects on
VEGF-A-stimulated signal transduction. Phospho-VEGFR2 (A), phospho-
PLCγ1 (B), phospho-Akt (C), phospho-p38 MAPK (D) and phospho-ERK1/2 (E)
levels in endothelial cells transfected with non-targeting, UBE2C or UBE2H,
UBEK or UBE2N siRNA and subjected to a VEGF-A (25 ng/ml) time course (0,
5, 15 min) followed by lysis and quantitative immunoblotting.. Error bars indicate
±SEM (n≥3). p<0.05 (*), p<0.01 (**), p<0.001 (***), p<0.0001 (****).
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Figure 4.5. A screen of UBE2C, UBE2H, UBE2K and UBE2N for effects on
VEGF-A-stimulated VEGFR2 levels. Quantification of VEGFR2 (A) and
VEGFR2-dervied 160 kD fragment (B) levels in endothelial cells transfected with
non-targeting, UBE2C or UBE2H, UBE2K or UBE2N siRNA and subjected to a
VEGF-A (25 ng/ml) time course (0, 5, 15, 30, 60 min) followed by lysis and
quantitative immunoblotting. Error bars indicate ±SEM (n≥3). p<0.05 (*), p<0.01
(**), p<0.001 (***).
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depleted cells and by 58% in UBE2D2-depleted cells (Fig. 4.7B). VEGF-A-stimulated
activation of the master regulator and serine/threonine protein kinase, Akt, was
increased by 57% and 56% in UBE2D1 and UBE2D2-depleted endothelial cells,
respectively (Fig. 4.7C). Phosphorylation and activation of the p38 MAPK pathway was
increased by 56% in UBE2D1-depleted cells and by 67% in UBE2D2-depleted cells
(Fig. 4.7D). A key feature of VEGF-A-stimulated signal transduction is activation of the
MAPK pathway involving ERK1/2 (Koch and Claesson-Welsh, 2012). ERK1/2
activation displayed a 68% increase in UBE2D1-depleted cells and a 53% increase in
UBE2D2-depleted cells (Fig. 4.7E). UBE2D1 and UBE2D2 thus modulate the VEGF-
A-stimulated response through a range of signal transduction pathways.
Quantification of basal VEGFR2 levels revealed a 2.3 fold increase in UBE2D1-
depleted cells and a 1.7 fold increase in UBE2D2-depleted cells (Fig. 4.7F). In control
cells, VEGFR2 underwent 52% VEGF-A-stimulated degradation over 60 min (Fig.
4.7F), whilst VEGFR2 was degraded by 57% and 42% upon VEGF-A stimulation of
UBE2D1- and UBE2D2-depleted cells, respectively (Fig. 4.7F). Thus, E2 depletion had
limited effect on the degradation rate of activated VEGFR2, however, VEGFR2 levels
did remain ~2 fold higher in UBE2D1- and UBE2D2-depleted cells after 60 min VEGF-
A stimulation (Fig. 4.7F).
Immunofluorescence microscopy of endothelial cells stained with antibodies to
VEGFR2 confirmed that basal VEGFR2 levels were elevated in UBE2D1- and
UBE2D2-depleted cells (Fig. 4.8A, B). In control cells depleted of another UBA1-
interacting E2, UBE2A, basal VEGFR2 levels were unaffected (Fig. 4.8A, B). UBE2D1
and UBE2D2 are thus E2 ubiquitin-conjugating enzymes that regulate basal VEGFR2
levels.
4.2.3. UBE2D1 and UBE2D2 regulate basal VEGFR2 degradation
Subjecting endothelial cells to a block in protein synthesis allows monitoring of mature
VEGFR2 degradation (Shaik et al., 2012). Using CHX to block new protein synthesis
thus provides a means of evaluating the effect of UBE2D1 and UBE2D2 depletion on
mature plasma membrane VEGFR2 turnover. To test how UBE2D1 or UBE2D2
depletion affects such basal VEGFR2 turnover, we used RNAi to deplete UBE2D1 or
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Figure 4.6. UBE2D1 and UBE2D2 depletion upregulates VEGF-A-stimulated
signal transduction. Endothelial cells transfected with non-targeting, UBE2D1
or UBE2D2 siRNA were treated with 25 ng/ml VEGF-A, lysed and
immunoblotted for phospho-VEGFR2 (Y1175), phospho-PLCγ1 (Y783),
phospho-Akt (S473), phospho-p38 MAPK (T180/Y182) and phospho-ERK1/2
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Figure 4.7. UBE2D1 and UBE2D2 depletion upregulates VEGF-A-stimulated
signal transduction. Quantification of phospho-VEGFR2 (A), phospho-PLCγ1
(B), phospho-Akt (C), phospho-p38 MAPK (D), phospho-ERK1/2 (E) and
VEGFR2 (F) levels in endothelial cells transfected with non-targeting, UBE2D1
or UBE2D2 siRNA and subjected to a VEGF-A (25 ng/ml) time course (0, 5, 15,
30, 60 min) followed by lysis and quantitative immunoblotting. Error bars
indicate ±SEM (n≥3). p<0.05 (*), p<0.01 (**), p<0.001 (***), p<0.0001 (****).
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Figure 4.8. UBE2D1 and UBE2D2 regulate basal VEGFR2 levels. (A)
Immunofluorescence microscopy of endothelial cells transfected with non-
targeting, UBE2D1, UBE2D2 or UBE2A siRNA and stained with antibodies to
VEGFR2 followed by fluorescent species-specific secondary antibodies (green).
Nuclei were stained with DNA-binding dye, DAPI (blue). Scale bar represents 70
μm. (B) Quantitative microscopy of VEGFR2 levels in endothelial cells treated
with non-targeting, UBE2D1, UBE2D2 or UBE2A siRNA. Error bars denote
±SEM (n≥3). p<0.05 (*), p<0.01 (**).
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UBE2D2 in endothelial cells, followed by CHX treatment to block protein synthesis
(Fig. 4.9A). Immunoblotting confirmed that basal (0 min) VEGFR2 levels were
elevated in UBE2D1- or UBE2D2-depleted endothelial cells in which RTK
phosphorylation/activation was not evident (Fig. 4.9A). Importantly, UBA1 depletion
did not affect levels of other plasma membrane receptors such TfR (Fig. 4.9A).
Quantification revealed that under control conditions, 59% of mature VEGFR2
underwent degradation over an 80 min period of CHX treatment (Fig. 4.9B). Upon
UBE2D1 depletion, VEGFR2 exhibited 49% basal degradation. In UBE2D2-depleted
endothelial cells, VEGFR2 was degraded by 31% after 80 min CHX treatment (Fig.
4.9B). Thus, E2 depletion substantially reduced the rate of constitutive VEGFR2
degradation (Fig. 4.9C). Endothelial cells depleted of both UBE2D1 and UBE2D2
exhibited a response in between that produced when UBE2D1 or UBE2D2 were
depleted individually (Fig. 4.9A).
Morphological analysis of VEGFR2 distribution using quantitative microscopy further
supported a role for UBE2D1 and UBE2D2 in basal VEGFR2 degradation and turnover
(Fig. 4.10). Comparison of control and UBE2D1- or UBE2D2-depleted endothelial cells
revealed that basal (0 min) VEGFR2 levels were 67% and 71% higher in UBE2D1- and
UBE2D2-depleted cells, respectively (Fig. 4.10B). Furthermore, in the presence of
CHX, control cells exhibited 47% degradation after 60 min (Fig. 4.10B). However,
basal VEGFR2 levels were reduced by only 15% upon UBE2D1 depletion and 25% in
UBE2D2-depleted cells (Fig. 4.10B). These findings confirm that UBE2D1 and
UBE2D2 regulate basal VEGFR2 turnover in a ligand-independent manner.
4.2.4. UBE2D1 and UBE2D2 regulate basal VEGFR2 ubiquitination
Direct ubiquitination could be one means through which UBE2D1 and UBE2D2
regulate basal VEGFR2 turnover. To test this idea, we immunoprecipitated mature
VEGFR2 from CHX-treated control, UBE2D1- or UBE2D2-depleted endothelial cells
and evaluated ubiquitination status by immunoblot analysis (Fig 4.11A). Although
levels of ubiquitinated receptor appear higher than in control cells, particularly upon
UBE2D2 depletion (Fig. 4.11A), this is counteracted by higher levels of VEGFR2 to
begin with in UBE2D1 or UBE2D2-depleted cells (Fig. 4.11A). In control cells
subjected to a CHX time course, basal VEGFR2 ubiquitination peaked after 40 min
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Figure 4.9. UBE2D1 and UBE2D2 regulate ligand-independent VEGFR2
degradation. (A) Endothelial cells transfected with non-targeting, UBE2D1 or
UBE2D2 siRNA were treated with 20 μg/ml CHX over a time course of 80 min
and immunoblotted for phospho-VEGFR2, VEGFR2, transferrin receptor (TfR),
UBE2D1, UBE2D2 or tubulin. (B) VEGFR2 levels in endothelial cells
transfected with non-targeting, UBE2D1 or UBE2D2 siRNA, treated with 20
μg/ml CHX (80 min) and analysed by quantitative immunoblotting. (C) VEGFR2
degradation rate quantified by comparison of the 0 min time point with
corresponding CHX-treated time points. Error bars denote ±SEM (n≥3). p<0.05
(*), p<0.01 (**), p<0.001 (***).
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Figure 4.10. Confirmation that UBE2D1 and UBE2D2 regulate ligand-
independent VEGFR2 degradation by quantitative microscopy. (A)
Endothelial cells transfected with non-targeting, UBE2D1 or UBE2D2 siRNA
were treated with 20 μg/ml CHX over a time course of 60 min and processed for
immunofluorescence microscopy using antibodies to VEGFR2 followed by
fluorescent species-specific secondary antibodies (green). Nuclei were stained
with DNA-binding dye, DAPI (blue). Scale bar represents 200 μm. (E) VEGFR2
levels in endothelial cells treated with 20 μg/ml CHX quantified using
microscopy datasets. Error bars denote ±SEM (n≥3). p<0.05 (*), p<0.01 (**),
p<0.001 (***), p<0.0001 (****).
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(Fig. 4.11B). In contrast, VEGFR2 ubiquitination did not peak until 80 min in
UBE2D1- or UBE2D2-depleted endothelial cells (Fig. 4.11B). These findings support a
role for UBE2D1 and UBE2D2 in regulating basal VEGFR2 ubiquitination to promote
ligand-independent degradation.
4.2.5. UBE2D1 and UBE2D2 regulate basal VEGFR2 recycling
RTK ubiquitination at the plasma membrane precedes internalisation and delivery to
early endosomes (Haglund and Dikic, 2012, Ewan et al., 2006, Clague and Urbe, 2001).
Ligand-stimulated VEGFR2 ubiquitination promotes trafficking to late endosomes and
terminal degradation in lysosomes (Ewan et al., 2006, Bruns et al., 2010). RTK de-
ubiquitination in early endosomes is associated with endosome-to-plasma membrane
recycling (Clague and Urbe, 2006). Furthermore, VEGFR2 undergoes substantial
constitutive, ligand-independent recycling via endosomes (Jopling et al., 2011). One
possibility is that upon UBE2D1 or UBE2D2 depletion, VEGFR2 undergoes decreased
basal ubiquitination which is a prerequisite for increased endosome-to-plasma
membrane recycling. To test this idea, we utilised a microscopy-based VEGFR2
recycling assay (Jopling et al., 2011). Here, control, UBE2D1- or UBE2D2-depleted
endothelial cells were incubated with extracellular domain-specific antibodies to
VEGFR2. Constitutive VEGFR2 endocytosis and recycling was monitored using
accessibility of VEGFR2-antibody complexes to a subsequent pulse of labelled
secondary antibody. Only VEGFR2-antibody complexes that had undergone
endocytosis followed by endosome-to-plasma membrane recycling were detected (Fig.
4.12A). Quantification revealed that UBE2D1- or UBE2D2-depleted endothelial cells
displayed 50% or 57% increase in basal VEGFR2 recycling, respectively (Fig. 4.12B).
VEGF-A-stimulated recycling was also increased in UBE2D1- or UBE2D2-depleted
cells, however, this increase was not VEGF-A-dependent and likely resulted from
elevated levels of resting VEGFR2 (Fig. 4.12B).
One prediction is that increased basal recycling of VEGFR2 increases overall plasma
membrane levels in UBE2D1- or UBE2D2-depleted cells. To test this hypothesis,
endothelial cells were treated with CHX to block new protein synthesis and subjected to
cell surface biotinylation followed by purification of biotinylated plasma membrane
proteins and immunoblot anaylsis (Fig. 4.13A). VEGFR2 plasma membrane levels were
clearly elevated upon UBE2D1 or UBE2D2 depletion, whereas another integral plasma
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Figure 4.11. UBE2D1 and UBE2D2 regulate basal ubiquitination of
VEGFR2. (A) Primary human endothelial cells transfected with non-targeting,
UBE2D1 or UBE2D2 siRNA were treated with 20 μg/ml CHX and lysed.
VEGFR2 was immunoprecipitated and immunoblotted for ubiquitin status using
a pan-ubiquitin antibody. (B) Quantification of ubiquitinated VEGFR2 (Ub-
VEGFR2) levels in endothelial cells transfected with non-targeting, UBE2D1 or
UBE2D2 siRNA and treated with 20 μg/ml CHX. Relative Ub-VEGFR2 levels
were normalised against IgG and VEGFR2. Error bars denote ±SEM (n≥3).
p<0.001 (***), p<0.0001 (****). IP; immunoprecipitate, WCL, whole cell lysate.
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Figure 4.12. UBE2D1 and UBE2D2 regulate basal recycling of VEGFR2. (A)
Endothelial cells transfected with non-targeting, UBE2D1 or UBE2D2 siRNA
were incubated with antibodies to VEGFR2 for 30 min at 37°C before being
treated with 25 ng/ml VEGF-A, acid-washed to strip cell surface antibodies and
incubated with fluorescent species-specific secondary antibodies for 30 min at
37°C (green). Cells were fixed prior to staining with DNA-binding dye, DAPI
(blue). Only VEGFR2 that underwent plasma membrane-to-endosome-to-plasma
membrane recycling is visible. Scale bar represents 200 μm. (B) Basal and
VEGF-A-stimulated VEGFR2 recycling quantified in cells transfected with non-
targeting, UBE2D1 or UBE2D2 siRNA. Error bars denote ±SEM (n≥3). p<0.01
(**), p<0.001 (***), p<0.0001 (****).
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membrane protein, TfR, was unaffected (Fig. 4.13A). Quantification revealed that under
control conditions, plasma membrane VEGFR2 levels were gradually reduced by 68%
over an 80 min period of CHX treatment (Fig. 4.13B). In UBE2D1-depleted cells
plasma membrane VEGFR2 levels remained relatively stable until 80 min after CHX
treatment when levels dropped by 35% (Fig. 4.13B). In contrast to control cells,
UBE2D2-depleted cells exhibited 31% increase in cell surface (0 min) VEGFR2 levels
which decreased by 45% after CHX treatment for 80 min (Fig. 4.13B). Taken together,
these data suggest that UBE2D1 and UBE2D2 regulate basal endosome-to-plasma
membrane recycling and plasma membrane VEGFR2 levels in an ubiquitin-dependent
manner. Biotinylation of plasma membrane proteins also revealed that whilst basal (0
min) plasma membrane VEGFR2 levels were higher in UBE2D1- and UBE2D2-
depleted cells (Fig. 4.14A), VEGF-A-stimulated internalisation was unaffected (Fig.
4.14B).
4.2.6. Basal VEGFR2 turnover by UBE2D1 and UBE2D2 regulates
VEGF-A-dependent endothelial cell tubulogenesis
VEGF-A-stimulated activation of VEGFR2 promotes downstream signal transduction
leading to new blood vessel sprouting, an essential feature of angiogenesis (Ferrara,
1999). In an endothelial-fibroblast co-culture assay, VEGF-A stimulated tubulogenesis
was revealed by staining for the endothelial-specific protein, PECAM-1 (Fig. 4.15A). In
the absence of VEGF-A, tubule growth of UBE2D1- or UBE2D2-depleted endothelial
cells was unaffected (Fig. 4.15B, C). Upon comparison of each non-stimulated
condition with the corresponding VEGF-A-stimulated condition for non-transfected,
control, UBE2D1, or UBE2D2 siRNA-treated cells VEGF-A-dependent tubulogenesis
of UBE2D1- and UBE2D2-depleted cells was significantly higher than that of control
cells (Fig. 4.15B, C). VEGF-A-stimulated endothelial tubule length increased by 55%
and 54% in UBE2D1- and UBE2D2-depleted cells, respectively (Fig. 4.15B).
Furthermore, UBE2D1- and UBE2D2-depleted endothelial cells displayed 3.5-fold and
2-fold increase in branch point number, respectively (Fig. 4.15C). Depletion of
UBE2D1 or UBE2D2 thus increases VEGF-A-stimulated tubulogenesis.
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Figure 4.13. UBE2D1 and UBE2D2 regulate plasma membrane VEGFR2
levels. (A) Primary human endothelial cells transfected with non-targeting,
UBE2D1 or UBE2D2 siRNA were treated with 20 μg/ml CHX. Cell surface
proteins were biotinylated, isolated and immunoblotted for plasma membrane
VEGFR2 (PM VEGFR2) or transferrin receptor (TfR). (B) Cell surface VEGFR2
levels in endothelial cells transfected with non-targeting, UBE2D1 or UBE2D2
siRNA and treated with 20 μg/ml CHX determined using quantitative
immunoblotting. Error bars denote ±SEM (n≥3). p<0.05 (*). IP;
immunoprecipitate, WCL; whole cell lysate.
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Figure 4.14. UBE2D1 and UBE2D2 regulate basal plasma membrane
VEGFR2 levels. (A) Endothelial cells transfected with non-targeting, UBE2D1
or UBE2D2 siRNA were treated with 25 ng/ml VEGF-A, cell surface biotinylated
and lysed. Biotinylated proteins were isolated and immunoblotted using
antibodies against VEGFR2. (B) Cell surface VEGFR2 levels over a time course
of 25 ng/ml VEGF-A stimulation in endothelial cells transfected with non-
targeting, UBE2D1 or UBE2D2 siRNA determined using quantitative
immunoblotting. Error bars denote ±SEM (n≥3). IP; immunoprecipitate, WCL;
whole cell lysate.
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Figure 4.15. Basal VEGFR2 turnover by UBE2D1 or UBE2D2 regulates the
VEGF-A-dependent endothelial response. (A) Primary human endothelial cells
transfected with non-targeting, UBE2D1 or UBE2D2 siRNA were co-cultured on
a bed of primary human fibroblasts for 7 days, treated with 25 ng/ml VEGF-A,
fixed and stained with an antibody to PECAM-1. Scale bar represents 1000 μm.
Quantification of total tubule length (B) and total number of branch points (C)
from non-transfected or non-targeting, UBE2D1 or UBE2D2 siRNA-treated
endothelial cells. Error bars denote ±SEM (n≥3). p<0.05 (*), p<0.01 (**),
p<0.001 (***), p<0.0001 (****).
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4.2.7. UBE2D1 and UBE2D2 regulate VEGF-A-stimulated
ubiquitination of VEGFR2
The identification of UBE2D1 and UBE2D2 as regulators of constitutive VEGFR2
ubiquitination raised the question of whether they also play a role in ligand-stimulated
VEGFR2 ubiquitination. To test this, control, UBE2D1- or UBE2D2-depleted
endothelial cells were stimulated with VEGF-A followed by analysis of VEGFR2
ubiquitination status (Fig. 4.16). Following VEGF-A stimulation, immunoisolated
VEGFR2 complexes were subjected to immunoblotting using antibodies specific for
K48- and K63-linked forms of polyubiquitin or a pan-ubiquitin (FK2) antibody (Fig.
4.16). In control cells, VEGFR2 ubiquitination peaked 5-15 min after VEGF-A
stimulation (Fig 4.16B). Although levels of ubiquitinated receptor appear higher than in
control cells (Fig. 4.16A), this is counteracted by higher levels of VEGFR2 to begin
with in UBE2D1 or UBE2D2-depleted cells (Fig. 4.16A). These results provide
evidence for UBE2D1- and UBE2D2-mediated ubiquitination of ligand-activated
VEGFR2. In UBE2D1-depleted cells, VEGF-A-stimulated VEGFR2 ubiquitination was
31% reduced (Fig. 4.16B), whilst UBE2D2 caused a 45% reduction in ubiquitination of
activated VEGFR2 (Fig. 4.16B). This 45% reduction could be significant enough to
explain the 10% decrease in VEGF-A-stimulated VEGFR2 degradation upon UBE2D2
depletion (Fig. 4.7F). Nonetheless, the effect of UBE2D2 depletion on ligand-activated
VEGFR2 degradation is minimal suggesting that further ubiquitin-linked degradative
pathways exist to control VEGF-A-stimulated VEGFR2 proteolysis.
4.3. Discussion
Ubiquitination is involved in VEGFR2 trafficking and degradation (Ewan et al., 2006,
Bruns et al., 2010). Previously we identified a novel pathway in which the E1 ubiquitin-
activating enzyme, UBA1, programs VEGFR2 for basal degradation. This ligand-
independent mechanism precisely influences net plasma membrane VEGFR2 levels,
thus controlling RTK-mediated signal transduction and the cellular response to
extracellular ligand (Fig. 4.17). This pathway for surveillance of basal VEGFR2 levels
provides a mechanism for modulating the duration and intensity of VEGF-A-stimulated
signal transduction. We provide evidence that the E2 ubiquitin-conjugating enzymes,
UBE2D1 and UBE2D2, work downstream of UBA1 to regulate basal VEGFR2
degradation. The UBE2D family of E2s consists of three highly homologous proteins,
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Figure 4.16. UBE2D1 and UBE2D2 regulate ubiquitination of VEGF-A-
activated VEGFR2. (A) Endothelial cells transfected with non-targeting,
UBE2D1 or UBE2D2 siRNA were treated with 25 ng/ml VEGF-A and lysed.
VEGFR2 was immunoprecipitated and immunoblotted for its ubiquitin status
using antibodies against K48-linked polyubiquitin, K63-linked polyubiquitin and
pan-ubiquitin. (B) Quantification of ubiquitinated VEGFR2 levels in endothelial
cells transfected with non-targeting, UBE2D1 or UBE2D2 siRNA and treated
with 25 ng/ml VEGF-A. Relative Ub-VEGFR2 levels were normalised against
IgG and VEGFR2. Error bars denote ±SEM (n≥3). p<0.05 (*), p<0.001 (***). IP;
immunoprecipitate, WCL; whole cell lysate.
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UBE2D1, UBE2D2 and UBE2D3. Perturbation of UBE2D1 or UBE2D2 function using
RNAi increases plasma membrane VEGFR2 availability and elevates VEGF-A-
stimulated signal transduction. Notably, elevated phosphorylation and activation of
VEGFR2, PLCγ1, p38 MAPK, Akt and ERK1/2 was evident in UBE2D1- and 
UBE2D2-depleted cells. The link between plasma membrane protein ubiquitination and
trafficking is highlighted by increased VEGFR2 endosome-to-plasma membrane
recycling upon UBE2D1 or UBE2D2 depletion. Finally, such regulation has significant
consequences for VEGF-A-stimulated cellular responses such as endothelial
tubulogenesis: reduction in UBE2D1 or UBE2D2 levels elevates the pro-angiogenic
response to VEGF-A.
Ligand-stimulated ubiquitination of VEGFR2 programs terminal degradation in
lysosomes (Ewan et al., 2006). Other studies implicate E3 ubiquitin ligases, c-Cbl and
β-TrCP1, in VEGF-A-stimulated VEGFR2 proteolysis (Duval et al., 2003, Murdaca et 
al., 2004, Shaik et al., 2012, Bruns et al., 2010, Singh et al., 2007). Interestingly,
UBE2D2 shows specific binding to the RING domain of c-Cbl and is required for c-
Cbl-linked ubiquitin transfer to downstream targets (Huang et al., 2009). For example,
UBE2D2 is the E2 ubiquitin-conjugating enzyme upstream of c-Cbl in mediating EGF-
stimulated polyubiquitination of EGFR, both at the plasma membrane and after
internalisation (Umebayashi 2008). UBE2D2 is also involved in polyubiquitination of
dopamine transporter (DAT) in cooperation with the E3 ligase, Nedd4 (Vina-Vilaseca
and Sorkin, 2010). Thus, UBE2D enzymes can be coupled to both HECT and RING
domain (c-Cbl) E3 ligases to promote polyubiquitination. Another study described
polyubiquitination of IκBα by β-TrCP2. In this model, polyubiquitination is initiated by 
UBE2D1-mediated transfer of a single ubiquitin to IκBα. Monoubiquitin acts as a 
receptor to direct cdc34 (UBE2R1)-mediated elongation of the ubiquitin chain to initiate
β-TrCP2-dependent polyubiquitination (Wu et al., 2010). Thus, UBE2D1 and UBE2D2 
are capable of initiating chain elongation independently of an E3 ligase. It is possible
that other E2s and their interacting E3s are involved in chain elongation to generate
polyubiquitin as a signal for VEGFR2 degradation. It is also interesting to note that
UBE2D1/UBE2D2 are E2s for c-Cbl and β-TrCP isoforms, both of which are 
implicated in VEGF-A-stimulated ubiquitination of VEGFR2 (Duval et al., 2003,
Murdaca et al., 2004, Shaik et al., 2012, Bruns et al., 2010, Singh et al., 2007).
Figure 4.17. Regulation of basal VEGFR2 ubiquitination by UBA1, UBE2D1
and UBE2D2. The E1 ubiquitin-activating enzyme, UBA1, and the E2 ubiquitin-
conjugating enzymes, UBE2D1 and UBE2D2, ubiquitinate VEGFR2 in a ligand-
independent manner to regulate basal VEGFR2 recycling and degradation.
Ubiquitinated VEGFR2 is trafficked to lysosomes (Lys) for degradation, whilst
de-ubiquitination in early endosomes (EE) promotes recycling to the plasma
membrane. Controlling the balance between basal VEGFR2 recycling and
degradation regulates plasma membrane VEGFR2 levels to set a threshold for
VEGF-A-stimulated signal transduction, thus impacting on downstream cellular
responses.
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UBE2D1 has been associated with hypoxia-linked angiogenesis and capillarisation in
skeletal muscle (Basic et al., 2014). TNF stimulation increases protein expression of
anti-angiogenic VHL, PHD2 and UBE2D1 in skeletal muscle myocytes, disturbing
angiogenesis-linked signal transduction under hypoxic conditions (Basic et al., 2014).
This association between systemic inflammation and impaired angiogenesis is linked to
muscle wasting and cachexia in chronic inflammatory diseases such as chronic
obstructive pulmonary disease (COPD) (Basic et al., 2014).
UBA1-mediated control of basal VEGFR2 turnover to regulate availability for VEGF-A
binding provides a dramatic alternative to the canonical view of regulating RTK signal
transduction. The existence of a kinase-independent pathway that controls basal
VEGFR2 levels to regulate VEGF-A-stimulated signal transduction provides new routes
for therapeutic intervention. This work reveals the role of UBA1-interacting, E2
ubiquitin-conjugating enzymes, UBE2D1 and UBE2D2, in regulating basal VEGFR2
turnover. Blocking activity of the regulatory components of this pathway could
upregulate RTK levels to alleviate disease states such as ischaemic heart disease by
promoting angiogenesis, revascularisation and tissue regeneration. Conversely,
promoting UBA1, UBE2D1 or UBE2D2 activity could hinder tumour growth in
response to circulating growth factors.
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CHAPTER 5
VEGFR2 signalling, trafficking and proteolysis is
regulated by the ubiquitin isopeptidase USP8
5.1. Introduction
VEGFR2 is the principal receptor through which VEGF-A transmits its pro-angiogenic
signals in vascular endothelial cells (Olsson et al., 2006, Shibuya, 2010). VEGF-A
binding to VEGFR2 promotes dimerisation and transautophosphorylation of several key
tyrosine residues present within its cytoplasmic kinase domain (Koch and Claesson-
Welsh, 2012). Upon activation, VEGFR2 enters the endosome-lysosome system
through incorporation into clathrin-coated vesicles and trafficking to early endosomal
vesicular compartments (Ewan et al., 2006).
Ubiquitination of activated VEGFR2 acts as an endosomal sorting signal that binds to
the UIM of ESCRT-0 components, Hrs and STAM (de Melker et al., 2001, Ewan et al.,
2006, Bruns et al., 2010). Internalised VEGFR2 recycles back to the plasma membrane
or is committed for lysosomal degradation (Bruns et al., 2010, Jopling et al., 2014).
Ubiquitination is a dynamic protein modification that co-ordinates receptor trafficking,
recycling and degradation (Clague et al., 2012). The reversibility of ubiquitination is
credited to the action of DUBs (Clague et al., 2012). These enzymes thus play a distinct
but crucial role in RTK trafficking and turnover (Clague et al., 2012).
DUBs are a superfamily of 91 enzymes that can be subdivided into five distinct
subfamilies with differing specificities for the isopeptide bond that links ubiquitin
chains (Gao et al., 2013). De-ubiquitination of plasma membrane receptors promotes
recycling and is essential for maintaining the free ubiquitin pool upon which receptor
trafficking is dependent. Similar to the co-ordinated but opposing effects of kinase and
phosphatase activity, ubiquitination is kept in balance by the activity of DUBs (Wing,
2003).
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Although it is known that VEGFR2 is recycled from endosomes back to the plasma
membrane, it is unknown which DUBs prevent its lysosomal degradation. USP8 is a
DUB known to be involved in EGFR trafficking (Row et al., 2006, Mizuno et al., 2006,
MacDonald et al., 2014). USP8 is a cysteine protease and member of the ubiquitin-
specific protease (UBP) family of DUB enzymes capable of catalysing complete
breakdown of both K48- and K63-linked polyubiquitin into its component monomers
(McCullough et al., 2004, Mizuno et al., 2005, Row et al., 2006). USP8 has diverse
roles in membrane trafficking ranging from endosomal regulation to retrograde
transport (Row et al., 2006, MacDonald et al., 2014). The early endosome ESCRT-0
subunit, STAM, is a USP8-binding partner (Tanaka, 1999, Kato et al., 2000). This
interaction occurs via the SH3 domain of STAM and the proline-rich STAM-binding
motif in USP8 (Kato et al., 2000). USP8 depletion inhibits EGFR degradation and
causes accumulation of ubiquitinated proteins on enlarged endosomes which co-localise
with early endosomal markers (Row et al., 2006, Mizuno et al., 2006).
Once internalised cargo is committed for degradation, conjugated ubiquitin must be
recycled and removed by endosomal DUBs such as USP8, which can also associate
with the ESCRT-III complex on late endosomes (Hurley and Yang, 2008, Clague et al.,
2012). A model was proposed in which USP8 acts further downstream of early
endosomes to recycle ubiquitin after endosomal sorting and prior to lysosomal
sequestration suggesting a role in facilitating membrane receptor degradation
(McCullough et al., 2004). USP8 thus functions at two stages of plasma membrane
receptor trafficking: in early endosomes via ESCRT-0 interaction or in late endosomes
via ESCRT-III interaction.
Activated VEGFR2 undergoes ubiquitination but the enzymes that regulate this post-
translational modification are unclear. In this chapter, the de-ubiquitinating enzyme,
USP8, is shown to regulate VEGFR2 trafficking, de-ubiquitination, signal transduction
and proteolysis. Depletion of USP8 caused VEGFR2 accumulation in early endosomes
and impaired signal transduction. Furthermore, USP8-depleted endothelial cells
displayed altered VEGFR2 ubiquitination and production of a unique VEGFR2
extracellular domain proteolytic fragment caused by perturbed trafficking in the
endosome-lysosome system. Thus, regulation of VEGFR2 ubiquitination and de-
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ubiquitination has important consequences for the endothelial cell response and vascular
physiology.
5.2. Results
5.2.1. USP8 regulates VEGFR2 trafficking
Previous studies report that USP8 depletion causes EGFR accumulation in early
endosomes and inhibits downstream degradation due to general defects in endosomal
sorting (Row et al., 2006). USP8 thus seemed a likely candidate for regulating VEGFR2
trafficking. To test this idea, we used siRNA duplexes to deplete USP8 in primary
human endothelial cells prior to VEGF-A stimulation and immunofluorescence
microscopy (Fig. 5.1A). In control cells treated with non-targeting siRNA, internalised
VEGFR2 was detected in punctate structures at early (0-15 min) stages of VEGF-A
stimulation (Fig. 5.1A). After VEGF-A stimulation for 60 min, VEGFR2 staining was
substantially reduced consistent with significant degradation (Fig. 5.1A).
However, in USP8-depleted endothelial cells resting VEGFR2 was already accumulated
in enlarged punctate structures (Fig. 5.1A). This pattern of VEGFR2 distribution
persisted following VEGF-A stimulation suggesting accumulation of VEGFR2 within
the endosome-lysosome system. Persistence of these enlarged, VEGFR2-enriched
punctate structures over a 60 min time course of VEGF-A stimulation indicated
perturbed VEGFR2 trafficking and degradation (Fig. 5.1A). VEGFR2 accumulation
also occurred when cells were treated with individual USP8 siRNAs to limit off-target
effects (Fig. 5.2). To quantify distribution of mature VEGFR2 in the endosomal
pathway, USP8-depleted endothelial cells were pre-treated with CHX to block protein
synthesis followed by VEGF-A stimulation (Fig. 5.1A). Although the biosynthetic pool
of Golgi-localised VEGFR2 was absent after CHX treatment, mature VEGFR2 still
accumulated in USP8-depleted cells (Fig.5.1A). Quantification of VEGFR2 residing in
the endosome-lysosome system upon CHX treatment revealed VEGFR2 levels were
30% higher in non-stimulated, USP8-depleted cells (Fig. 5.1B). In addition, VEGFR2
underwent 20% VEGF-A-stimulated degradation in control cells. Contrastingly, high
levels of accumulated VEGFR2 persisted in USP8-depleted cells, undergoing only 5%
VEGF-A-stimulated degradation (Fig. 5.1B).
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Figure 5.1. USP8 is essential for VEGFR2 trafficking. (A) Endothelial cells
transfected with non-targeting or USP8 siRNA, pre-treated with CHX and
stimulated with 25 ng/ml VEGF-A were fixed and processed for
immunofluorescence microscopy using antibodies to VEGFR2 followed by
fluorescent species-specific secondary antibodies (green). Nuclei were stained
with DNA-binding dye, DAPI (blue). Scale bar represents 200 μm. (B) VEGFR2
levels residing in the endosome-lysosome system in endothelial cells pre-treated
with CHX and stimulated with VEGF-A determined using quantitative
microscopy. Errors bars indicate ±SEM (n≥3). p<0.05 (*), p<0.0001 (****).
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Figure 5.2. Individual USP8 siRNAs perturb VEGFR2 trafficking. (A)
Endothelial cells transfected with non-targeting or individual USP8 siRNAs and
stimulated with 25 ng/ml VEGF-A were fixed and processed for
immunofluorescence microscopy using antibodies to VEGFR2 followed by
fluorescent species-specific secondary antibodies (green). Nuclei were stained
with DNA-binding dye, DAPI (blue). Scale bar represents 200 μm. (B) To
confirm USP8 depletion, endothelial cells transfected with non-targeting or
individual USP8 siRNAs were lysed and immunoblotted with antibodies against
USP8.
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To ascertain the nature of these VEGFR2-enriched structures, USP8-depleted
endothelial cells were stained for VEGFR2 and an early endosome marker, early
endosome antigen-1 (EEA-1) (Fig. 5.3A). Quantification revealed increased co-
distribution between VEGFR2 and EEA1 before and after VEGF-A stimulation in
USP8-depleted cells (Fig. 5.3B). To determine localisation of the remaining VEGFR2,
USP8-depleted cells were co-stained with markers for the plasma membrane
(PECAM1), Golgi (TGN46), early endosomes (EEA1), late endosomes (CD63) and
lysosomes (LAMP2) (Fig. 5.4A). Quantification revealed that VEGFR2 distribution
across other organelles was minimally affected by USP8 depletion whilst accumulation
took place in EEA1-positive early endosomes (Fig. 5.4B).
VEGFR2 also accumulated in EEA1-positive early endosomes when cells were treated
with individual USP8 siRNAs to limit off-target effects (Fig. 5.5). In addition, the
enlarged VEGFR2-positive endosomes did not co-distribute with late endosome marker,
CD63 (Fig. 5.6). These findings confirm that VEGFR2 accumulates in early endosomes
of USP8-depleted cells. Thus, USP8 is essential for VEGFR2 trafficking through the
endosome-lysosome system.
5.2.2. USP8 regulates VEGFR2 proteolysis
VEGFR2 proteolysis is regulated by ubiquitination (Bruns et al., 2010, Bruns et al.,
2012). A characteristic feature of VEGFR2 activation is trafficking through the
endosome-lysosome system and generation of a transient ~160 kDa N-terminal lumenal
fragment in endosomes (Bruns et al., 2010). Immunoblotting revealed that the 160 kDa
VEGFR2 proteolytic fragment was generated in both control and USP8-depleted
endothelial cells (Fig. 5.7). However, a novel ~120 kDa VEGFR2-derived proteolytic
fragment was also produced in USP8-depleted cells (Fig. 5.7). Notably, this VEGFR2-
related fragment was also immunoprecipitated from USP8-depleted cells (Fig. 5.9A, B
and 5.10A).
The novel 120 kDa VEGFR2-derived proteolytic fragment was present at very low
levels in control cells (Fig. 5.7, 5.8A). However, levels increased >3-fold upon USP8
depletion (Fig. 5.8B). Treatment with CHX to block new protein synthesis did not
prevent appearance of the 120 kDa fragment, confirming that it is derived from
proteolytic cleavage of mature VEGFR2 (Fig. 5.8A, B). USP8-depleted cells also
Figure 5.3. USP8 depletion causes VEGFR2 accumulation in early
endosomes. (A) Endothelial cells transfected with control or USP8 siRNA and
stimulated with 25 ng/ml VEGF-A for 15 min were fixed and processed for
immunofluorescence microscopy using antibodies to VEGFR2 (green) and EEA1
(red) followed by fluorescent species-specific secondary antibodies. Nuclei were
stained with DNA-binding dye, DAPI (blue). Scale bar represents 70 μm. (B) Co-
distribution between VEGFR2 and EEA1 in endothelial cells treated with non-
targeting or USP8 siRNA and stimulated with VEGF-A prior to quantitative
microscopy. Errors bars indicate ±SEM (n≥3). p<0.05 (*), p<0.0001 (****).
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Figure 5.4. Cellular distribution of VEGFR2 in USP8-depleted cells. (A)
Endothelial cells transfected with non-targeting or USP8 siRNA were fixed and
processed for immunofluorescence microscopy using antibodies to VEGFR2
(green) and PECAM1, LAMP2, TGN46, EEA1 or CD63 (red) followed by
species-specific secondary antibodies. Nuclei were stained with DNA-binding
dye, DAPI (blue). Scale bar represents 70 μm. (B) Co-distribution between
VEGFR2 and cellular markers in endothelial cells treated with control or USP8
siRNA determined using quantitative microscopy. Error bars denote ±SEM (n≥3).
p<0.05 (*). 123
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Figure 5.5. Individual USP8 siRNAs cause VEGFR2 accumulation in early
endosomes. Endothelial cells transfected with individual USP8 siRNAs and
stimulated with 25 ng/ml VEGF-A for 15 min were fixed and processed for
immunofluorescence microscopy using antibodies to VEGFR2 (green) and EEA1
(red) followed by fluorescent species-specific secondary antibodies. Nuclei were
stained with DNA-binding dye, DAPI (blue). Arrows indicate enlarged VEGFR2-
positive early endosomes. Scale bar represents 70 μm. Izma Abdul Zani
(Ponnambalam Laboratory, University of Leeds) contributed to the data shown in
this figure.
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Figure 5.6. Individual USP8 siRNAs do not cause VEGFR2 accumulation in
late endosomes. Endothelial cells transfected with individual USP8 siRNAs and
stimulated with 25 ng/ml VEGF-A for 15 min were fixed and processed for
immunofluorescence microscopy using antibodies to VEGFR2 (green) and CD63
(red) followed by fluorescent species-specific secondary antibodies. Nuclei were
stained with DNA-binding dye, DAPI (blue). Arrows indicate enlarged VEGFR2-
positive early endosomes. Scale bar represents 70 μm. Izma Abdul Zani
(Ponnambalam Laboratory, University of Leeds) contributed to the data shown in
this figure.
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Figure 5.7. USP8 depletion promotes accumulation of a novel 120 kDa
VEGFR2 proteolytic cleavage fragment. Endothelial cells transfected with
non-targeting or USP8 siRNA were treated with 25 ng/ml VEGF-A, lysed and
immunoblotted with antibodies against VEGFR2. Numbered arrowheads denote
the 160 kDa VEGFR2 fragment (1) and the novel 120 kDa VEGFR2 fragment
(2).
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Figure 5.8. USP8 depletion promotes accumulation of a novel 120 kDa
VEGFR2 proteolytic cleavage fragment. (A) Endothelial cells transfected with
non-targeting or USP8 siRNA were treated with 20 μg/ml CHX and 25 ng/ml
VEGF-A, lysed and immunoblotted with antibodies against VEGFR2.
Quantification of 120 kDa (B) or 160 kDa (C) VEGFR2 fragment levels in
endothelial cells transfected with non-targeting or USP8 siRNA and treated with
20 μg/ml CHX and 25 ng/ml VEGF-A. Error bars denote ±SEM (n≥3). p<0.05
(*), p<0.01 (**). Numbered arrowheads denote the 160 kDa VEGFR2 fragment
(1) and the novel 120 kDa VEGFR2 fragment (2).
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displayed increased production of the 160 kDa proteolytic fragment (Fig. 5.8C). Thus,
the 160 kDa VEGFR2 fragment could be a precursor of the smaller 120 kDa fragment.
Alternatively, the 120 kDa fragment may be a unique proteolytic cleavage product that
is not cleared efficiently due to a block in forward transport towards the lysosome in
USP8-depleted cells. To resolve the identity of the 120 kDa VEGFR2 fragment,
VEGFR1 and VEGFR2 were immunoprecipitated from USP8-depleted cells followed
by immunoblot analysis with antibodies to the extracellular and cytoplasmic domains of
VEGFR2 (Fig. 5.9A). The VEGFR2 extracellular domain antibody detected all species
of VEGFR2 in USP8-depleted cells. In contrast, the cytoplasmic domain antibody only
detected full length immature and mature VEGFR2 (Fig. 5.9A). Thus, similarly to the
160 kDa fragment, the 120 kDa VEGFR2 cleavage product is N-terminal. These
findings suggest that USP8 is vital for efficient clearance of VEGFR2 proteolytic
cleavage products.
5.2.3. USP8 regulates VEGFR2 de-ubiquitination
VEGF-A binding programs VEGFR2 ubiquitination, endocytosis and proteolysis (Ewan
et al., 2006, Bruns et al., 2010, Bruns et al., 2012). De-ubiquitination is required to
divert internalised VEGFR2 away from lysosomal degradation and towards recycling
(Clague et al., 2012). Based on the above findings, one possibility is that perturbed
VEGFR2 endosome-lysosome trafficking is linked to altered VEGFR2 ubiquitination
status in USP8-depleted cells. To assess VEGFR2 ubiquitination in control and USP8-
depleted cells, VEGFR2 immunoprecipitates were probed by immunoblotting using
K48- and K63-linked polyubiquitin-specific antibodies or a pan-ubiquitin antibody (Fig.
5.10A). In control cells, VEGFR2 ubiquitination peaked 15 min after VEGF-A
stimulation (Fig. 5.10A). Accumulation of proteolytic cleavage products in USP8-
depleted cells reduced levels of mature VEGFR2 and resulted in lower levels of
ubiquitinated full-length receptor (Fig. 5.10A). However, a lower molecular weight
species of ubiquitinated VEGFR2 that corresponds to the 160 kDa proteolytic fragment
and represents increased and persistent ubiquitination of this cleavage product was
evident in USP8-depleted cells (Fig. 5.10A, arrowhead). USP8 depletion increased
levels of this K48- and K63-linked polyubiquitinated species of VEGFR2. Unlike in
control cells, this species of ubiquitinated VEGFR2 was present in non-stimulated cells
and persisted over a time course of VEGF-A stimulation (Fig. 5.10A). Quantification of
immunoblot data showed that whereas ligand-stimulated VEGFR2 ubiquitination
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Figure 5.9. USP8 depletion promotes generation of a novel 120 kDa VEGFR2
proteolytic cleavage fragment. (A) VEGFR1 or VEGFR2 were
immunoprecipitated from endothelial cells transfected with non-targeting or
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Figure 5.10. USP8 regulates VEGFR2 de-ubiquitination. (A) Endothelial cells
transfected with non-targeting or USP8 siRNA were treated with 25 ng/ml
VEGF-A and lysed. VEGFR2 was immunoprecipitated and immunoblotted for its
ubiquitination status using antibodies against K48-linked polyubiquitin, K63-
linked polyubiquitin and pan-ubiquitin. Arrowheads denote the ubiquitinated
VEGFR2 species present at higher levels in USP8-depleted cells. (B)
Quantification of ubiquitinated VEGFR2 levels in endothelial cells transfected
with non-targeting or USP8 siRNA and treated with 25 ng/ml VEGF-A. Error
bars denote ±SEM (n≥3). p<0.001 (***). IP; immunoprecipitate, WCL; whole
cell lysate.
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displayed a characteristic peak and decline, under conditions of USP8 depletion
VEGFR2 ubiquitination persisted (Fig. 5.10B). One possibility is that reduced de-
ubiquitination of accumulated, mature VEGFR2 in USP8-depleted cells increases
susceptibility to proteolysis. Thus, proteolytic cleavage products remain ubiquitinated
and accumulate in early endosomes. These data suggest that USP8 is a key regulator of
VEGFR2 de-ubiquitination.
5.2.4. VEGF-A-stimulated VEGFR2 signal transduction is perturbed
by USP8 depletion
VEGF-A stimulates multiple signal transduction pathways in endothelial cells (Koch et
al., 2011) that regulate many cellular responses (Zhang et al., 2008). Furthermore,
VEGF-A-stimulated signal transduction is dependent on positional location of VEGFR2
at the plasma membrane or within endosome-related compartments (Bruns et al., 2010,
Koch et al., 2011, Horowitz and Seerapu, 2012). However, the role of the
ubiquitination/de-ubiquitination cycle in RTK signal transduction is unclear. Perturbed
VEGFR2 endosomal trafficking caused by USP8 depletion could modulate endosome-
linked signal transduction. Control or USP8-depleted endothelial cells were subjected to
a time course of VEGF-A stimulation followed by immunoblot analysis to assess
VEGFR2 activation and downstream signal transduction (Fig. 5.11A). VEGF-A binding
causes autophosphorylation of VEGFR2 cytoplasmic residue Y1175, creating a key
binding site for downstream effectors (Koch et al., 2011). Quantification of immunoblot
analysis revealed VEGFR2-pY1175 levels were ~60% reduced in USP8-depleted
endothelial cells (Fig. 5.11B). VEGF-A-stimulated activation of the master regulator
and serine/threonine protein kinase, Akt, was ~90% reduced in USP8-depleted cells
(Fig. 5.11C). In addition, VEGF-A-stimulated activation of the MAPK pathway
involving ERK1/2 was ~60% reduced in USP8-depleted cells (Fig. 5.11D).
Interestingly, USP8 depletion did not significantly affect plasma membrane-associated
phosphorylation and activation of p38 MAPK or PLCγ1 (Fig. 5.11E, F). USP8 activity 
thus modulates VEGF-A-stimulated Akt and ERK1/2 activation but does not affect
other VEGFR2-associated signal transduction pathways.
Levels of mature, full-length VEGFR2 appear reduced in USP8-depleted cells (Fig.
5.11A) yet VEGFR2 is accumulated in early endosomes (Fig. 5.1A). VEGFR2
proteolysis in early endosomes generates 120 kDa and 160 kDa N-terminal fragments.
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Figure 5.11. USP8 depletion inhibits VEGF-A-stimulated VEGFR2 signal
transduction. Endothelial cells transfected with non-targeting or USP8 siRNA
were treated with 25 ng/ml VEGF-A, lysed and immunoblotted for phospho-
VEGFR2 (Y1175), phospho-Akt (S473), phospho-ERK1/2 (T202/Y204)
phospho-p38 MAPK (T180/Y182), and phospho-PLCγ1 (Y783). Levels of
phospho-VEGFR2 (B), phospho-Akt (C), phospho-ERK1/2 (D), phospho-p38
MAPK (E), phopho-PLCγ1 (F) and VEGFR2 (G) in endothelial cells transfected
with non-targeting or USP8 siRNA determined using quantitative
immunoblotting. Numbered arrowheads denote mature VEGFR2 (1) and
proteolytic VEGFR2 fragments (2). Errors bars indicate ±SEM (n≥3). p<0.01
(**), p<0.0001 (****). 132
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Proteolytic cleavage products of mature VEGFR2 accumulate in early endosomes of
USP8-depleted cells after failure to reach a degradative compartment thus causing an
overall increase in total VEGFR2 levels (Fig. 5.11G).
5.2.5. VEGFR2 plasma membrane dynamics
In USP8-depleted endothelial cells non-stimulated VEGFR2 displayed accumulation in
early endosomes (Fig. 5.12A). Reduced VEGFR2 availability at the plasma membrane
could thus diminish response to exogenously added VEGF-A. To investigate this
possibility, we used cell surface biotinylation to compare plasma membrane VEGFR2
pools in control and USP8-depleted cells (Fig. 5.12A). Quantification revealed little
difference in non-stimulated, plasma membrane VEGFR2 levels between control and
USP8-depleted cells (Fig. 5.12B). Furthermore, USP8 depletion had little effect on
relative VEGFR2 levels at the plasma membrane over a 60 min time course of VEGF-A
stimulation. Thus reduced plasma membrane VEGFR2 availability did not account for
diminished VEGF-A-dependent Akt and ERK1/2 activation (Fig 5.11C, D and 5.12B).
Monitoring peak VEGFR2-Y1175 phosphorylation at the plasma membrane also
revealed little difference between control and USP8-depleted cells (Fig. 5.12C). Thus,
inhibition of VEGFR2 phosphorylation (Fig. 5.11B) in USP8-depleted cells likely
represents an effect on the total VEGFR2 pool which continues to be phosphorylated
after internalisation. These findings suggest that USP8 does not regulate VEGFR2
levels and subsequent activation at the plasma membrane.
5.2.6. USP8 regulates VEGFR2 endosome-to-plasma membrane
recycling
Previous studies showed VEGFR2 undergoes ligand-independent endosome-to-plasma
membrane recycling (Jopling et al., 2014, Gampel et al., 2006). Ubiquitination of
plasma membrane-associated VEGFR2 precedes endocytosis and delivery via the
endosome-lysosome system for terminal degradation (Ewan et al., 2006). Contrastingly,
RTK de-ubiquitination in early endosomes is associated with recycling back to the
plasma membrane (Clague and Urbe, 2006). To test a role for USP8 in endosome-to-
plasma membrane recycling of VEGFR2, we used a previously described microscopy-
based recycling assay (Jopling et al., 2011) (Fig. 5.13C). Control or USP8-depleted
endothelial cells were incubated with extracellular domain-specific VEGFR2 antibodies
to label plasma membrane VEGFR2. Endocytosis and recycling over a time course of
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Figure 5.12. USP8 depletion does not affect VEGFR2 levels or activation at
the plasma membrane. (A) Endothelial cells transfected with non-targeting or
USP8 siRNA were treated with 25 ng/ml VEGF-A, cell surface biotinylated and
lysed. Biotinylated proteins were isolated using neutravidin-agarose and
immunoblotted using antibodies against phospho-VEGFR2 (Y1175) and
VEGFR2. Quantification of cell surface VEGFR2 (B) or phospho-VEGFR2 (C)
levels over a time course of VEGF-A stimulation in endothelial cells transfected
with non-targeting or USP8 siRNA. Error bars denote ±SEM (n≥3). IP;
immunoprecipitate, WCL; whole cell lysate.
134
AB C
Control
siRNA
USP8
siRNA
VEGF-A (min) No Strip Monensin No 2°
0 30 60
VEGFR2
0 30 60 0 30 60
0.0
0.5
1.0
1.5
2.0
2.5
Control siRNA
USP8 siRNA
*
***
VEGF-A stimulation (mins)
R
el
at
iv
e
VE
G
FR
2
le
ve
ls
Acid strip
4°c
37°c 37°c
+ VEGF-A
Figure 5.13. Endosome-to-plasma membrane VEGFR2 recycling is inhibited
in USP8-depleted cells. (A) Endothelial cells transfected with non-targeting or
USP8 siRNA were incubated with primary antibodies to VEGFR2 for 30 min at
37°C and treated with 20 μM monensin (endosome-to-plasma membrane
recycling inhibitor) or stimulated with VEGF-A for 15 or 30 min before stripping
of cell surface primary antibodies and incubation with fluorescent species-
specific secondary antibodies for 15 or 30 min (30 or 60 min total recycling time
respectively) at 37°C (green). No strip controls represent both cell surface and
recycled VEGFR2. Cells were fixed prior to staining with DNA-binding dye,
DAPI (blue). Only VEGFR2 that underwent plasma membrane-endosome-plasma
membrane recycling is visible. Scale bar represents 200 μm. (B) Quantification of
VEGFR2 recycling in cells transfected with non-targeting or USP8 siRNA and
treated with 25 ng/ml VEGF-A. Error bars denote ±SEM (n≥3). p<0.05 (*),
p<0.001 (***). (C) Schematic outline of the antibody-based assay to monitor
VEGFR2 recycling between the plasma membrane and internal compartments.
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VEGF-A stimulation were assessed using accessibility of the VEGFR2-antibody
complex to exogenous, labelled secondary antibody (Fig. 5.13A). Monensin is an
ionophore that inhibits endosome-to-plasma membrane recycling. Pre-treatment with
monensin inhibited VEGFR2 recycling (Fig 5.13A). In controls with no secondary
antibody incubation, VEGFR2 was not detected (Fig. 5.13A). Only VEGFR2 that had
undergone endocytosis followed by endosome-to-plasma membrane recycling was
detected in this assay (Fig 5.13A). Quantification revealed that addition of VEGF-A
caused ~2-fold increase in VEGFR2 recycling in control cells (Fig. 5.13B). However,
USP8-depleted cells underwent ~60% reduction in re-appearance of plasma membrane
VEGFR2 under both non-stimulated and VEGF-A stimulated conditions (Fig. 5.13C).
USP8 is thus required for constitutive and ligand-stimulated endosome-to-plasma
membrane recycling of VEGFR2.
VEGFR2 accumulates in early endosomes and recycling is profoundly affected in
USP8-depleted cells yet plasma membrane levels are unaffected (Fig. 5.1A, 5.12B,
5.13B). One possibility is that plasma membrane VEGFR2 is replenished by newly
synthesised receptor. To test this we used biotinylation to compare plasma membrane
and internal VEGFR2 pools in control and USP8-depleted cells treated with CHX.
Biotinylated plasma membrane proteins were isolated and internal VEGFR2 was
immunoprecipitated followed by immunoblot analysis (Fig 5.14A). Quantification
revealed that levels of internal VEGFR2 were significantly higher in USP8-depleted
cells after accumulation in early endosomes, whilst plasma membrane VEGFR2 was
unaffected. Upon CHX treatment, cell surface VEGFR2 levels were significantly
reduced in USP8-depleted cells. Thus, plasma membrane VEGFR2 that accumulates in
early endosomes following cleavage into proteolytic fragments is replenished by the
biosynthetic pool of receptor.
5.2.7. USP8 depletion inhibits VEGF-A-stimulated tubulogenesis
A key functional aspect of VEGF-A-stimulated signal transduction in endothelial cells
is the capacity to stimulate the formation of tubes which resemble hollow blood vessels
(Fearnley et al., 2014). Control or USP8-depleted cells were monitored for the
formation of endothelial tubes i.e. tubulogenesis, using an endothelial-fibroblast co-
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Figure 5.14. Plasma membrane VEGFR2 is replenished by newly synthesised
receptor in USP8-depleted cells. (A) Endothelial cells transfected with non-
targeting or USP8 siRNA were treated with 10 μg/ml CHX, cell surface
biotinylated and lysed. Biotinylated proteins were isolated using neutravidin-
agarose and internal VEGFR2 immunoprecipitated (from the supernatant)
followed by immunoblot analysis using antibodies to VEGFR2. (B) VEGFR2
levels in cells transfected with non-targeting or USP8 siRNA and treated with 10
μg/ml CHX determined using quantitative immunoblotting. Numbered
arrowheads denote mature VEGFR2 (1) and proteolytic VEGFR2 fragments (2).
Error bars denote ±SEM (n≥3). p<0.05 (*).
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Figure 5.15. USP8 depletion inhibits VEGF-A-stimulated tubulogenesis. (A)
Primary human endothelial cells transfected with non-targeting or USP8 siRNA
were co-cultured on a bed of primary human fibroblasts for 7 days, treated with
25 ng/ml VEGF-A, fixed and stained with an antibody to PECAM-1 (red).
Quantification of total endothelial tubule length (B) and total number of
endothelial branch points (C) relative to controls treated with non-targeting
siRNA. Error bars denote ±SEM (n≥3). p<0.001 (***). Scale bar represents 1000
μm. Gareth Fearnley (Ponnambalam Laboratory, University of Leeds) contributed
to the data shown in this figure.
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culture assay (Fig. 5.15). Endothelial tubules were stained with the endothelial-specific
marker PECAM-1 to reveal complex tubular networks in response to VEGF-A
stimulation (Fig. 5.15A). Quantification of both tubule length and number of branch
points revealed >90% inhibition of endothelial-specific tubulogenesis in USP8-depleted
cells relative to controls (Fig. 5.15B, C).
5.3. Discussion
In this study we show that USP8 plays a key role in VEGFR2 trafficking and
proteolysis in the endosome-lysosome system. In this model, sustained VEGFR2
ubiquitination in the absence of USP8 promotes generation of a novel 120 kDa
VEGFR2 proteolytic fragment (Fig. 5.16). In addition, USP8-mediated de-
ubiquitination and trafficking of VEGFR2 is linked to spatio-temporal control of
VEGF-A-stimulated signal transduction (Fig. 5.16).
Our conclusions are based on four lines of evidence. First, USP8 depletion leads to
VEGFR2 accumulation within an endosome-like compartment that also contains the
early endosome marker, EEA-1. Secondly, the appearance of a novel ~120 kDa
VEGFR2-derived proteolytic fragment indicates the existence of a sequence of
compartmental-specific machinery that regulates VEGFR2 proteolysis. Depletion of
USP8 is marked by aberrant VEGFR2 ubiquitination, recycling and turnover, hallmarks
of perturbed ubiquitination and sorting in the endosome-lysosome system. Whereas
ERK1/2 and Akt signalling is inhibited by USP8 depletion, other signal transduction
pathways are unaffected. The temporal sequence of events in this pathway suggests that
ubiquitination and de-ubiquitination are closely associated with endosomes and have
major implications for cellular decision making processes e.g. tubulogenesis.
Endosomal DUBs are postulated to remove ubiquitin chains on membrane ‘cargo’ to
prevent terminal degradation in lysosomes. Previous work reported that USP8 depletion
severely inhibits EGFR degradation (Row et al., 2006). Ubiquitinated EGFR
accumulated in EEA1-positive endosomes caused by failure to reach a terminal
degradative compartment (Row et al., 2006). Other work also supported the view that
EGFR down-regulation is USP8-dependent (Mizuno et al., 2006). Our study now shows
that a different RTK, VEGFR2, accumulates in early endosomes of USP8-depleted
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Figure 5.15. Regulation of VEGFR2 trafficking, signalling and proteolysis by
USP8. Sustained VEGFR2 residence and ubiquitination in early endosomes leads
to proteolysis that generates 160 kDa and 120 kDa VEGFR2-derived fragments in
USP8-depleted cells. The 160 kDa fragment remains ubiquitinated and both
VEGFR2 cleavage products accumulate in early endosomes due to an indirect
effect of USP8 depletion on the ESCRT-0 trafficking machinery. Both reduced
de-ubiquitination and enhanced proteolysis of accumulated VEGFR2 down-
regulate endosome-linked signal transduction.
VEGF-A
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cells. It is likely that both full-length and partially proteolysed VEGFR2 accumulates in
these endosomes upon USP8 depletion.
Ubiquitin-linked enzyme activity of DUBs plays vital roles in RTK trafficking (Clague
and Urbe, 2010). USP8 modulates EGFR trafficking by regulating STAM de-
ubiquitination on early endosomes (Row et al., 2006). STAM protection from
proteasomal degradation facilitates forward movement of ubiquitinated receptors
through the endosome-lysosome system. USP8 depletion causes almost complete
STAM degradation and hinders further trafficking of cargo proteins (McCullough et al.,
2004). Our studies also lead to the conclusion that USP8 regulates endosomal
machinery (e.g. ESCRT-0) that is essential for onward trafficking of activated VEGFR2
through the endosome-lysosome system.
VEGFR2 localisation in early endosomes is linked to subsequent 26S proteasome-
dependent proteolysis and production of a 160 kDa proteolytic fragment (Bruns et al.,
2010). Furthermore, production of the 160 kDa fragment has been linked to down-
regulation of VEGFR2 endosomal signal transduction (Bruns et al., 2010). This study
shows that USP8 depletion is linked to generation of a novel 120 kDa proteolytic
fragment derived from mature, plasma membrane VEGFR2. We postulate that the 230
kDa mature VEGFR2 protein undergoes sequential proteolysis in the endosomal
network into 160 kDa and 120 kDa extracellular domain fragments. However, these
VEGFR2 fragments could also be individual cleavage products that remain trapped in
early endosomes and inaccessible to lysosomal degradation due to disruption of
ESCRT-0 components and endosome-lysosome delivery in USP8-depleted cells.
Another possibility is that an imbalance in the levels of hydrolases as a result of USP8
depletion promotes increased VEGFR2 processing and release of the extracellular
domain within early endosomes.
USP8 regulates de-ubiquitination of EGFR/ErbB1 and ErbB2 (Mizuno et al., 2005,
Row et al., 2006, Meijer and van Leeuwen, 2011). We now provide evidence that USP8
de-ubiquitinates VEGFR2. Whereas VEGFR2 ubiquitination showed a ligand-
dependent peak and decline in control cells, ubiquitination of the 160 kDa VEGFR2
proteolytic fragment persisted over a time course of VEGF-A stimulation in USP8-
depleted cells. Reduced VEGFR2 de-ubiquitination upon USP8 depletion did not
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promote increased lysosomal degradation due to the indirect effect of USP8 depletion
on the trafficking machinery, causing accumulation of ubiquitinated VEGFR2 in early
endosomes. This ubiquitinated VEGFR2 was susceptible to proteolysis which reduced
levels of full length receptor but caused accumulation of cleavage products in the
endosome-lysosome system. VEGFR2 proteolytic fragments of 160 and 120 kDa thus
accumulated in early endosomes causing an overall increase in total VEGFR2 levels.
K48-linked polyubiquitin chains are associated with proteasomal degradation whilst
K63-linked chains are associated with membrane receptor trafficking and targeting in
the endosome-lysosome system (Pickart, 2001, Adhikari and Chen, 2009). Our finding
that increased levels of both K48- and K63-linked polyubiquitin are present on
VEGFR2 upon USP8 depletion agrees with other studies that USP8 removes both such
polyubiquitin chains from protein substrates (McCullough et al., 2004).
VEGFR2 signal transduction is postulated to be location-dependent with different
outcomes at the plasma membrane vs. endosomes (Horowitz and Seerapu, 2012). A
requirement for USP8 was evident in VEGF-A-stimulated ERK1/2 and Akt activation
but not in p38 MAPK and PLCγ1 activation. This outcome could be linked to perturbed 
VEGFR2 localisation in endosomes whilst plasma membrane dynamics are unaffected
due to replenishment from the biosynthetic pool in USP8-depleted cells. Other studies
have also linked activated VEGFR2 residence in endosomes to ERK1/2 (Lanahan et al.,
2010, Bruns et al., 2010, Jopling et al., 2009, Horowitz and Seerapu, 2012, Koch et al.,
2011) and Akt (Lanahan et al., 2010, Sawamiphak et al., 2010, Horowitz and Seerapu,
2012, Koch et al., 2011) activation. One possible explanation is that activated VEGFR2
must undergo USP8-mediated de-ubiquitination on early endosomes as a pre-requisite
for engagement with ERK1/2 and Akt-linked signal transduction machinery.
A key conclusion is that USP8 regulates VEGFR2 recycling. De-ubiquitination of
activated VEGFR2 on early endosomes by a USP8-regulated mechanism could precede
recycling back to the plasma membrane. However, reduced VEGFR2 recycling in
USP8-depleted cells could be an indirect effect caused by perturbation of the ESCRT-0
complex. The pathway for VEGFR2 endosome-to-plasma membrane recycling has been
shown to require Rab4a (Jopling et al., 2014) and c-Src (Gampel et al., 2006). An
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alternate Rab11a endosome-to-plasma membrane pathway specifically regulates
recycling of activated VEGFR2-NRP1 complexes (Ballmer-Hofer et al., 2011).
Our model proposes that sustained VEGFR2 residence and ubiquitination in early
endosomes leads to proteolysis that generates 160 kDa and 120 kDa VEGFR2
fragments in USP8-depleted cells. (Fig. 5.16). Although the 160 kDa fragment remains
ubiquitinated, both VEGFR2 cleavage products accumulate in early endosomes due to
the indirect effect of USP8 depletion on trafficking machinery. Both reduced de-
ubiquitination and enhanced proteolysis of accumulated VEGFR2 down-regulate
endosome-linked signal transduction (Fig. 5.16).
USP8 is required for efficient VEGFR2 trafficking, de-ubiquitination, signal
transduction, recycling and proteolysis. This study emphasises the idea that plasma
membrane receptor ubiquitination and de-ubiquitination is more complex than a simple
system for targeting receptor degradation in lysosomes. The modulation of VEGFR2
ubiquitination status could provide a new and alternative therapeutic strategy to target
disease states that display aberrant angiogenesis.
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CHAPTER 6
Novel artificial binding proteins modulate VEGFR
signal transduction and endothelial function
6.1. Introduction
VEGF-A is a potent pro-angiogenic growth factor involved in regulating angiogenesis
(Koch and Claesson-Welsh, 2012). Pathological conditions associated with VEGF-A-
stimulated angiogenesis include cancer and age-related macular degeneration whilst
insufficient angiogenesis leads to tissue ischaemia and heart disease. VEGFR2 is the
principal RTK through which VEGF-A transmits its pro-angiogenic signals in vascular
endothelial cells (Olsson et al., 2006, Shibuya, 2010). VEGF-A binding to VEGFR2
promotes dimerisation and transautophosphorylation of several key cytoplasmic domain
tyrosine residues, leading to activation of signalling proteins including PLCγ1, ERK1/2 
and Akt (Koch and Claesson-Welsh, 2012). Functional cellular responses of the
VEGFR2-VEGF-A axis include endothelial cell proliferation, migration, survival and
ultimately formation of endothelial tubules (Koch and Claesson-Welsh, 2012). In
contrast, VEGFR1 is considered a ‘decoy’ receptor in endothelial cells due to its low
tyrosine kinase activity and existence of a soluble VEGFR1 isoform which restrict the
VEGF-A-stimulated response (Robinson and Stringer, 2001). Thus, inhibiting
VEGFR1-VEGF-A binding could promote VEGF-A-induced VEGFR2 signal
transduction and stimulate angiogenesis in ischaemic tissues.
Antibodies are the most commonly used binding proteins with several clinically
approved to inhibit VEGFR2 activity in cancer and >240 candidates in clinical
development (Reichert, 2010, Tugues et al, 2011). Nonetheless, limitations of
antibodies include their large size as multimeric proteins that require glycosylation and
disulphide bonds for stability. Antibody production is expensive and relies upon the use
of animals whilst clinical application requires humanised versions. Improved non-
antibody-based artificial binding proteins (Adhirons) have been developed to mimic the
molecular recognition properties of antibodies but with improved properties i.e they are
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monomeric, soluble, stable and have no cysteine or glycosylation sites (Tiede et al.,
2014, Gebauer and Skerra, 2009). Adhirons contain a cystatin-like fold based on a
phytocystatin consensus sequence. Two variable peptide regions containing 9 amino
acids facilitate generation of a phage display library with approximately 1.3 x 1010
clones (Tiede et al, 2014). Interestingly, other non-antibody binding proteins called
DARPins have been shown to inhibit VEGFR2 activity (Hyde et al, 2012). In this
chapter, we used Adhirons screened by ELISA to specifically bind the extracellular
domains of VEGFR1 or VEGFR2. Here we show that VEGFR1 Adhirons promote
VEGFR2 activation and VEGF-A-stimulated signal transduction and enhance VEGF-A-
stimulated endothelial tube formation. Contrastingly, VEGFR2 Adhirons inhibit VEGF-
A-stimulated signal transduction and endothelial tube formation. These highly specific
binding proteins have potential in vivo clinical applications including vascular imaging.
In addition, Adhirons could be used as therapeutic agents in tissue ischaemia,
retinopathies or the tumour microenvironment through pro- or anti-angiogenic targeting
of VEGFR1 or VEGFR2, respectively.
6.2. Results
6.2.1. VEGFR2-specific Adhirons inhibit VEGF-A-stimulated signal
transduction
Phage display was used to select Adhirons that bind to recombinant soluble VEGFR1 or
VEGFR2 proteins. In these studies, 4 VEGFR1-binding Adhirons and 3 VEGFR2-
binding Adhirons were selected for further analysis. Two VEGFR2 Adhirons that
demonstrated inhibitory potential were chosen for detailed functional analysis. Of the 4
VEGFR1 Adhirons screened for their potential to regulate endothelial cell
tubulogenesis, 1 promoted VEGF-A-stimulated tubule formation and was chosen for
detailed analysis. An analysis of Adhiron-specific binding to VEGFR1 or VEGFR2
proteins was carried out by the Tomlinson laboratory (University of Leeds, UK) using
biophysical techniques (data not shown). It was reported that these Adhirons displayed
dissociation constants for VEGFRs in the nanomolar range (C. Tiede and D. Tomlinson,
University of Leeds, personal communication).
VEGFR2 is activated upon VEGF-A-induced structural changes in the receptor
extracellular domain which initiate transautophosphorylation and downstream signal
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transduction (Koch et al., 2011). VEGFR2-Adhiron binding could prevent VEGFR2-
VEGF-A interaction or inhibit the structural changes required to initiate receptor
activation. To test this idea, endothelial cells were subjected to pre-treatment with
varying concentrations of VEGFR2-specific Adhirons 30 min prior to stimulation with
25 ng/ml VEGF-A. Downstream signal transduction events were analysed by
quantitative immunoblotting (Fig. 6.1A, 6.3A, 6.5A, 6.7A). VEGF-A binding causes
VEGFR2 autophosphorylation of cytoplasmic residue Y1175, creating a key binding
site for downstream effectors (Koch et al., 2011). Quantification of immunoblot
analysis revealed VEGFR2-pY1175 levels were 72% reduced in endothelial cells
treated with 150 μg B8 Adhiron (Fig. 6.2A). Plasma membrane VEGFR2 activation is 
associated with recruitment, tyrosine phosphorylation and activation of PLCγ1 (Koch et 
al., 2011). Cells treated with B8 Adhiron exhibited 92% reduction in PLCγ1 
phosphorylation (Fig. 6.2B). VEGF-A-stimulated activation of the serine/threonine
protein kinase, Akt, was 46% reduced in B8 Adhiron-treated cells (Fig. 6.2C). In
addition, VEGF-A-stimulated activation of the MAPK pathway involving ERK1/2 was
67% inhibited in cells treated with B8 Adhiron (Fig. 6.2D). Phosphorylation of eNOS
and p38 MAPK was inhibited by 93% in B8 Adhiron-treated endothelial cells (Fig.
6.2E, F). Adhiron-induced inhibition of VEGF-A-stimulated VEGFR2 signal
transduction showed a dose-dependent decline.
In cells treated with A9 Adhiron VEGF-A-stimulated VEGFR2 (Y1175) and PLCγ1 
phosphorylation was inhibited by 75% (Fig. 6.4A, B). Activation of Akt and ERK1/2
was inhibited by 94% and 89%, respectively (Fig. 6.4C, D). In contrast, eNOS
phosphorylation was not significantly inhibited. Although p38 MAPK phosphorylation
was up to 90% reduced in cells treated with A9 Adhiron this was not significant (Fig.
6.4E, F). In cells treated with a control Adhiron that does not bind VEGFR2, VEGF-A-
stimulated VEGFR2 phosphorylation and activation of downstream signalling proteins
was not significantly inhibited (Fig. 6.6). Another VEGFR2-specific Adhiron, H5, did
not inhibit VEGF-A-stimulated signal transduction (Fig.6.8). These results showed that
only VEGFR2-specific Adhirons, A9 and B8, inhibit VEGF-A-stimulated signal
transduction.
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6.2.2. Functional characterisation of VEGFR2-specific Adhirons
VEGF-A-stimulated activation of VEGFR2 promotes downstream signal transduction
and leads to new blood vessel sprouting, an essential feature of angiogenesis (Ferrara,
1999). In an endothelial-fibroblast co-culture assay, VEGF-A stimulated tubulogenesis
was revealed by staining for the endothelial-specific protein PECAM-1. Co-cultures
were pre-treated with Adhiron 30 min before VEGF-A stimulation every 2 days for a 7
day period to screen VEGFR2 Adhirons for effects on the VEGF-A-stimulated
endothelial response (Fig. 6.9A). Quantification of tubule length and number of branch
points revealed that B8 Adhiron significantly inhibited VEGF-A-stimulated endothelial
tubulogenesis (Fig. 6.9A). Tubule length was reduced by 80% whilst number of branch
points was reduced by 98% (Fig. 6.9B, C). Treatment with A9 Adhiron had a less
pronounced effect on VEGF-A-stimulated tubulogenesis (Fig. 6.9). In addition, there
was no reduction in tubule length or number of branch points following treatment with a
control Adhiron that does not bind VEGFR2 (Fig. 6.9). These results highlight that the
VEGFR2-specific Adhiron, B8, inhibits VEGF-A-stimulated endothelial tubulogenesis.
6.2.3. Functional characterisation of VEGFR1-specific Adhirons
VEGFR1 is considered a negative regulator of VEGFR2 activity by preferentially
binding VEGF-A (Devries et al., 1992). Adhirons to VEGFR1 could prevent VEGFR1-
VEGF-A interaction, thus promoting increased VEGFR2-VEGF-A binding and
increasing the endothelial response to VEGF-A. VEGFR1 Adhirons were screened for
effects on VEGF-A-stimulated tubulogenesis (Fig. 6.10A). Of the 4 Adhirons screened,
treatment with 35c Adhiron produced a significant increase in both basal and VEGF-A-
stimulated tubulogenesis (Fig. 6.10A). Quantification revealed a 51% increase in tubule
length and 84% increase in branch point number under basal conditions (Fig. 6.10B, C).
Under VEGF-A-stimulated conditions, tubule length increased by 15% and branch point
number increased by 26% (Fig. 6.10B, C). Thus, VEGFR1 Adhirons promote
endothelial tubulogenesis.
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Figure 6.1. VEGFR2-specific Adhiron B8 inhibits VEGF-A-stimulated signal
transduction. Endothelial cells were pre-treated with 0, 50, 100 or 150 μg/ml B8
(30 min) prior to 25 ng/ml VEGF-A stimulation, lysed and immunoblotted for
phospho-VEGFR2 (Y1175), phospho-PLCγ1, phospho-Akt (S473), phospho-
ERK1/2 (T202/Y204), phospho-p38 MAPK (T180/Y182) and phospho-eNOS
(S117).
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Figure 6.2. Quantification of VEGFR2-specific Adhiron B8 inhibition of
VEGF-A-stimulated signal transduction. Phospho-VEGFR2 (A), phospho-
PLCγ1 (B), phospho-Akt (C), phospho-ERK1/2 (D), phospho-p38 MAPK (E) and
phospho-eNOS (F) levels in endothelial cells pre-treated with 0, 50, 100 or 150
μg/ml B8 (30 min) prior to 25 ng/ml VEGF-A stimulation and quantitative
immunoblot analyses. Errors bars indicate +SEM (n≥3). p<0.05 (*), p<0.01 (**),
p<0.001 (***).
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Figure 6.3. VEGFR2-specific Adhiron A9 inhibits VEGF-A-stimulated signal
transduction. Endothelial cells were pre-treated with 0, 50, 100 or 150 μg/ml A9
(30 min) prior to 25 ng/ml VEGF-A stimulation, lysed and immunoblotted for
phospho-VEGFR2 (Y1175), phospho-PLCγ1, phospho-Akt (S473), phospho-
ERK1/2 (T202/Y204), phospho-p38 MAPK (T180/Y182) and phospho-eNOS
(S117).
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Figure 6.4. Quantification of VEGFR2-specific Adhiron A9 inhibition of
VEGF-A-stimulated VEGFR2 signal transduction. Levels of phospho-
VEGFR2 (A), phospho-PLCγ1 (B), phospho-Akt (C), phospho-ERK1/2 (D),
phospho-p38 MAPK (E) and phospho-eNOS (F) in endothelial cells pre-treated
with 0, 50, 100 or 150 μg/ml A9 (30 min) prior to 25 ng/ml VEGF-A stimulation
and quantitative immunoblot analyses. Errors bars indicate +SEM (n≥3). p<0.05
(*), p<0.01 (**), p<0.001 (***).
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Figure 6.5. Control Adhiron does not inhibit VEGF-A-stimulated signal
transduction. Endothelial cells were pre-treated with 0, 50, 100 or 150 μg/ml
control Adhiron (30 min) prior to 25 ng/ml VEGF-A stimulation, lysed and
immunoblotted for phospho-VEGFR2 (Y1175), phospho-PLCγ1, phospho-Akt
(S473), phospho-ERK1/2 (T202/Y204), phospho-p38 MAPK (T180/Y182) and
phospho-eNOS (S117).
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Figure 6.6. Control Adhiron does not inhibit VEGF-A-stimulated signal
transduction. Quantification of phospho-VEGFR2 (A), phospho-PLCγ1 (B),
phospho-Akt (C), phospho-ERK1/2 (D), phospho-p38 MAPK (E) and phospho-
eNOS (F) levels in endothelial cells pre-treated with 0, 50, 100 or 150 μg/ml
control (30 min) prior to 25 ng/ml VEGF-A stimulation and quantitative
immunoblot analyses. Errors bars indicate +SEM (n≥3).
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Figure 6.7. VEGFR2-specific Adhiron H5 does not inhibit VEGF-A-
stimulated signal transduction. Endothelial cells were pre-treated with 0, 50,
100 or 150 μg/ml H5 Adhiron (30 min) prior to 25 ng/ml VEGF-A stimulation,
lysed and immunoblotted for phospho-VEGFR2 (Y1175), phospho-PLCγ1,
phospho-Akt (S473), phospho-ERK1/2 (T202/Y204), phospho-p38 MAPK
(T180/Y182) and phospho-eNOS (S117).
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Figure 6.8. VEGFR2-specific Adhiron H5 does not inhibit VEGF-A-
stimulated signal transduction. Quantification of phospho-VEGFR2 (A),
phospho-PLCγ1 (B), phospho-Akt (C), phospho-ERK1/2 (D), phospho-p38
MAPK (E) and phospho-eNOS (F) levels in endothelial cells pre-treated with 0,
50, 100 or 150 μg/ml H5 (30 min) prior to 25 ng/ml VEGF-A stimulation and
quantitative immunoblot analyses. Errors bars indicate +SEM (n≥3).
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Figure 6.9. VEGFR2-specific Adhirons inhibit VEGF-A-stimulated
endothelial cell tubulogenesis. (A) Primary human endothelial cells were co-
cultured on a bed of primary human fibroblasts for 7 days, treated with 100 μg/ml
control, A9, or B8 VEGFR2 Adhiron 30 min prior to stimulation with 25 ng/ml
VEGF-A, fixed and stained with an antibody to PECAM-1. Scale bar represents
1000 μm. Quantification of VEGF-A-stimulated total endothelial tubule length
(B) and total number of endothelial branch points (C) following treatment with
control, A9 or B8 Adhirons. Error bars denote ±SEM (n≥3). p<0.05 (*), p<0.01
(**).
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6.2.4. VEGFR1-specific Adhirons promote VEGF-A-stimulated
VEGFR2 activation
VEGFR1 forms a non-productive signalling complex upon VEGF-A binding and thus
sequesters VEGF-A to limit the VEGF-A-stimulated VEGFR2 signal transduction
response (Robinson and Stringer, 2001). Adhirons specific for VEGFR1 could prevent
VEGFR1-VEGF-A interaction; increasing availability of VEGF-A to bind VEGFR2
and upregulating VEGF-A-stimulated signal transduction. To test this idea, endothelial
cells were pre-treated with VEGFR1-specific Adhirons 30 min before stimulation with
25 ng/ml VEGF-A. Downstream signal transduction events were analysed by
quantitative immunoblotting (Fig. 6.11). VEGFR2 (Y1175) phosphorylation increased
by 24% in cells treated with 35c Adhiron (Fig. 6.12A). In addition, activation of PLCγ1, 
Akt and eNOS increased by 64%, 52% and 75%, respectively (Fig. 6.12B, C, F). Whilst
ERK1/2 activation was not effected by treatment with 35c Adhiron, p38 MAPK
activation was 45% increased, although this was not significant (Fig. 6.12D, E). Thus,
VEGFR1-specific Adhirons have the capacity to promote VEGFR2 phosphorylation
and activation of downstream signal transduction cascades.
Treatment of endothelial cells with 37c Adhiron, which did not significantly increase
endothelial tubule formation, had limited effects on VEGF-A-stimulated VEGFR2
phosphorylation and activation of downstream signal transduction (Fig. 6.12).
6.2.5. Adhirons to VEGFR1 or VEGFR2 have opposing effects on
endothelial cell migration and proliferation
To test the effect of Adhirons on additional cellular outcomes we performed cell
migration and proliferation assays (Fig. 6.13). Pre-treatment of endothelial cells with
VEGFR2-specific Adhiron, B8, reduced cell migration by 63% and cell proliferation by
22% (Fig. 6.13, 6.14A, B). Contrastingly, pre-treatment of endothelial cells with
VEGFR1-specific Adhiron, 35c, increased cell migration by 36% and cell proliferation
by 25% (Fig. 6.13, 6.14A, B). To exclude the possibility that toxic side effects were
responsible for inhibition of endothelial cell responses, we performed cell viability
assays. All of the Adhirons were non-toxic at the concentration used in tubulogenesis,
migration and proliferation experiments, with a cell viability of >90% (Fig. 6.14C).
A B
C
- VEGF-A + VEGF-A
Control
Adhiron
1-2c
Adhiron
35c
Adhiron
37c
Adhiron
78c
Adhiron
+
VE
G
F-
A
+
VE
G
F-
A
+
VE
G
F-
A
+
VE
G
F-
A
+
VE
G
F-
A
0
1
2
3
4
5
6
Control Adhiron
1-2c Adhiron
35c Adhiron
37c Adhiron
78c Adhiron
***
**
To
ta
lt
ub
ul
e
le
ng
th
+
VE
G
F-
A
+
VE
G
F-
A
+
VE
G
F-
A
+
VE
G
F-
A
+
VE
G
F-
A
0
10
20
30
40
50
Control Adhiron
1-2c Adhiron
35c Adhiron
37c Adhiron
78c Adhiron
***
*
To
ta
ln
um
be
ro
fb
ra
nc
h
po
in
ts
Figure 6.10. VEGFR1-specific Adhirons promote VEGF-A-stimulated
endothelial cell tubulogenesis. (A) Primary human endothelial cells were co-
cultured on a bed of primary human fibroblasts for 7 days, treated with 100 μg/ml
control or VEGFR1 Adhirons 30 min prior to 25 ng/ml VEGF-A stimulation,
fixed and stained with an antibody to PECAM-1. Scale bar represents 1000 μm.
Quantification of VEGF-A-stimulated total endothelial tubule length (B) and total
number of endothelial branch points (C) following treatment with control and 1-
2c, 35c, 37c or 78c VEGFR1 Adhirons. Error bars denote ±SEM (n≥3). p<0.05
(*), p<0.01 (**), p<0.001 (***).
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Figure 6.11. VEGFR1-specific Adhiron 35c promotes VEGF-A-stimulated
VEGFR2 phosphorylation and downstream signal transduction. Endothelial
cells were pre-treated with 100 μg/ml control, 35c or 37c VEGFR1 Adhirons (30
min) prior to stimulation with 25 ng/ml VEGF-A, lysed and immunoblotted for
phospho-VEGFR2 (Y1175), phospho-PLCγ1, phospho-Akt (S473), phospho-
ERK1/2 (T202/Y204), phospho-p38 MAPK (T180/Y182) and phospho-eNOS
(S117).
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Figure 6.12. VEGFR1-specific Adhiron 35c promotes VEGF-A-stimulated
VEGFR2 phosphorylation and downstream signal transduction. Phospho-
VEGFR2 (A), phospho-PLCγ1 (B), phospho-Akt (C), phospho-ERK1/2 (D),
phospho-p38 MAPK (E) and phospho-eNOS (F) levels in endothelial cells pre-
treated with 100 μg/ml VEGFR1-specific 35c or 37c Adhirons (30 min) prior to
25 ng/ml VEGF-A stimulation and quantitative immunoblot analyses. Errors bars
indicate +SEM (n≥3). p<0.05 (*), p<0.01 (**), p<0.0001 (****).
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Figure 6.13. Adhirons specific for either VEGFR1 or VEGFR2 have opposing
effects on endothelial cell migration. Primary human endothelial cells were
seeded into transwell migration chambers and pre-treated with 100 μg/ml control,
VEGFR1 (35c and 37c) or VEGFR2 (A9 and B8) Adhirons for 30 min prior to
stimulation with 25 ng/ml VEGF-A. Cells that had migrated towards a
chemotactic gradient of VEGF-A over 24 h were fixed and stained with crystal
violet. Scale bar represents 1000 μm.
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Figure 6.14. Adhirons to VEGFR1 or VEGFR2 have opposing effects on
endothelial cell migration and proliferation. (A) Levels of VEGF-A-dependent
endothelial cell migration upon treatment with 100 μg/ml control, VEGFR1 (35c
and 37c) or VEGFR2 (A9 and B8) Adhirons. (B) Levels of VEGF-A-dependent
endothelial cell proliferation upon treatment with 100 μg/ml control, VEGFR1
(35c and 37c) or VEGFR2 (A9 and B8) Adhirons for 30 min prior to 25 ng/ml
VEGF-A stimulation were monitored by ELISA. (C) Endothelial cell viability
upon pre-treatment with 100 μg/ml control, VEGFR1 (35c and 37c) or VEGFR2
(A9 and B8) Adhirons for 30 min prior to 25 ng/ml VEGF-A stimulation was
monitored by an MTS assay. Error bars denote ±SEM (n≥3). p<0.05 (*).
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6.3. Discussion
We have developed VEGFR-specific synthetic protein scaffolds called Adhirons which
inhibit VEGFR1 or VEGFR2 activity to promote or restrict VEGF-A-stimulated signal
transduction, respectively (Fig. 6.15). Incubating endothelial cells with VEGFR2-
specific Adhirons prior to VEGF-A stimulation can significantly decrease receptor
phosphorylation and inhibit downstream activation of signalling targets including
PLCγ1, Akt, ERK1/2, p38 MAPK and eNOS in a dose-dependent manner (Fig. 6.15). 
Tubulogenesis is an in vitro assay that mimics angiogenic sprouting. The VEGFR2
Adhiron, B8, effectively blocked VEGF-A-induced endothelial tubule formation.
Incubating endothelial cells with the VEGFR1-specific Adhiron, 35c, prior to VEGF-A
stimulation increased VEGFR2 phosphorylation and downstream activation of PLCγ1, 
Akt and eNOS (Fig. 6.15). In addition, 35c Adhiron promoted VEGF-A-stimulated
tubulogenesis. Thus, VEGFR1-Adhiron binding could prevent sequestration of VEGF-
A, facilitating increased VEGFR2-VEGF-A interaction and promoting enhanced
VEGF-A-stimulated signal transduction and tubulogenesis (Fig. 6.15). Endothelial cells
were treated with Adhiron and stimulated with VEGF-A every 2 days for a 7 day
period. Endothelial cell growth media contains low levels of VEGF-A so a more
pronounced effect on basal tubule growth was not unexpected if treatment with
VEGFR1 Adhirons acted over a period of prolonged, continuous exposure to low levels
of ligand. Furthermore, the opposing effects of VEGFR1 and VEGFR2 Adhirons on
VEGF-A-dependent tubulogenesis highlighted their specificity for individual RTKs.
The molecular mechanism for VEGFR inhibition could involve preventing VEGF-A-
VEGFR binding or obstruction of the correct three dimensional organisation of receptor
monomers in ligand-bound dimers. Previous work has shown that artificial ankyrin
repeat proteins (DARPins) screened to specifically interact with VEGFR2 extracellular
Ig domains inhibit VEGFR2 signal transduction (Hyde et al., 2012). DARPins that
interact with Ig domain, D23, block VEGF-A binding, receptor dimerisation and
activation, whilst those that interact with D4 or D7 inhibit receptor activity without
blocking dimerisation (Hyde et al., 2012). Differential inhibition of PLCγ1, Akt and 
ERK1/2 but not p38 MAPK or eNOS implies that VEGFR2-specific Adhiron, A9, does
not prevent ligand binding but interferes with VEGF-A-induced receptor dimerisation.
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Figure 6.15. Adhirons specific for either VEGFR1 or VEGFR2 show
opposing modulatory effects on VEGF-A-stimulated signal transduction.
VEGFR2-specific Adhirons inhibit VEGF-A-stimulated activation and
downstream signal transduction. In contrast, VEGFR1-specific Adhirons prevent
VEGF-A binding to VEGFR1, increasing VEGF-A availability for VEGFR2
binding and stimulating downstream intracellular signalling events in endothelial
cells.
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In this study, we have identified novel inhibitory proteins of VEGFR1 or VEGFR2
which can be used to manipulate VEGF-A-stimulated signal transduction and
endothelial cell tubulogenesis. Furthermore, we demonstrate that VEGFR1- and
VEGFR2-specific Adhirons show high receptor specificity and modulate multiple
cellular outputs associated with specific disease states. These reagents represent novel
VEGFR regulators that could have in vivo applications including anti- or pro-angiogenic
therapies or medical diagnostics.
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CHAPTER 7
GENERAL DISCUSSION
The studies presented in this PhD thesis provide new insights into the mechanisms
underlying VEGFR2 ubiquitination, trafficking and proteolysis in primary human
endothelial cells. This chapter provides a broad overview of the role of ubiquitination in
VEGFR2 trafficking, signal transduction, proteolysis and endothelial responses, and
potential therapeutic implications for cancer and other vascular diseases.
7.1. VEGFR2 ubiquitination
VEGF-A-stimulated VEGFR2 tyrosine phosphorylation is linked to internalisation and
endocytic trafficking towards lysosomal degradation (Koch and Claesson-Welsh, 2012).
Work on other RTKs, such as EGFR, revealed that receptor ubiquitination at the plasma
membrane is a prerequisite for recognition by ESCRT-0 trafficking machinery to
initiate transport through the endosome-lysosome system and limit responsiveness to
growth factor (McCullough et al., 2004, de Melker et al., 2001).
Although the E3 ubiquitin ligases, c-Cbl and β-TrCP, have been implicated in ligand-
stimulated ubiquitination and degradation of EGFR and VEGFR2, the existence of
multiple pathways to control activated RTK degradation complicate these studies
(Duval et al., 2003, Murdaca et al., 2004, Shaik et al., 2012, Bruns et al., 2010, Singh et
al., 2007). Depletion of the 8 E1s or the UBA1-associated E2s did not inhibit VEGF-A-
stimulated VEGFR2 degradation suggesting that contrary to other reports,
ubiquitination of activated VEGFR2 is not essential for its ligand-stimulated down-
regulation. A reason for this discrepancy could be incomplete siRNA knockdown,
especially since UBE2D2 depletion did result in a small inhibitory effect on VEGFR2
degradation following exposure to VEGF-A. Alternatively, a principle role for
VEGFR2 ubiquitination could be to regulate ligand-independent turnover and/or
endosome-lysosome trafficking. A drawback of this study is the absence of
UBA1/UBE2D1/UBE2D2 overexpression studies, mutational analysis or RNAi rescue
experiments to validate the results produced exclusively by siRNA depletion.
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Although many studies have attempted to identify pathways for ligand-activated RTK
degradation, work presented in this thesis describes for the first time an ubiquitin-
dependent pathway for controlling ligand-independent VEGFR2 turnover. This pathway
is important for regulating plasma membrane levels of VEGFR2 and the endothelial
response to VEGF-A. Kinase-independent regulation of RTK function has previously
been highlighted by studies on FGFR2 and EGFR. FGFR2 can undergo ligand-
independent activation whilst EGFR undergoes ligand-independent ubiquitination and
endocytosis (Katz et al., 2002, Lin et al., 2012). In addition, previous studies from our
laboratory provided evidence for constitutive endocytosis and recycling of VEGFR2
(Jopling et al., 2011). Work presented in this thesis reveals that upon depletion of the
DUB, USP8, disruption to endosomal trafficking causes ubiquitinated and proteolysed
VEGFR2 to accumulate in early endosomes of resting cells. These findings confirm that
VEGFR2 undergoes basal internalisation and recycling (Fig. 7.1).
Whilst the E1 and E2 components of the ubiquitin cascade for ligand-independent
VEGFR2 turnover have been identified in this work, future experiments should include
screening E3 ubiquitin ligases that interact with UBE2D1 and UBE2D2. Whilst UBA1
is the predominant E1 enzyme in humans and thus has wide ranging roles across
multiple cell types, the downstream E3 ligase involved in basal VEGFR2 ubiquitination
and turnover could present a more direct therapeutic target. There is also evidence that
the E2 enzymes, UBE2D1 and UBE2D2, can attach ubiquitin to lysine residues on
target substrates in the absence of a downstream E3 ligase (Wu et al., 2010).
Work in this thesis suggests that ubiquitination is important for regulating VEGFR2
recycling (Fig. 7.1). Ubiquitination down-regulates ligand-independent recycling and
de-ubiquitination of either the endosomal sorting machinery or VEGFR2 itself is
essential for endosome-to-plasma membrane recycling. Previous work reported that
ligand-stimulated recycling prolongs the cellular response to ligand, whilst in non-
stimulated cells recycling RTKs may be directed to specific membrane domains (Jones
et al., 2006).
Work on EGFR and VEGFR2 has highlighted the co-ordinated role of ubiquitin and
ESCRT-0 components, Hrs and STAM, in endosomal trafficking of internalised RTK
(Ewan et al., 2006, Bruns et al., 2010, Row et al., 2006). Importantly, the DUB, USP8,
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regulates the stability of both Hrs and STAM. This is supported by evidence in this
thesis that USP8 is essential for VEGFR2 trafficking from early endosomes. In addition,
correct endosomal trafficking of VEGFR2 is essential for VEGF-A-stimulated signal
transduction through the Akt and ERK1/2 pathways. These findings support other work
that suggested VEGFR2 signal transduction is location-dependent (Horowitz and
Seerapu, 2012). Other studies have also linked activated VEGFR2 residence in
endosomes to ERK1/2 (Lanahan et al., 2010, Bruns et al., 2010, Jopling et al., 2009,
Horowitz and Seerapu, 2012, Koch et al., 2011) and Akt (Lanahan et al., 2010,
Sawamiphak et al., 2010, Horowitz and Seerapu, 2012, Koch et al., 2011) activation.
Furthermore, links between endocytosis and signal transduction have been identified for
other RTKs and ERK1/2 does localise to endosomes (Sorkin and Von Zastrow, 2002).
USP8 activity is essential for VEGFR2 trafficking by mediating de-ubiquitination of
both the endosomal trafficking machinery (ESCRT-0) and VEGFR2. Work in this thesis
focused on USP8 due to its role in EGFR trafficking however it would be interesting to
determine whether any of the remaining 90 DUBs are also involved in VEGFR2 de-
ubiquitination and endosome-lysosome transport.
Previous work linked VEGFR2 proteolysis to early endosomes (Bruns et al., 2010).
Work in this thesis identifies a novel VEGFR2 cleavage fragment that is generated upon
accumulation of ubiquitinated VEGFR2 in early endosomes of USP8-depleted
endothelial cells. Thus, VEGFR2 proteolysis is a staggered process that takes place
gradually during transport from the plasma membrane to lysosomes for terminal
degradation (Fig. 7.1), possibly as a mechanism to restrict endosome-linked signal
transduction. The 120 kDa VEGFR2 fragment is also produced in non-transfected cells
at low levels suggesting a potential functional role. One possibility is that the VEGFR2
fragment recycles to the cell surface where it binds VEGF-A but is unable to signal due
to the absence of a kinase domain. The role of this negative feedback cycle could be to
sequester VEGF-A, limiting the temporal response to ligand and preventing excess pro-
angiogenic signalling. Previous work has identified soluble VEGFR2 as a ~75 kDa N-
terminal splice variant (Albuquerque et al., 2009). Perhaps the 120 kDa fragment is a
precursor of soluble VEGFR2 which could also be produced by proteolytic cleavage in
response to VEGF-A.
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Figure 7.1. Ubiquitin-dependent VEGFR2 trafficking through the endosome-
lysosome system. Ligand-independent ubiquitination of VEGFR2 promotes
internalisation and downstream proteolysis and reduces recycling. The opposing
effect of USP8-mediated de-ubiquitination promotes VEGFR2 recycling and
reduces proteolytic cleavage.
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7.2. Targeting ubiquitin homeostasis in disease
Collateral arteries provide an alternative blood supply to preserve myocardial tissue
perfusion in the event of obstructive coronary artery disease (CAD). Recent studies
have revealed genetic heterogeneity between CAD patients with sufficient or
insufficient collateral vessels. CAD patients that exhibit a well-developed collateral
network are less vulnerable to adverse cardiac events and demonstrate better
preservation of myocardial function and slower lesion progression (Hakimzadeh et al.,
2014). Insufficient collateral vessel growth is associated with rapid plaque progression,
resulting in severe ischaemia, hypoxia, necrosis and scar tissue formation. Progress is
been made to re-evaluate molecular and cellular targets in CAD. Patients with poor
collateral vessel development are genetically predisposed to overexpression of
signalling pathways that inhibit arteriogenesis. Thus a new focus in pro-angiogenic
research includes blocking such inhibitory pathways to promote arteriogenesis
(Hakimzadeh et al., 2014). Ubiquitin-dependent, ligand-independent degradation of
VEGFR2 could be one such inhibitory pathway of the VEGF-A-stimulated pro-
angiogenic response in diseases such as CAD. The ubiquitination enzymes involved in
this pathway ultimately impact on the ligand-stimulated response and could be cellular
targets for future therapeutics. Further work into ligand-independent VEGFR2 turnover
could involve identification of suitable clinical endpoints to enable appropriate
assessment of therapeutic outcomes. In addition, CAD patients could be screened for
perturbed UBA1 gene expression to identify a canonical role for UBA1 and ubiquitin
homeostasis in cardiovascular disease. Alternatively, the more substrate-specific E2
enzymes, UBE2D1 or UBE2D2, could be considered viable therapeutic targets.
Interestingly, VEGF-A is a trophic factor for nerve cells, cardiac muscle fibres and lung
epithelial cells, with insufficient VEGF-A levels linked to neurodegeneration, cardiac
failure and respiratory diseases. Thus, VEGF-A and its cognate receptors are important
therapeutic targets for a range of diseases.
UBA1 is an essential cellular enzyme expressed by many cells and tissues. Notably,
suppression of UBA1 activity in Schwann cells disrupts ubiquitin homeostasis, causing
aberrant accumulation of target proteins and neuromuscular degeneration in spinal
muscular atrophy (Sugaya et al., 2015, Aghamaleky Sarvestany et al., 2014). In
Huntington’s disease, a gradual decrease in UBA1 expression leads to selective
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accumulation of toxic forms of huntingtin protein in the brain (Groen and Gillingwater,
2015). UBA1-mediated surveillance could be utilised for controlling RTK levels and
cellular responses in different tissues. Other studies used chemical inhibitors as novel
anti-cancer agents to identify UBA1 as a target for the treatment of haematological
malignancies (Yang et al., 2007, Xu et al., 2010). The therapeutic potential and
biological effects of inhibiting ubiquitination/UBA1 are poorly understood. However,
UBA1 inhibition causes an unfolded protein response that induces cell death in
malignant cells over normal cells (Xu et al., 2013). Paradoxically, certain cancers (e.g.
prostate cancer) show reduced UBA1 levels (http://www.proteinatlas.org/). From this
standpoint, decreased UBA1 expression could be linked to increased angiogenesis in
cancer.
7.3. Therapies using anti-angiogenic or pro-angiogenic agents
Work in this thesis identified VEGFR2-specific Adhirons as inhibitors of in vitro
angiogenesis. Advancement in anti-angiogenic therapies is required since current TKIs
prolong survival of responsive patients by months rather than providing long-term
progression-free survival and are often only effective in combination with
chemotherapy. Inhibition of a single RTK does not provide long term benefits due to a
reduction in tumour dependency on VEGF-A (Sennino and McDonald, 2012).
Combination therapy or design of multi-targeted TKIs is considered a more attractive
proposition to overcome resistance mechanisms (Caglevic et al., 2015). It would be
interesting to test whether VEGFR2-specific Adhirons have inhibitory effects on other
RTK signalling pathways in endothelial cells, such as those of FGFR1.
Although currently used drugs such as Sutent and Avastin provide some benefit in terms
of short-term progression-free survival in RCC, they are relatively uneffective in
metastatic disease or more aggressive cancers. Thus, improving anti-angiogenic
therapies requires overcoming significant challenges (Sennino and McDonald, 2012).
Identification of predictive biomarkers to indicate responsive patients and discovery of
resistance mechanisms which drive tumour progression in patients for which VEGFR2
inhibition has limited benefit would provide steps forward. In addition, the duration and
frequency of combination therapies should be optimised on an individual basis with the
assistance of known genetic predisposition. For example, a single nucleotide
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polymorphism in the tyrosine kinase domain of VEGFR1 in genomic DNA correlates
with overall survival in bevacizumab-treated patients with metastatic pancreatic cancer
(Sennino and McDonald, 2012).
In this thesis, novel non-antibody based artificial binding proteins screened to bind
VEGFR1 or VEGFR2 were tested for effects on VEGF-A-stimulated signal
transduction and the downstream endothelial response. It would be interesting to
identify which extracellular VEGFR2 domain the Adhirons bind to and whether this
prevents ligand binding or receptor dimerisation. Further research could test VEGFR2-
specific Adhirons as novel anti-cancer agents to inhibit tumour angiogenesis in mouse
models.
Other research aims to discover pro-angiogenic drugs to treat patients with
cardiovascular disease. Atherosclerosis is the principle pathological disorder responsible
for cardiovascular disease which accounts for 30% of deaths worldwide. Peripheral
arterial disease (PAD) is a manifestation of atherosclerosis that is evident by blockages
in the major arteries and limbs. In these patients, there is a clinical need to promote
vascular regeneration after angioplasty, stenting or bypass surgery due to the
progressive nature of atherosclerosis and limited longevity of the aforementioned
techniques (Mughal et al., 2012). Frequently, patients re-present with worsening critical
limb ischaemia which in the absence of a pharmacological solution often leads to
amputation.
Current pro-angiogenic therapies focus on using gene therapy to express a range of pro-
angiogenic factors including VEGF, FGF and hepatocyte growth factor (HGF) (Mughal
et al., 2012). As the most extensively studied pro-angiogenic growth factor, VEGF-A
has been subjected to multiple clinical trials aimed at promoting new blood vessel
formation in PAD patients. VEGF-A gene therapy promotes angiogenesis in ischaemic
tissues (Makinen et al., 2002, Isner, 1998). However, the latest clinical trials on
therapeutic angiogenesis provide few satisfactory results. Although the efficacy of
VEGF gene therapy appears promising in preclinical and Phase I trials, this has not
transcribed into meaningful benefits in Phase II trials (Mughal et al., 2012). Thus, it is
important to identify new agents for disease therapy.
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VEGFR1-specific Adhirons inhibit VEGF-A binding to VEGFR1, promoting increased
VEGFR2-VEGF-A interaction to increase VEGF-A-stimulated signal transduction and
the endothelial response. Using Adhirons as pro-angiogenic agents could be beneficial
to cardiovascular disease patients. Alternative growth factors, delivery methods and
dose regimens need to be explored to enhance the clinical benefit of therapeutic
angiogenesis (Ribatti and Baiguera, 2013). An alternative approach could be to use
Adhirons to inhibit negative regulators of angiogenesis, such as VEGFR1. This could be
used to increase pro-angiogenic ligand availability following VEGF-A gene therapy.
7.4. Conclusion
The work in this thesis has demonstrated the importance of ubiquitination in regulating
VEGFR2 trafficking, signal transduction and proteolysis. A novel ubiquitin-dependent
pathway regulates basal plasma membrane VEGFR2 levels to control the intensity of
the VEGF-A-stimulated response. This pathway is mediated by the E1 ubiquitin-
activating enzyme, UBA1, and the E2 ubiquitin-conjugating enzymes, UBE2D1 and
UBE2D2. In addition, USP8-mediated de-ubiquitination is essential for normal
VEGFR2 trafficking through the endosome-lysosome system and endosome-linked
signal transduction, whilst preventing excess VEGFR2 proteolysis in early endosomes.
Novel non-antibody-based artificial binding proteins (Adhirons) can be used to promote
or inhibit VEGF-A-stimulated signal transduction. Unlike studies based on transformed
cell lines and overexpressed RTKs, the primary cell system used in these studies
provides a better model for relating endogenous RTK function to human physiology.
Thus, this cell system and the mechanisms uncovered for VEGFR2 ubiquitination,
trafficking, signalling and proteolysis may be useful for development of improved pro-
and anti-angiogenic therapeutics.
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